

NOV 08 '02 11:36 FR PATHOLOGY/LAB MED. 905 577 0198 TO  
SENT BY: VAN DYKE & ASSOCIATES, P.A.; 407 228 0329; NOV-7-02 4:24PM;

PAGE 2 P.02



DECLARATION OF JACK GAULDIE, Ph.D.  
Examining Group 1635  
Patent Application  
Docket No. GDI-1CPA1  
Serial No. 09/360,199

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Schnizer, Richard  
Art Unit : 1635  
Applicants : Gauldie et al.  
Serial No. : 09/360,199  
Docket No. : GDI-1CPA1  
Filed : 07/23/1999  
For : Intestinal Gene Therapy

Assistant Commissioner for Patents  
Washington, D.C. 20231

DECLARATION OF JACK GAULDIE, Ph.D.

I Jack Gauldie, Ph.D. hereby declare and say as follows:

THAT, I am employed as Professor and Chairman, Department of Pathology and  
Molecular Medicine at McMaster University, Hamilton, Ontario, Canada;

THAT, I earned my Ph.D. in Biological Chemistry in 1968 from University College,  
University of London UK, a copy of my curriculum vitae is attached hereto as Exhibit  
A;

THAT, I am one of the above-named Applicants and inventors of the subject matter  
described and claimed in the above-identified patent application;

THAT, by virtue of my educational and employment background, my attendance at  
seminars, my ongoing research, my continuing review of scientific periodicals and journals, and  
through correspondence with professional colleagues, I am aware of the level of skill of one  
ordinarily skilled in the art of immunology and vaccinology;

THAT, I have studied the application Serial No. 09/360,199 and all office actions which have been issued during prosecution of this application (including cited references), as well as all responses which have been filed on the Applicants' behalf, and being thus duly qualified declare as follows:

1. The Office action questions whether the vaccination methods taught in the specification and claimed in the subject application achieve the desired therapeutic effect of immunizing an animal against a predetermined pathogen. The office action cites a number of references to allege that gene therapy and genetic immunization are unpredictable arts. In particular, the office action questions whether the cytotoxic T cell assay (CTL assay) is reliable enough to establish whether the claimed methods achieve a therapeutic effect. The office action cites Bachmann et al (1994) for the proposition that comparative studies have shown that CTL responses readily detectable after in vitro restimulation may not be detected by any in vivo assay. Citing Bachmann, the office actions states the following: "One should therefore be very cautious not to 'over-interpret' cytotoxicity found only by  $^{51}\text{Cr}$ -release after secondary in vitro restimulation; without in vivo confirmation the result may be biologically irrelevant." The office action further states that the "Applicant . . . has not provided sufficient evidence or reasoning to support the position that a protective immune response will be generated against any antigen by the claimed methods or composition." I respectfully disagree with the Examiner's position. Since the publication by Bachmann, a number of gene based vaccine approaches have been developed, primarily aimed at developing anti-tumor immunity, in which protection from tumor challenge is associated with the presence of CTL determined by in vitro secondary expansion of T cells and  $\text{Cr}^{51}$  CTL assays. Moreover, the details we now supply demonstrate direct protective effects of this immunization protocol and all are associated with CTL detection. There may be some instances, such as those quoted by Bachmann, in which CTL assays after secondary in vitro expansion do not correlate with protection, however, most data recently published show correlation, including the data supplied herein.

2. Although I believe that the CTL assay example provided in the specification is sufficient to support a claim to therapeutic value in the present case, as further evidence, I provide herewith *in vivo* data from two different studies, which unquestionably demonstrate that the claimed methods do indeed immunize against targeted pathogens. These studies are provided as Exhibits B and C. Exhibit B demonstrates that Adenoviral-based gene delivery in the lower GI tract induces antigen-specific immune responses and protection from Tumour challenge, correlating with the presence of CTL positive reactions in spleen cells from immunized animals. Exhibit C demonstrates that Adenoviral based antigen gene delivery to rectal epithelium induces protective local immunity against HSV-2 infection, challenged either by vaginal or rectal administration of the pathogen.. In view of these two studies, there can be no question that the claimed methods, as claimed in Applicants' most recent response filed September 15, 2002, are directed to a useful, therapeutic vaccination methodology.

3. The claims as pending before Applicants' September 15, 2002 amendment were rejected over Wang and Henning (PCT publication and U.S. patents). The amendments to the claims so distinguish the prior art that it cannot be said that the Wang and Henning references anticipate or render obvious the now pending claims. I have carefully reviewed the Wang and Henning references. The Examiner correctly asserts that "neither Wang nor Henning teach a working example of a therapeutic effect," see page 15, paragraph 2 of the last office action. The Henning references disclose a method of introducing nucleic acid into the intestine using naked DNA or using various viral vectors. Henning discloses a few hypothetical examples of introducing DNA into intestinal cells. I point out that none of the examples discuss the use of an adenoviral vector; they are limited to retrovirus vectors, which are of limited use *in vivo*. Furthermore, Henning provides no working example, either *in vitro* or *in vivo*, of a methodology that may act to immunize an animal. Based on the teachings of Henning, one skilled in the art is still left wondering whether cells can be transfected in the intestine *in vivo* to express a given gene. One skilled in the art knows no more about whether a gene can be reproducibly expressed in the intestine, much less whether an animal can be immunized against a specific pathogen by expression of a given gene.

There is simply no connection between the method of exposing intestinal cells to a nucleic acid taught by Henning and successfully expressing a gene, whereby such expression leads to a successful vaccination of an animal against a given pathogen. The subject application is the first demonstration, as far as I am aware, that shows successful introduction of a gene into genitourinary epithelial cells using an adenoviral vector, whereby a protein antigen is generated that induces an immune response.

4. With respect to the Wang et al. reference, it discloses a specific study involving the exposure of vaginal mucosa to a non-viral vector expressing HIV-1 envelope proteins. The study shows that exposure to the non-viral based DNA plasmid produces immunoglobulins that showed activity in the in vitro cell-free infection assay. The assay involved taking vaginal washes from treated and non-treated animals and combining the wash with HIV-1/MN cell-free virus. The cell free virus was then combined with MT-2 cells, and the ability of the virus to infect the cells was observed. In some cases, it does appear that something in the vaginal wash affects the ability of the virus to infect the MT-2 cells. It is conjectured by Wang et al. that it is immunoglobulins present in the vaginal wash that is affecting the ability of the cell-free virus to infect the MT-2 cells. This study provides little additional information over Henning as to whether a given viral vector is able to be introduced into mucosal cells, express a gene of interest, and induce a protective immune response against a given pathogen. There is the suggestion that it may be worthwhile to study different routes of administration using different vectors. However, in view of either Henning or Wang, it cannot be said that any given route of administration, using non viral or viral vectors, would vaccinate a treated animal with a reasonable expectation of success. The Applicants of the present application are the first to demonstrate that specific vaccination is achievable through gastrointestinal or genitourinary routes by application of an adenoviral vector encoding a specific antigen gene..

5. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information in belief are believed to be true; and further that these statements were made with the knowledge that willful false statements in the like so made are punishable by fine or imprisonment, or both, under

§1001 of title 18 of the U.S.C. and that such willful false statements made jeopardize the  
validity of the application or of any patent issuing thereon.

Further declarant sayeth naught.



*Jack Gaudie*

Jack Gaudie, Ph.D.

*Nov 8/02*

Date

Exhibit A: Dr. Jack Gauldie's *Curriculum Vitae*





**CURRICULUM VITAE**  
**DR. JACK GAULDIE**

Date of Birth: November 14, 1942  
Place of Birth: Greenock, Scotland  
Nationality: Canadian  
Marital Status: Married, 2 children

Business Address: Department of Pathology and Molecular Medicine  
Room 2N16  
McMaster University  
1200 Main Street West  
Hamilton, Ontario  
Canada L8N 3Z5

Tel: (905) 521-2100 Ext. 76332  
FAX: (905) 577-0198  
Email: gauldie@mcmaster.ca

Home Address: 55 Bond Street South  
Hamilton, Ontario, Canada L8S 1S8  
Tel: (905) 529-3514

Degrees:

1964 B.Sc.	Chemistry, McMaster University, Hamilton, Ontario, Canada
1968 Ph.D.	Biological Chemistry, University College, London, England
1984 Fellow	Canadian Academy of Clinical Biochemistry
1995 Fellow	Canadian Academy of Clinical Biochemistry Fellow in Clinical Immunology - FCACB(I)

Awards:

1964	Chemistry in Industry Merit Award
1965-1968	Canadian National Research Council Special Studentship (overseas)
1968-1970	British National Research & Development Corporation Post-Doctoral Fellowship University College, London, England
1970-1971	Canadian Medical Research Council Post-Doctoral Fellowship McMaster University, Hamilton, Ontario, Canada
1978	Queen's Silver Jubilee Medal

1993 Distinguished Alumni Scholar Award, McMaster University

1997 Fellow, Royal Society of Canada

1998 Bernhard Cinader Award, The Canadian Society for Immunology

1998 Medal of Honour, Canadian Medical Association

1999 Who's Who in Healthcare Award

2002 Ortho Clinical Diagnostics Award, Ontario Society of Clinical Chemists

### APPOINTMENTS:

1971-1973 Professional Assistant, Department of Medicine  
McMaster University, Hamilton, Ontario

1973-1975 Lecturer, Department of Pathology  
McMaster University, Hamilton, Ontario

1975-1978 Assistant Professor, Department of Pathology  
McMaster University, Hamilton, Ontario

1978-1984 Associate Professor, Department of Pathology  
McMaster University, Hamilton, Ontario

1976- Special Professional Staff  
Department of Laboratory Medicine  
McMaster University Medical Centre  
Hamilton, Ontario

1976- Director, Clinical Immunology Laboratory  
McMaster University Medical Centre  
Hamilton, Ontario

1984- Chief of Service of Immunology  
Department of Laboratory Medicine  
Chedoke-McMaster Hospitals, MUMC Division  
Hamilton, Ontario

1984- Professor, Department of Pathology  
McMaster University, Hamilton, Ontario

Jan - Sept 1988 Visiting Professor, Department of Immunology  
Scripps Clinic, La Jolla, CA

1989- Chairman, Department of Pathology and Molecular Medicine  
McMaster University, Hamilton, Ontario





- 1995-1998 Chief of the Department of Laboratory Medicine  
Chedoke-McMaster Hospitals, Hamilton, Ontario
- 1997- Associate Member, Department of Biochemistry  
McMaster University, Hamilton, Ontario
- 1998- Special Professional Staff, Department of Laboratory Medicine  
St. Joseph's Hospital
- 1999- University Professor, Department of Pathology and Molecular Medicine  
McMaster University, Hamilton, Ontario
- July 1999 - January 2000 Visiting Professor, The University of Edinburgh  
Edinburgh, Scotland
- Jan 1, 2000 - June 30, 2005 John Bienenstock Chair in Molecular Medicine



### **PROFESSIONAL ORGANIZATIONS:**

American Association for Cancer Research  
The American Association for Clinical Chemistry  
American Association of Immunologists  
The American Society for Investigative Pathology  
American Thoracic Society  
Canadian Chairs of Pathology and Laboratory Medicine  
The Canadian Society of Clinical Chemists  
The Canadian Society for Immunology  
Canadian Thoracic Society  
European Respiratory Society  
International Cytokine Society  
The Royal Society of Canada  
United States and Canadian Academy of Pathology  
Olympic Club of Canada (Munich 1972)

### **SCHOLARLY AND PROFESSIONAL ACTIVITIES**


#### **Editorial Board:**

American Journal of Physiology: Lung Cellular and Molecular Physiology  
American Journal of Respiratory Cell and Molecular Biology  
Cytokine  
International Journal of Biochemistry and Cell Biology  
Journal of Clinical Investigation  
Journal of Immunology  
Journal of Interferon and Cytokine Research

### Scientific Advisory Board:

Rhone Poulenc Rorer, USA	1995-1998
Astra Draco, Sweden	1997-
Neurochem, Canada	1997-

### Scientific Advisory Committees



MRC Centre for Inflammation Research at the University of Edinburgh	2001-
Norman Salvesen Emphysema Research Trust, University of Edinburgh	2001-
CIHR Institute of Infection and Immunity	
Institute Advisory Board Member	2001-
Strategic and Scientific Advisory Board (SSAB) of BioOntario	2002-

### Grant Committees:

The Arthritis Society  
 - Research Advisory Committee  
 1996-1999 Member

Canadian Institutes for Health Research (CIHR)  
 - Groups Peer Review Committee  
 2001- Member  
 - Canada Research Chairs College of Reviewers  
 2000 - Member

Francis Families Foundation  
 - Council of Scientific Advisors  
 1994- 1998 Member

Medical Research Council of Canada  
 - Grants Committee for Immunology and Transplantation  
 1990-1994 Member  
 1991-1994 Chairman  
 - Peer Review Restructuring Committee  
 1995 Member

Searle  
 - Arthritis and Prostaglandins Research Challenge Review Committee  
 1991-1993 Member

### Journal Referee

American Journal of Pathology  
 American Journal of Respiratory Cell & Molecular Biology  
 American Journal of Respiratory and Critical Care Medicine  
 Arthritis and Rheumatism  
 Canadian Respiratory Journal  
 Gene Therapy  
 Infection and Immunity

International Journal of Biochemistry & Cell Biology  
 The Journal of Allergy and Clinical Immunology  
 The Journal of Clinical Investigation  
 The Journal of Immunology  
 Journal of Interferon and Cytokine Research  
 Journal of Leukocyte Biology



### External Grant Reviews

Alberta Lung Association  
 The Arthritis Society  
 British Lung Foundation  
 B.C. Health Research Foundation  
 Canadian Institutes of Health Research  
 NSERC  
 North Carolina Biotechnology Center  
 Wellcome Trust

### COURSES TAUGHT (last five years)

#### Undergraduate

B.Sc.N. Program Medical Microbiology Unit III	1994-
M.D. Immunology Large Group Session Unit 2	1990-
BHSc – Health Sciences 3J03	2002-

#### Graduate

MS723 Biochemistry	1998-
MS703 Gene Therapy	2001-

### SUPERVISORSHIPS

#### Masters

D. Williams	1979-1981
C. Richards	1983-1984
J. Wakeham	1997-1999
T. Galt	1997-2001
C. Thomson	1998-2001
M. Panju	1999-2001
S. Baral	1999-2001
V. Nethercot	1999-2001
G. Harder	2000-2002
L. Patton	2000-2002
M. Kelly	2000-
E. Safroneeva	2001-
S. Takenaka	2002-



### Doctoral

L. Lamontagne	1977-1982
T. Egwang	1980-1984
A. Stadnyk	1983-1987
C. Richards	1984-1987
M. Jordana	1984-1989
Z. Xing, MD	1988-1994
M. Geisterfer	1988-1995
D. Torry	1988-1995
T. Braciak	1989-1996
K. Palmer	1994-2001
P. Emtage	1995-1998
S. Gyorffy	1996-1999
Q. Zhu	1999-
P. Margetts, MD	1999-
J. Robertson	2002-

### Post-doctoral

L. Irving, MD	1985-1987
C. Vancheri, MD	1986-1988
C. Bradley, MD	1987-1989
A. Xaubet, MD	1988-1989
G. Cox, MD	1988-1990
I. Ohno, MD	1990-1992
J. Sallenave, PhD	1992-1995
G. Tremblay, PhD	1993-1995
P. Sime, MD	1993-1998
R. Foley, MD	1993-1997
L. Waldhauser, PhD	1994-1998
J. Bramson, PhD	1994-1997
Y. Wan, PhD	1995-1998
A. Redington, MD	1996-1997
K. Takahashi, PhD	1996-1997
P. Jones, PhD	1998-2000
Y. Chen, MD	1998-2001
J. Tao, MD, PhD	1998-1999
M. Kolb, MD	1999-
C. Dabrosin, MD, PhD	1999-2001
S. Gyorffy, PhD	2000-2001
P. Bonniaud, MD	2001-
J.C. Rodriguez, DVM, PhD	2002-

### Supervisory Committees

R. Slapsys, PhD	1981-1986
J. Ramwani, PhD	1982-1986
J. Rudolph, PhD	1982-1989

A. Faggioto, PhD	1983-1985
D. Gasangwa, MSc	1985-1987
S. Polyak, PhD	1988-1993
A. Agro, PhD	1988-1996
R. Quezuda-Calvillo, PhD	1989-1994
K. Woolley, PhD	1990-1993
C. Addison, PhD	1992-1997
G. Gauvreau, PhD	1993-1998
B. Cowan, PhD	1994-1998
S. Ruiz, PhD	1994-1996
N. Radojevic, MSc	1996-1998
P. Heritage, PhD	1997-1999
P. Koeberle, PhD	1997-
B. Gajewska, PhD	1997-
K. Sussman, MSc	1997-
A. Kashyap, MSc	1997-2001
S. Ritz, PhD	1998-
M. Rosenblatt, MSc	1999-2001
R. Leigh, PhD	2000-
M. Landis, MSc	2001-
J. Bezchlibnyk, PhD	2001-
F. Swirski, PhD	2001-
Y. Trieu, MSc	2001-
R. Wiley, PhD	2001-
A. Kwant, MSc	2002-
D. Smyth, MSc	2002-
P. Hew, MSc	2002-
R. Fattouh, MSc	2002-
D. Smyth, MSc	2002-

## **ADMINISTRATIVE RESPONSIBILITIES**

### **International:**

IUIS Clinical Immunology Committee  
1991- CSI Representative

Keystone Symposia - "The Cellular and Molecular Regulation of the Acute Inflammatory Response"  
February 7-12, 1994, Durango, Colorado  
Co-organizer

2nd International Cytokine Conference  
October 1-5, 1994, Banff, Alberta  
Organizing Committee

American Thoracic Society - Assembly in Allergy, Immunology & Inflammation  
1994-1998 - Program Committee Member  
1994-1997 - Long-Range Planning Committee Member

**National:**

Arthritis Society of Canada  
1996- Member, Research Advisory Committee

Association of Canadian Medical Schools and Colleges  
1980-1982 Chairman, M.D. Admissions Officers Subcommittee

Canada Research Chairs  
2000- College of Reviewers

Canadian Society for Immunology  
1993-1997 Council Member

Canadian Society for Laboratory Technologists  
1976-1979 Clinical Immunology Chief Examiner

Medical Research Council of Canada  
1993-1994 Advisory Committee for Peer Review

National Research Council Canada  
1993-1997 Advisory Board - Institute for Biological Sciences (IBS)

**Local:**

The Regional Municipality of Hamilton-Wentworth  
The Renaissance Project  
1993 - 1995 Member

**Hamilton Health Sciences Laboratory Program**

Academic Advisory Committee  
1976- Member  
1989- Chairman

Operational Management Committee  
1989- Member  
1995-1998 Chairman

Coordinating Committee  
1989- Member

**Faculty of Health Sciences**

School of Medicine  
1978-1982 Chairman, M.D. Admissions Committee

Committee on Scientific Development  
1981-1982 Member

1982-1985 Executive

Striking Committee

1981-1982

Member

1982-1985

Chairman

Board of Comprehensive Examiners

1981-1983

Member

1983-1986

Chairman

Dean's Executive

1989-1990

Faculty Executive

1989-

Council of the Faculty of Health Sciences

1989-

Clinical Chairmen Committee

1989-

Health Services Advisory Committee Executive

1989-1993

Ad Hoc Advisory Group - Institute for Molecular Biology & Biotechnology

1989-

Faculty Finance Committee

1990-1994

Primate Research Review Committee

1990-1991

Rheumatology Task Force

1990-1993

Life Sciences Council

1991-

Implementation Coordinating Committee

1993-1994

Task Force on Molecular and Physiological Sciences

1993-1994

Chair

McMaster/Mohawk Joint Initiative Concept Team

1993-1994

**RESEARCH FUNDING** (last five years)AstraZeneca**"Airways tissue remodelling"**

Jack Gauldie

January 1 – December 31, 1998

\$134,400 pa

January 1 – December 31, 1999

\$134,400 pa

January 1 – December 31, 2000

\$115,500 pa

Baxter Healthcare Corp.**"A model of peritoneal fibrosis"**

Jack Gauldie

December 15, 1998 – December 14, 1999

\$123,250 pa

November 30, 1999 – November 30, 2000

\$133,000 pa

Breast Cancer Society of Canada**"Dendritic cell and gene-based therapy of breast cancer using HER-2/neu antigen"**

Yonghong Wan, Jack Gauldie

July 1, 1999 – June 30, 2000

\$ 25,000 pa

July 1, 2000 – June 30, 2001

\$ 25,000 pa

Canadian Institutes of Health Research**"Cytokine gene transfer modulation of mucosal immunity"**

Jack Gauldie

April 1, 1999 – March 31, 2004

\$146,256 pa

**"The pathogenesis of pulmonary fibrosis"**

Jack Gauldie

October 1, 1997 - September 30, 2002

\$ 88,975 pa

**"Genetic immunotherapy of cancer"**

A. Keith Stewart, Jack Gauldie, Frank L. Graham, Mary Hitt, John Trachtenberg

October 1, 1998 – September 30, 2001

\$103,000 pa

October 1, 2001 – September 30, 2006

\$168,700 pa

**"Phase II Study, Multiple injections of autologous CD34<sup>+</sup>"**

Ronan Roley, Jack Gauldie, Mark Levine, Dave Tozer

April 1, 2000 – March 31, 2002

\$ 82,100 pa

**"TH2 cytokine gene transfer in regulation of inflammation and immunity"**

Jack Gauldie

July 1, 1994 - March 31, 1999

\$ 83,916 pa

Geron Corporation**"Development of telomerase-based cancer vaccine"**

Jack Gauldie

September 1, 2000 – August 31, 2001

\$ 97,440



Glaxo

"Adenovirus vector-mediated cytokine gene transfer to the lung"

Jack Gauldie

June 30, 1997 – June 30, 1998

\$137,850 pa

HHSC Foundation Sloat Fund

Ronan Foley, Peter Dent, Jack Gauldie, Peter McCulloch, Ralph Meyer,  
J. Rusthoven, R. Tozer, Yonghong Wan

1998

\$ 58,860 pa

1999

\$ 58,860 pa

Leukemia Research Fund of Canada

"Gene therapy of CLL"

Ronan Foley, Jack Gauldie, Yonghong Wan

July 1, 1998 – June 30, 2000

\$ 25,000 pa

NCE – CANVAC

CANVAC 3.2.4 "Adenovector modified dendritic cells expressing tumor antigen (HER)"

Jack Gauldie

April 1, 2000 – March 31, 2007

\$ 90,000 pa

CANVAC 3.4.2 "Tumor antigen delivery via adenovirus modified dendritic cells – clinical studies"

Jack Gauldie

April 1, 2000 – March 31, 2007

\$115,000 pa

CANVAC CORE – "Models for testing delivery systems"

Jack Gauldie

April 1, 2000 – March 31, 2007

\$ 50,000 pa

CANVAC 3.2.3 – "Modifying adenovectors to allow sustained antigen delivery (SEROAD)"

Jack Gauldie and Frank Graham

April 1, 2000 – March 31, 2007

\$110,000 pa

NIH

Subcontract Agreement for Grant #PO1 HL60231-01 with Children's Hospital of Los Angeles

"Molecular basics of lung morphogenesis, injury and repair"

Jack Gauldie

April 1, 1998 – March 31, 2003

US \$ 41,376 pa

Ontario Thoracic Society

"Modifications of intranasal immunity using cytokine expressing adenoviruses"

Mark McDermott, Jack Gauldie

July 1, 1998 – June 30, 1999

\$ 23,250 pa

Roche (Boehringer-Mannheim GmbH)

"Research program for the construction and characterization of CDA vector"

Jack Gauldie, Frank Graham

July 1, 1998 – June 30, 2000

July 1, 2000 – June 30, 2001

February 1, 2001 – January 31, 2002

\$250,800 pa

\$125,400 pa

\$ 80,080 pa



015

**PATENTS****United States Patent**

**Patent Number:** 4,973,478  
**Date of Patent:** November 27, 1990  
**Inventors:** Jack Gauldie, Carl Richards and Peter M. Lansdorp  
**Title:** Treating inflammation with hepatocyte stimulating factor interferon E2

**United States Patent**

**Patent Number:** 7,935,097  
**Date Filed:** August 26, 1992  
**Inventors:** Carl Richards, Mohammed Shoyab, Jack Gauldie and Tom Brown  
**Title:** Regulation of cellular invasiveness

**United States Patent**

**Patent Number:** 8,250,885  
**Date Filed:** May 31, 1994  
**Inventors:** Frank Graham, Jack Gauldie, William Muller and Christina Addison  
**Title:** Direct intratumoral injection of recombinant adenovirus vectors and viral particles that encode cytokines, to obtain shrinkage and elimination of tumors.  
**Description:** The patent describes the use of adenovirus vectors expressing cytokines for immunotherapy of cancer. Vectors have been shown to cause the shrinkage and total regression of tumors in a transgenic murine model system for breast cancer following direct intratumoral injection.

**United States Patent Pending**

**Patent Number:** 09/360,199  
**Inventors:** Bruce A. Vallance, Stephen M. Collins, Jack Gauldie, Yonghong Wan  
**Title:** Intestinal gene therapy

**United States Patent Pending**

**Patent Number:** Filed September 25, 1999  
**Inventors:** Yonghong Wan, William J. Muller, Jack Gauldie, Jonathan Bramson  
**Title:** Cancer immunotherapy targeting ErbB-3

**United States Patent Pending**

**Patent Number:** Filed September 25, 1999  
**Inventors:** Yonghong Wan, William J. Muller, Jack Gauldie, Niki Sharan, Kay Palmer, Peter Emtage  
**Title:** Application of modified receptor tyrosine kinases for cancer gene therapy

**United States Patent Pending**

**Patent Number:** Filed December 13, 1999  
**Inventors:** Yonghong Wan, Jack Gauldie, Jonathan Bramson  
**Title:** Blockade of T cell activation pathway for inducing auto-immunity

## United States Patent Pending

Patent Number: Filed April 26, 2000

Inventors: Yonghong Wan, Jonathan Bramson, Jack Gauldie

Title: Methods of modulating the immune system response to self-antigens

## United States Patent Pending

Patent Number: 09/742,892 Filed 12/21/2000

Inventors: Todd Braciak, Vipin Kumar, Eli Sercarz, Jack Gauldie, Peter Emtage, Frank Graham

Title: Recombinant genetic vaccine for the prevention and treatment of acne

Papers Published or In Press in Refereed Journals

1. Vernon, C.A., Gauldie, J., Hanson, J.M., Humphreys, J.M., Smith, P.E., Lawrence, A.J. and Banks, B.E.C. Acid Phosphatases. *Nature* 208:382-383, 1965.
2. Banks, B.E.C., Doonan, S., Gauldie, J., Lawrence, A.J. and Vernon, C.A. The dissociation into subunits of aspartate aminotransferase from pig-heart muscle. *Eur. J. Biochem.* 6:507-513, 1968.
3. Hillcoat, B.L., Marshall, L., Gauldie, J. and Hiebert, M. Stabilization of dihydrofolate reductase by inhibitors *in vivo* and *in vitro*. *Ann. NY Acad. Sci.* 186:187-208, 1971.
4. Hiebert, M., Gauldie, J. and Hillcoat, B.L. Multiple enzyme forms from protein-bromophenol blue interaction during gel electrophoresis. *Anal. Biochem.* 46:433-437, 1972.
5. Gauldie, J. and Hillcoat, B.L. Purification of tetrahydrofolate dehydrogenase by affinity chromatography. *Biochim. Biophys. Acta* 268:35-40, 1972.
6. Bienenstock, J., Perey, D.Y.E., Gauldie, J. and Underdown, B.J. Chicken immunoglobulin resembling gamma A. *J. Immunol.* 109:403-406, 1972.
7. Gauldie, J., Marshall, L. and Hillcoat, B.L. Purification and properties of dihydrofolate reductase from cultured mammalian cells. *Biochem. J.* 133:349-356, 1973.
8. Bienenstock, J., Perey, D.Y.E., Gauldie, J. and Underdown, B.J. Chicken gamma A: Physiochemical and immunochemical characteristics. *J. Immunol.* 110:524-533, 1973.
9. Dolovich, J., Hargreave, F.E., Chalmers, R., Shier, K.J., Gauldie, J. and Bienenstock, J. Late cutaneous allergic responses in isolated IgE-dependent reactions. *J. Allergy Clin. Immunol.* 52:38-46, 1973.
10. Mant, M.J., Hirsh, J., Gauldie, J., Bienenstock, J., Pineo, G.F. and Luke, K.H. Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. *Blood* 42:429-436, 1973.
11. Bienenstock, J., Gauldie, J. and Perey, D.Y.E. Synthesis of IgG, IgA, IgM by chicken tissues: Immunofluorescent and <sup>14</sup>C amino acid incorporation studies. *J. Immunol.* 111:1112-1118, 1973.
12. Gauldie, J., Bhandari, S.C. and Singal, D.P. Alteration of the HL-A antigenic site *in situ*. *Immunol. Commun.* 4:465-476, 1975.
13. Mant, M.J., Doery, J.C.G., Gauldie, J. and Sims, H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. *Scand. J. Haematol.* 15:161-171, 1975.
14. Clancy, R.L., Gauldie, J., Vallieres, M., Bienenstock, J., Day, R.P. and Pineo, G.F. An approach to immunotherapy using antibody to IgE in mast cell leukemia. *Cancer* 37:693-696, 1976.

15. Keane, P.M., Walker, W.H.C., Gauldie, J. and Abraham, G.E. Thermodynamic aspects of some radioassays. *Clin. Chem.* 22:70-73, 1976.
16. Moore, S., Friedman, R.J., Singal, D.P., Gauldie, J., Blajchman, M.A. and Roberts, R.S. Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. *Thromb. Haemost. (Stuttg.)* 35:70-81, 1976.
17. Gauldie, J., Hanson, J.M., Rumjanek, F.D., Shipolini, R.A. and Vernon, C.A. The peptide components of bee venom. *Eur. J. Biochem.* 61:369-376, 1976.
18. Luxton, A.W., Walker, W.H.C., Gauldie, J., Ali, M.A.M. and Pelletier, C. A radioimmunoassay for serum ferritin. *Clin. Chem.* 23:683-689, 1977.
19. Friedman, R.J., Stemmerman, M.B., Wenz, B., Moore, S., Gauldie, J., Gent, M., Tiell, M. and Spaet, T.H. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. I. Smooth muscle cell proliferation and re-endothelialization. *J. Clin. Invest.* 60:1191-1201, 1977.
20. Gauldie, J., Hanson, J.M., Shipolini, R.A. and Vernon, C.A. The structures of some peptides from bee venom. *Eur. J. Biochem.* 83: 405-410, 1978.
21. Koj, A., Regoeczi, E., Toews, C.J., Leveille, R. and Gauldie, J. Synthesis of antithrombin III and alpha-1-antitrypsin by the perfused rat liver. *Biochim. Biophys. Acta* 539:496-504, 1978.
22. Reimer, C.B., Smith, S.J., Hannon, W.H., Ritchie, R.F., van Es, L., Becker, W., Markowitz, H., Gauldie, J. and Anderson, S.G. Progress towards international reference standards for human serum proteins. *J. Biol. Standardization* 6:133-158, 1978.
23. Armstrong, R.W., Gauldie, J. and Younglai, E.V. Effects of active immunization of female rabbits against testosterone. *J. Endocrinol.* 79: 339-347, 1978.
24. Gauldie, J., Horsewood, P. and Koekkebakker, M. Nephelometric activity as a criterion of adequate antisera for use in immunofluorescence. *Int. Arch. Allergy Appl. Immunol.* 60:186-194, 1979.
25. Track, N.S., Watters, L.M. and Gauldie, J. Motilin, human pancreatic polypeptide (HPP) and gastrin plasma concentrations in fasting subjects. *Clin. Biochem.* 12:109-117, 1979.
26. Kelton, J.G., Neame, P.B., Bishop, J., Ali, M., Gauldie, J. and Hirsh, J. The direct assay for platelet-associated IgG (PAIgG): Lack of association between antibody level and platelet size. *Blood* 53:73-80, 1979.
27. Kelton, J.G., Neame, P.B., Gauldie, J. and Hirsh, J. Elevated platelet associated IgG in the thrombocytopenia of septicemia. *New Engl. J. Med.* 300:760-764, 1979 and 301:271-272, 1979.

28. Ferrier, B.M. and Gauldie, J. Process for selection of medical students at McMaster University. PLET. 16:303-307, 1979.
29. Brotherton, T.W., Chui, D.H.K., Gauldie, J. and Patterson, M. Hemoglobin ontogeny during normal mouse fetal development. Proc. Natl. Acad. Sci. USA 76:2853-2857, 1979.
30. Gauldie, J., Tang, H.K., Corsini, A. and Walker, W.H.C. Solid-phase radioimmunoassay with protein-A-bearing *Staphylococcus aureus* cells used to assay a protein (ferritin) and a hapten (digoxin). Clin. Chem. 26: 37-40, 1980.
31. Lamontagne, L.R. and Gauldie, J. Ontogeny of mouse and rat antithrombin III. Thromb. Res. 20:417-424, 1980.
32. Gauldie, J., Lamontagne, L.R., Horsewood, P. and Jenkins, E. Immunohistochemical localization of alpha-1-antitrypsin in normal mouse liver and pancreas. Am. J. Pathol. 101:723-736, 1980.
33. Koj, A., Wasylewski, Z., Dubin, A. and Gauldie, J. Some immunochemical properties of bovine and rat rhodanese. Folia Biol. 28:121-126, 1980.
34. Vanderbroucke, A.C., Cairns, J.A., Missirlis, E. and Gauldie, J. Radioimmunoassay for dog myoglobin. J. Immunoassay 1:251-269, 1980.
35. Gauldie, J. Selection of medical students. Med. Educ. 14:241-242, 1980.
36. Lamontagne, L.R., Gauldie, J. and Koj, A. Ontogeny and tissue distribution of alpha-1-antitrypsin of the mouse. Biochim. Biophys. Acta 662:15-21, 1981.
37. Kelton, J.G., Moore, J., Gauldie, J., Neame, P.B., Hirsh, J. and Tozman, E. The development and application of a serum assay for platelet-bindable IgG (S-PBIgG). J. Lab. Clin. Med. 98:272-279, 1981.
38. Denburg, J.A., Blajchman, J., Gauldie, J., Horsewood, P., Gill, G., Thomson, G., Beattie, H., Evans, G. and Bienenstock, J. Hypersensitivity to tobacco glycoprotein in human peripheral vascular disease. Ann. Allergy 47:8-13, 1981.
39. Clark, D.A., Gauldie, J., Szewczuk, M.R. and Sweeney, G.D. Enhanced suppressor cell activity as a mechanism of immunosuppression by TCDD. Proc. Soc. Exp. Biol. Med. 168:290-299, 1981.
40. Befus, A.D., Pearce, F.L., Gauldie, J., Horsewood, P. and Bienenstock, J. Mucosal mast cells. I. Isolation and functional characteristics of rat intestinal mast cells. J. Immunol. 128: 2475-2480, 1982.
41. Pearce, F.L., Befus, A.D., Gauldie, J. and Bienenstock, J. Mucosal mast cells. II. Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells. J. Immunol. 128:2481-2486, 1982.

42. Heatley, R.V., Thomas, P., Prokipchuk, E.J., Gauldie, J., Sieniewicz, D.J. and Bienenstock, J. Pulmonary function abnormalities in patients with inflammatory bowel disease. *Q. J. Med.* 203: 241-250, 1982.
43. Kelton, J.G., Denomme, G., Walker, C., Horsewood, P. and Gauldie, J. The measurement of platelet-associated IgG using an immunoradiometric assay. *J. Immunoassay* 4:65-82, 1983.
44. Kelton, J.G., Keystone, J., Moore, J., Denomme, G., Tozman, E., Glynn, M., Neame, P.B., Gauldie, J. and Jensen, J. Immune-mediated thrombocytopenia of malaria. *J. Clin. Invest.* 71:832-836, 1983.
45. Barr, R.D., Storbeck, M.M., Johnston, M.A., Horsewood, P. and Gauldie, J. Detection of human fetal fibrinogen in umbilical cord plasma by parallel assays of immunoreactive and thrombin-clottable protein. *Ann. Clin. Res.* 15:104-108, 1983.
46. Clark, D.A., Sweeney, G.D., Safe, S., Hancock, E., Kilburn, D.G. and Gauldie, J. Cellular and genetic basis for suppression of cytotoxic T cell generation by haloaromatic hydrocarbons. *Immunopharmacology* 6: 143-153, 1983.
47. Gauldie, J., Richards, C.D. and Lamontagne, L.R. Fc receptors for IgA and other immunoglobulins on resident and activated alveolar macrophages. *Mol. Immunol.* 20:1029-1037, 1983.
48. Egwang, T.G., Gauldie, J. and Befus, A.D. Lack of specificity of the C3-opsonized zymosan reagent for the assay of membrane complement receptors. *J. Immunol. Methods.* 61:253-257, 1983.
49. Egwang, T.G., Gauldie, J. and Befus, A.D. Complement-dependent killing of *Nippostrongylus brasiliensis* infective larvae by rat alveolar macrophages. *Clin. Exp. Immunol.* 55:149-156, 1984.
50. Egwang, T.G., Gauldie, J. and Befus, A.D. Broncho-alveolar leucocyte responses during primary and secondary *Nippostrongylus brasiliensis* infection in the rat. *Parasite Immunol.* 6:191-201, 1984.
51. Nagarkatti, P.S., Sweeney, G.D., Gauldie, J. and Clark, D.A. Sensitivity to suppression of cytotoxic T cell generation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on the *Ah* genotype of the murine host. *Toxicol. Appl. Pharmacol.* 72:169-176, 1984.
52. DeBanne, M.T., Bolyos, M., Gauldie, J. and Regoeczi, E. Two populations of prelysosomal structures transporting asialoglycoproteins in the rat liver. *Proc. Natl. Acad. Sci. USA* 81:2995-2999, 1984.
53. Lamontagne, L.R., Gauldie, J., Befus, A.D., McAdam, K.P.W.J., Baltz, M.L. and Pepys, M.B. The acute phase response in parasite infection. *Nippostrongylus brasiliensis* in the mouse. *Immunology* 52:733-741, 1984.



54. Koj, A., Gauldie, J., Regoeczi, E., Sauder, D.N. and Sweeney, G.D. The acute-phase response of cultured rat hepatocytes. System characterization and the effect of human cytokines. *Biochem. J.* 224:505-514, 1984.
55. Entrican, J.H., Denburg, J.A., Gauldie, J. and Kelton, J.G. Angioimmunoblastic lymphadenopathy associated with reserpine. *Lancet* 2:820-821, 1984.
56. Kelton, J.G., Carter, C.J., Rodger, C., Bebenek, G., Gauldie, J., Sheridan, D., Kassam, Y.B., Kean, W.F., Buchanan, W.W., Rooney, P.J., Bianchi, F. and Denburg, J.A. The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function. *Blood* 63:1434-1438, 1984.
57. Koj, A., Regoeczi, E., Chindemi, P.A. and Gauldie, J. Synthesis and turnover of prothrombin during experimental inflammation in rats. *Br. J. Exp. Pathol.* 65:691-700, 1984.
58. Egwang, T.G., Befus, A.D. and Gauldie, J. Activation of alveolar macrophages following infection with the parasitic nematode *Nippostrongylus brasiliensis*. *Immunology* 54:581-588, 1985.
59. Lamontagne, L.R., Stadnyk, A.W. and Gauldie, J. Synthesis of alpha-1-protease inhibitor by resident and activated mouse alveolar macrophages. *Am. Rev. Respir. Dis.* 131:321-325, 1985.
60. Lamontagne, L.R., Gauldie, J., Stadnyk, A.W., Richards, C.D. and Jenkins, E. *In vivo* initiation of unstimulated *in vitro* interleukin-1 release by alveolar macrophages. *Am. Rev. Respir. Dis.* 131:326-330, 1985.
61. Koj, A., Gauldie, J., Sweeney, G.D., Regoeczi, E. and Sauder, D.N. A simple bioassay for monocyte-derived hepatocyte stimulating factor: Increased synthesis of alpha-2-macroglobulin and reduced synthesis of albumin by cultured rat hepatocytes. *J. Immunol. Methods* 76:317-327, 1985.
62. Richards, C.D. and Gauldie, J. IgA-mediated phagocytosis by mouse alveolar macrophages. *Am. Rev. Respir. Dis.* 132:82-85, 1985.
63. Egwang, T.G., Richards, C.D., Stadnyk, A.W., Gauldie, J. and Befus, A.D. Multinucleate giant cells in murine and rat lungs during *Nippostrongylus brasiliensis* infections. A study of the kinetics of the response *in vivo*, cytochemistry, IgG- and C3-mediated functions. *Parasite Immunol.* 7:11-18, 1985.
64. Kelton, J.G., Singer, J., Rodger, C., Gauldie, J., Horsewood, P. and Dent, P. The concentration of IgG in the serum is a major determinant of Fc-dependent reticuloendothelial function. *Blood* 66:490-495, 1985.
65. Gauldie, J., Lamontagne, L.R. and Stadnyk, A.W. Acute phase response in infectious disease. *Surv. Synth. Pathol. Res.* 4:126-151, 1985.
66. Mitchell, L.A., Pearson, T.W. and Gauldie, J. Interleukin-1 and interleukin-2 production in resistant and susceptible inbred mice infected with *Trypanosoma congolense*. *Immunology* 57:291-296, 1986.

67. Stuart, M.J., Walenga, R.W., Sadowitz, P.D., Maltby, A., Kelton, J.G. and Gauldie, J. Bleeding time in hemophilia A: potential mechanisms for prolongation. *J. Pediatr.* 108:215-218, 1986.
68. Befus, A.D., Lee, T.D.G., Ernst, P., Egwang, T.G., McElroy, P.J., Gauldie, J. and Bienenstock, J. Unique characteristics of local responses in host resistance to mucosal parasitic infections. *Vet. Parasitol.* 20:175-194, 1986.
69. Koj, A., Rokita, H., Magielska-Zero, D., Kurdowska, A., Bereta, J. and Gauldie, J. Enhanced uptake of amino acids by rat hepatocytes cultured in the presence of macrophage cytokines. *Prot. Biol. Fluids* 34: 537-540, 1986.
70. Gauldie, J., Sauder, D.N., McAdam, K.P.W.J. and Dinarello, C.A. Purified interleukin-1 (IL-1) from human monocytes stimulates acute-phase protein synthesis by rodent hepatocytes *in vitro*. *Immunology* 60:203-207, 1987.
71. Koj, A., Kurdowska, A., Magielska-Zero, D., Rokita, H., Sipe, J., Dayer, J.M., Demczuk, S. and Gauldie, J. Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. *Biochem. Int.* 14:553-560, 1987.
72. Bienenstock, J., Tomioka, M., Stead, R., Ernst, P., Jordana, M., Gauldie, J., Dolovich, J. and Denburg, J. Mast cell involvement in various inflammatory processes. *Am. Rev. Respir. Dis.* 135:S5-S8, 1987.
73. Jordana, M., Newhouse, M.T. and Gauldie, J. Alveolar macrophage/ peripheral blood monocyte-derived factors modulate proliferation of primary lines of human lung fibroblasts. *J. Leukoc. Biol.* 42:51-60, 1987.
74. Magielska-Zero, D., Rokita, H., Cieszka, K., Kurdowska, A., Koj, A., Sipe, J.D. and Gauldie, J. Comparison of the acute phase response of cultured Morris hepatoma 7777 cells and of rat hepatocytes. *Br. J. Exp. Pathol.* 68:485-492, 1987.
75. Baumann, H., Onorato, V., Gauldie, J. and Jahreis, G.P. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. *J. Biol. Chem.* 262:9756-9768, 1987.
76. Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. and Baumann, H. Interferon  $\beta_2$ /B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. *Proc. Natl. Acad. Sci. USA* 84:7251-7255, 1987.
77. Egwang, T.G., Gauldie, J. and Befus, A.D. The role of rat C3 and C3 receptor-bearing alveolar macrophages in *in vitro* attrition of infective larvae of *Nippostrongylus brasiliensis*. *J. Parasitol.* 73:1270-1273, 1987.

78. Baumann, H., Richards, C. and Gauldie, J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. *J. Immunol.* 139:4122-4128, 1987.
79. Pillai, P.S., Reynolds, S.D., Scott, D.W., Gauldie, J. and Sauder, D.N. Role of epidermal cell thymocyte-activating factor in the proliferation and differentiation of murine B cells. *J. Leukoc. Biol.* 42:222-229, 1987.
80. Smith, S.J., Cooper, G.R., Henderson, L.O., Hannon, W.H. and the Apolipoprotein Standardization Collaborating Group: Alaupovic, P., Assmann, G., Bachorik, P.S., Calvert, G.D., Connelly, P.W., Demacker, P.N.M., Dolphin, P.J., Fruchart, J.C., Gauldie, J., Ginsberg, H., Goldberg, R.B., Havekes, L., Herbert, P.N., Kostner, G.M., Lopes-Virella, M.F., Muesing, R., Prasad, S.C., Patsch, W., Riesen, W., Rosseneu, M., Rudel, L.L., Schonfeld, G., Smith, R.S., Stein, E.A., Tanaka, A. and Weisweiler, P. An international collaborative study on standardization of apolipoproteins A-I and B. Part I. Evaluation of a lyophilized candidate reference and calibration material. *Clin. Chem.* 33:2240-2249, 1987.
81. Jordana, M., Schulman, J., McSharry, C., Irving, L.B., Newhouse, M.T., Jordana, G. and Gauldie, J. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. *Am. Rev. Respir. Dis.* 137:579-584, 1988.
82. Koj, A., Gordon, A.H. and Gauldie, J. An alternative regulatory pathway of the acute phase response: the role of fibroblast-derived interferon- $\beta$ 2. *Experientia* 44:9-10, 1988.
83. Jordana, M., Richards, C., Irving, L.B. and Gauldie, J. Spontaneous *in vitro* release of alveolar-macrophage cytokines after the intratracheal instillation of bleomycin in rats. Characterization and kinetic studies. *Am. Rev. Respir. Dis.* 137:1135-1140, 1988.
84. Bienenstock, J. and Gauldie, J. Cellular interactions in lung inflammation and immunity. *Postgrad. Med. J.* 64: 111-119, 1988.
85. Jordana, M., Dolovich, M., Irving, L.B., Tomioka, M., Befus, A.D., Gauldie, J. and Newhouse, M.T. Solute movement across the alveolar-capillary membrane after intratracheally administered bleomycin in rats. *Am. Rev. Respir. Dis.* 138:96-100, 1988.
86. Jordana, M., Befus, A.D., Newhouse, M.T., Bienenstock, J. and Gauldie, J. Effect of histamine on proliferation of normal human adult lung fibroblasts. *Thorax* 43:552-558, 1988.
87. Magielska-Zero, D., Bereta, J., Czuba-Pelech, B., Pajdak, W., Gauldie, J. and Koj, A. Inhibitory effect of human recombinant interferon gamma on synthesis of acute phase proteins in human hepatoma Hep G2 cells stimulated by leukocyte cytokines, TNF $\alpha$  and IFN- $\beta$ 2/BSF-2/IL-6. *Biochem. Int.* 17:17-23, 1988.

88. Luo, H.-Y., Clarke, B.J., Gauldie, J., Patterson, M., Liao, S.-K. and Chui, D.H.K. A novel monoclonal antibody based diagnostic test for  $\Delta$ -Thalassemia-1 carriers due to the (-SEA/) deletion. *Blood* 72:1589-1594, 1988.
89. Modha, J., Parikh, V., Gauldie, J. and Doenhoff, M.J. An association between schistosomes and contrapsin, a mouse serine protease inhibitor (serpin). *Parasitology* 96:99-109, 1988.
90. Koj, A., Magielska-Zero, D., Bereta, J., Kurdowska, A., Rokita, H. and Gauldie, J. The cascade of inflammatory cytokines regulating synthesis of acute phase proteins. *Tokai J. Exp. Clin. Med.* 13:255-264, 1988.
91. Jordana, M., Xaubet, A. and Gauldie, J. Fibrosis of the Lung: current perspectives. *Arch. de Bronconeum.* 25:336-344, 1989.
92. Jordana, M., Vancheri, C., Ohtoshi, T., Harnish, D., Gauldie, J., Dolovich, J. and Denburg, J. Hemopoietic function of the microenvironment in chronic airway inflammation. *Agents Actions Suppl.* 28:85-95, 1989.
93. Sestini, P., Dolovich, M., Vancheri, C., Stead, R.H., Marshall, J.S., Perdue, M., Gauldie, J. and Bienenstock, J. Antigen-induced lung solute clearance in rats is dependent on capsaicin-sensitive nerves. *Am. Rev. Respir. Dis.* 139:401-406, 1989.
94. Bereta, J., Kurdowska, A., Koj, A., Hirano, T., Kishimoto, T., Content, J., Fiers, W., Van Damme, J. and Gauldie, J. Different preparations of natural and recombinant human interleukin-6 (IFN- $\beta$ 2, BSF-2) similarly stimulate acute phase protein synthesis and uptake of  $\Delta$ -aminoisobutyric acid by cultured rat hepatocytes. *Int. J. Biochem.* 21:361-366, 1989.
95. Vancheri, C., Gauldie, J., Bienenstock, J., Cox, G., Scicchitano, R., Stanis, A. and Jordana, M. Human lung fibroblast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) mediates eosinophil survival *in vitro*. *Am. J. Respir. Cell Mol. Biol.* 1:289-295, 1989.
96. Penney, C.L., Gauldie, J., Eveleigh, M., Penney, M.T., Chong, D. and Horsewood, P. Polycarbonate membranes: A novel surface for solid phase determinations with utility in field format serological assays. *J. Immunol. Methods* 123:185-192, 1989.
97. Gaddy-Kurten, D., Hickey, G.J., Fey, G.H., Gauldie, J. and Richards, J.S. Hormonal regulation and tissue-specific localization of  $\Delta$ 2-macroglobulin in rat ovarian follicles and corpora lutea. *Endocrinology* 125:2985-2995, 1989.
98. Flores, E.A., Drabik, M., Gauldie, J., Blackburn, G.L., Dinarello, C.A. and Bistrian, B.R. Leukocyte endogenous mediator fails to alter protein dynamics in a model of liver dysfunction. *J. Lab. Clin. Med.* 113:211-220, 1989.

99. Gauldie, J., Richards, C., Northemann, W., Fey, G. and Baumann, H. IFN $\beta$ /BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. *Ann. NY Acad. Sci. USA* 557:46-59, 1989.
100. Fey, G.H., Hattori, M., Northemann, W., Abraham, L.J., Baumann, M., Braciak, T.A., Fletcher, R.G., Gauldie, J., Lee, F. and Reymond, M.F. Regulation of rat liver acute phase genes by Interleukin-6 and production of hepatocyte stimulating factors by rat hepatoma cells. *Ann. NY Acad. Sci. USA* 557:317-331, 1989.
101. Stadnyk, A.W., Befus, A.D. and Gauldie, J. Characterization of nonspecific esterase activity in macrophages and intestinal epithelium of the rat. *J. Histochem. Cytochem.* 38:1-6, 1990.
102. Rokita, H., Bereta, J., Koj, A., Gordon, A.H. and Gauldie, J. Epidermal growth factor and transforming growth factor-E differently modulate the acute phase response elicited by interleukin-6 in cultured liver cells from man, rat and mouse. *Comp. Biochem. Physiol.* 95A:41-45, 1990.
103. Baumann, H. and Gauldie, J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. *Mol. Biol. Med.* 7:147-159, 1990.
104. Stadnyk, A.W., Baumann, H. and Gauldie, J. The acute phase protein response in parasite infection. *Nippostrongylus brasiliensis* and *Trichinella spiralis* in the rat. *Immunology* 69:588-595, 1990.
105. LaMarre, J., Wollenberg, G.K., Gauldie, J. and Hayes, M.A.  $\Delta$ 2-macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-E2 in rat hepatocytes. *Lab. Invest.* 62:545-551, 1990.
106. Gauldie, J., Northemann, W. and Fey, G.H. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. *J. Immunol.* 144:3804-3808, 1990.
107. Northemann, W., Hattori, M., Baffet, G., Braciak, T.A., Fletcher, R.G., Abraham, L.J., Gauldie, J., Baumann, M. and Fey, G.H. Production of interleukin 6 by hepatoma cells. *Mol. Biol. Med.* 7:273-285, 1990.
108. Stadnyk, A.W., McElroy, P.J., Gauldie, J. and Befus, A.D. Characterization of *Nippostrongylus brasiliensis* infection in different strains of mice. *J. Parasitol.* 76:377-382, 1990.
109. Bereta, J., Szuba, K., Fiers, W., Gauldie, J. and Koj, A. Transforming growth factor-E and epidermal growth factor modulate basal and interleukin-6-induced amino acid uptake and acute phase protein synthesis in cultured rat hepatocytes. *FEBS Lett.* 266:48-50, 1990.
110. Denburg, J.A., Dolovich, J., Ohtoshi, T., Cox, G., Gauldie, J. and Jordana, M. The microenvironmental differentiation hypothesis of airway inflammation. *Am. J. Rhinol.* 4:29-32, 1990.

111. Stadnyk, A.W. and Gauldie, J. The acute phase protein response during parasitic infection. *Immunol. Today* 12:A7-A12, 1991.
112. Ohtoshi, T., Tsuda, T., Vancheri, C., Abrams, J.S., Gauldie, J., Dolovich, J., Denburg, J.A. and Jordana, M. Human upper airway epithelial cell-derived granulocyte-macrophage colony-stimulating factor induces histamine-containing cell differentiation of human progenitor cells. *Int. Arch. Allergy Appl. Immunol.* 95:376-384, 1991.
113. Ohtoshi, T., Vancheri, C., Cox, G., Gauldie, J., Dolovich, J., Denburg, J. and Jordana, M. Monocyte-macrophage differentiation induced by human upper airway epithelial cells. *Am. J. Respir. Cell Mol. Biol.* 4:255-263, 1991.
114. Vancheri, C., Ohtoshi, T., Cox, G., Xaubet, A., Abrams, J.S., Gauldie, J., Dolovich, J., Denburg, J. and Jordana, M. Neutrophilic differentiation induced by human upper airway fibroblast-derived granulocyte/ macrophage colony-stimulating factor (GM-CSF). *Am. J. Respir. Cell Mol. Biol.* 4:11-17, 1991.
115. Cox, G., Ohtoshi, T., Vancheri, C., Denburg, J.A., Dolovich, J., Gauldie, J. and Jordana, M. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. *Am. J. Respir. Cell Mol. Biol.* 4:525-531, 1991.
116. Braciak, T.A., Gauldie, J., Fey, G.H. and Northemann, W. The expression of interleukin-6 by a rat macrophage-derived cell line. *FEBS Lett.* 280:277-280, 1991.
117. Baffet, G., Braciak, T.A., Fletcher, R.G., Gauldie, J., Fey, G.H. and Northemann, W. Autocrine activity of interleukin 6 secreted by hepatocarcinoma cell lines. *Mol. Biol. Med.* 8:141-156, 1991.
118. Wollenberg, G.K., LaMarre, J., Semple, E., Farber, E., Gauldie, J. and Hayes, M.A. Counteracting effects of dexamethasone and  $\Delta 2$ -macroglobulin on inhibition of proliferation of normal and neoplastic rat hepatocytes by transforming growth factors-E type 1 and type 2. *Int. J. Cancer* 47:311-316, 1991.
119. Richards, C., Gauldie, J. and Baumann, H. Cytokine control of acute phase protein expression. *Eur. Cytokine Netw.* 2:89-98, 1991.
120. Denburg, J.A., Gauldie, J., Dolovich, J., Ohtoshi, T., Cox, G. and Jordana, M. Structural cell-derived cytokines in allergic inflammation. *Int. Arch. Allergy Appl. Immunol.* 94:127-132, 1991.
121. Kordula, T., Rokita, H., Koj, A., Fiers, W., Gauldie, J. and Baumann, H. Effects of interleukin-6 and leukemia inhibitory factor on the acute phase response and DNA synthesis in cultured rat hepatocytes. *Lymphokine Cytokine Res.* 10:23-26, 1991.
122. Ohno, I. Lea, R., Finotto, S., Marshall, J., Denburg, J., Dolovich, J., Gauldie, J. and Jordana, M. Granulocyte/macrophage colony-stimulating factor (GM-CSF) gene expression by eosinophils in nasal polyposis. *Am. J. Respir. Cell Mol. Biol.* 5:505-510, 1991.

123. Rothwell, N.J., Busbridge, N.J., LeFeuvre, R.A., Hardwick, A.J., Gauldie, J. and Hopkins, S.J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. *Can. J. Physiol. Pharmacol.* 69:1465-1469, 1991.
124. Gauldie, J., Jordana, M., Cox, G., Ohtoshi, T., Dolovich, J. and Denburg, J. Fibroblasts and other structural cells in airway inflammation. *Am. Rev. Respir. Dis.* 145:S14-S17, 1992.
125. Ludwin, D., Sandler, S., Russell, J.D., Churchill, D.N. and Gauldie, J. The relationship between cadaver donor interleukin 6 levels and delayed graft function in kidney transplantation. *Transplantation* 53:222-223, 1992.
126. Xing, Z., Jordana, M. and Gauldie, J. IL-1E and IL-6 gene expression in alveolar macrophages: modulation by extracellular matrices. *Am. J. Physiol.* 262:L600-L605, 1992.
127. Xing, Z., Ohtoshi, T., Ralph, P., Gauldie, J. and Jordana, M. Human upper airway structural cell-derived cytokines support human peripheral blood monocyte survival: a potential mechanism for monocyte/macrophage accumulation in the tissue. *Am. J. Respir. Cell Mol. Biol.* 6:212-218, 1992.
128. Cox, G., Gauldie, J. and Jordana, M. Bronchial epithelial cell-derived cytokines (G-CSF and GM-CSF) promote the survival of peripheral blood neutrophils *in vitro*. *Am. J. Respir. Cell Mol. Biol.* 7:507-513, 1992.
129. Ohno, I., Lea, R.G., Flanders, K.C., Clark, D.A., Banwatt, D., Dolovich, J., Denburg, J., Harley, C.B., Gauldie, J. and Jordana, M. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor E1 gene (TGFE1). *J. Clin. Invest.* 89:1662-1668, 1992.
130. Richards, C.D., Brown, T.J., Shoyab, M., Baumann, H. and Gauldie, J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes *in vitro*. *J. Immunol.* 148:1731-1736, 1992.
131. Hill, R.J., Warren, M.K., Levin, J. and Gauldie, J. Evidence that interleukin-6 does not play a role in the stimulation of platelet production after induction of acute thrombocytopenia. *Blood* 80:346-351, 1992.
132. Gauldie, J., Richards, C. and Baumann, H. IL6 and the acute phase reaction. *Res. Immunol.* 143:755-759, 1992.
133. Gu, Y., Jayatilak, P.G., Parmer, T.G., Gauldie, J., Fey, G.H. and Gibori, G.  $\Delta 2$ -macroglobulin expression in the mesometrial decidua and its regulation by decidual luteotropin and prolactin. *Endocrinology* 131:1321-1328, 1992.
134. Podor, T.J., Joshua, P., Butcher, M., Seiffert, D., Loskutoff, D. and Gauldie, J. Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. *Ann. NY Acad. Sci.* 667:173-177, 1992.

135. Sierra, F., Coeytaux, S., Juillerat, M., Ruffieux, C., Gauldie, J., Guigoz, Y. Serum T-kininogen levels increase shortly before death. *Ann. NY Acad. Sci.* 663:479-480, 1992.
136. Sierra, F., Coeytaux, S., Juillerat, M., Ruffieux, C., Gauldie, J., Guigoz, Y. Serum T-kininogen levels increase two to four months before death. *J. Biol. Chem.* 267:10665-10669, 1992.
137. Podor, T.J., Hirsh, J., Gelehrter, T.D., Zeheb, R., Torry, D., Guigoz, Y., Sierra, F. and Gauldie, J. Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6 and hepatocyte-dependent synthesis. *J. Immunol.* 150:225-235, 1993.
138. Geisterfer, M., Richards, C., Baumann, M., Fey, G., Gwynne, D. and Gauldie, J. Regulation of IL-6 and the hepatic IL-6 receptor in acute inflammation *in vivo*. *Cytokine* 5:1-7, 1993.
139. Marshall, J.S., Gauldie, J., Nielsen, L. and Bienenstock, J. Leukemia inhibitory factor production by rat mast cells. *Eur. J. Immunol.* 23:2116-2120, 1993.
140. Xing, Z., Jordana, M., Braciak, T., Ohtoshi, T. and Gauldie, J. Lipopolysaccharide induces expression of granulocyte/macrophage colony-stimulating factor, interleukin-8 and interleukin-6 in human nasal, but not lung, fibroblasts: Evidence for heterogeneity within the respiratory tract. *Am. J. Respir. Cell Mol. Biol.* 9:255-263, 1993.
141. Xing, Z., Kirpalani, H., Torry, D., Jordana, M. and Gauldie, J. Polymorphonuclear leukocytes as a significant source of tumor necrosis factor- $\alpha$  in endotoxin-challenged lung tissue. *Am. J. Pathol.* 143:1009-1015, 1993.
142. Richards, C.D., Shoyab, M., Brown, T.J. and Gauldie, J. Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. *J. Immunol.* 150:5596-5603, 1993.
143. Braciak, T.A., Mittal, S.K., Graham, F.L., Richards, C.D. and Gauldie, J. Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes: An approach to investigate *in vivo* cytokine function. *J. Immunol.* 151:5145-5153, 1993.
144. Baumann, H. and Gauldie, J. The acute phase response. *Immunol. Today* 15:74-80, 1994.
145. Xing, Z., Jordana, M., Kirpalani, H., Driscoll, K.E., Schall, T.J. and Gauldie, J. Cytokine expression by neutrophils and macrophages *in vivo*: Endotoxin induces tumor necrosis factor  $\alpha$ , macrophage inflammatory protein-2, interleukin-1E, and interleukin-6, but not RANTES or transforming growth factor- $\beta$ 1 mRNA expression in acute lung inflammation. *Am. J. Respir. Cell Mol. Biol.* 10:148-153, 1994.
146. Torry, D.J., Richards, C.D., Podor, T.J. and Gauldie, J. Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue. *J. Clin. Invest.* 93:1525-1532, 1994.



147. Henderson, J.T., Seniuk, N.A., Richardson, P.M., Gauldie, J. and Roder, J.C. Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. *J. Clin. Invest.* 93:2632-2638, 1994.
148. Xing, Z., Braciak, T., Jordana, M., Croitoru, K., Graham, F.L. and Gauldie, J. Adenovirus-mediated cytokine gene transfer at tissue sites: Overexpression of IL-6 induces lymphocytic hyperplasia in the lung. *J. Immunol.* 153:4059-4069, 1994.
149. Sallenave, J.-M., Schulman, J., Crossley, J., Jordana, M. and Gauldie, J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. *Am. J. Respir. Cell Mol. Biol.* 11:733-741, 1994.
150. Finotto, S., Ohno, I., Marshall, J.S., Gauldie, J., Denburg, J.A., Dolovich, J., Clark, D.A. and Jordana, M. TNF- $\Delta$  production by eosinophils in upper airways inflammation (nasal polyposis). *J. Immunol.* 153:2278-2289, 1994.
151. Wallace, V.A., Kondo, S., Kono, T., Xing, Z., Timms, E., Furlonger, C., Keystone, E., Gauldie, J., Sauder, D.N., Mak, T.W. and Paige, C.J. A role for CD4<sup>+</sup> T cells in the pathogenesis of skin fibrosis in tight skin mice. *Eur. J. Immunol.* 24:1463-1466, 1994.
152. Geisterfer, M., Richards, C.D. and Gauldie, J. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). *Cytokine* 7:503-509, 1995.
153. Addison, C.L., Braciak, T., Ralston, R., Muller, W.J., Gauldie, J. and Graham, F.L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. *Proc. Natl. Acad. Sci. USA* 92:8522-8526, 1995.
154. Teoh, K.H.T., Bradley, C.A., Gauldie, J. and Burrows, H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. *Circulation* 92:II347-II353, 1995.
155. Seiffert, D., Geisterfer, M., Gauldie, J., Young, E. and Podor, T.J. IL-6 stimulates vitronectin gene expression *in vivo*. *J. Immunol.* 155:3180-3185, 1995.
156. Addison, C.L., Gauldie, J., Muller, W.J. and Graham, F.L. An adenoviral vector expressing Interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. *Int. J. Oncol.* 7: 1253-1260, 1995.
157. Richards, C.D., Braciak, T., Xing, Z., Graham, F. and Gauldie, J. Adenovirus vectors for cytokine gene expression. *Ann. NY Acad. Sci.* 762:282-293, 1995.
158. Bramson, J.L., Graham, F.L. and Gauldie, J. The use of adenoviral vectors for gene therapy and gene transfer *in vivo*. *Curr. Opin. Biotechnol.* 6:590-595, 1995.

159. Richards, C.D., Langdon, C., Pennica, D. and Gauldie, J. Murine cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells. *J. Interferon Cytokine Res.* 16:69-75, 1996.
160. Torry, D.J., Richards, C.D., Podor, T.J. and Gauldie, J. Modulation of the anchorage-independent phenotype of human lung fibroblasts obtained from fibrotic tissue following culture with retinoid and corticosteroid. *Exp. Lung Res.* 22:231-244, 1996.
161. Geisterfer, M. and Gauldie, J. Regulation of signal transducer, gp130, and the LIF receptor in acute inflammation *in vivo*. *Cytokine* 8:283-287, 1996.
162. Bramson, J., Hitt, M., Gallichan, W.S., Rosenthal, K.L., Gauldie, J. and Graham, F.L. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: *In vitro* and *in vivo* production of biologically active interleukin 12. *Hum. Gene Ther.* 7:333-342, 1996.
163. Xing, Z., Ohkawara, Y., Jordana, M., Graham, F.L. and Gauldie, J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis and fibrotic reactions. *J. Clin. Invest.* 97:1102-1110, 1996.
164. Gauldie, J., Graham, F., Xing, Z., Braciak, T., Foley, R. and Sime, P.J. Adenovirus vector mediated cytokine gene transfer to lung tissue. *Ann. NY Acad Sci.* 796:235-244, 1996.
165. Xing, Z., Braciak, T., Ohkawara, Y., Sallenave, J.M., Foley, R., Sime, P.J., Jordana, M., Graham, F.L. and Gauldie, J. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. *J. Leukoc. Biol.* 59:481-488, 1996.
166. Tremblay, G.M., Sallenave, J.-M., Israel-Assayag, E., Cormier, Y. and Gauldie, J. Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and Farmer's Lung. *Am. J. Respir. Crit. Care Med.* 154:1092-1098, 1996.
167. Foley, R., Driscoll, K., Wan, Y., Braciak, T., Howard, B., Xing, Z., Graham, F. and Gauldie, J. Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung. *Am. J. Pathol.* 149:1395-1403, 1996.
168. Braciak, T.A., Northemann, W., Chong, D.K., Schroeder, J.A. and Gauldie, J. Vector-derived expression of recombinant rat interleukin-6. *Protein Expr. Purif.* 7:269-274, 1996.
169. Bell, M.D., Taub, D.D., Kunkel, S.J., Strieter, R.M., Foley, R., Gauldie, J. and Perry, V.H. Recombinant human adenovirus with rat MIP-2 gene insertion causes prolonged PMN recruitment to the murine brain. *Eur. J. Neurosci.* 8:1803-1811, 1996.
170. Thibault, V., Terlain, B. and Gauldie, J. Characterization and biological activities of recombinant rat soluble Interleukin-6 receptor. *J. Interferon Cytokine Res* 16:973-981, 1996.

171. Braciak, T.A., Bacon, K., Xing, Z., Torry, D.J., Graham, F.L., Schall, T.J., Richards, C.D., Croitoru, K. and Gauldie, J. Overexpression of RANTES using a recombinant Adenovirus vector induces the tissue-directed recruitment of monocytes to the lung. *J. Immunol.* 157:5076-5084, 1996.
172. Bramson, J.L., Hitt, M., Addison, C.L., Muller, W.J., Gauldie, J. and Graham, F.L. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. *Hum. Gene Ther.* 7:1995-2002, 1996.
173. Greenberger, M.J., Kunkel, S.L., Strieter, R.M., Lukacs, N.W., Bramson, J., Gauldie, J., Graham, F.L., Hitt, M., Danforth, J.M. and Standiford, T.J. IL-12 gene therapy protects mice in lethal *Klebsiella pneumoniae*. *J. Immunol.* 157:3006-3012, 1996.
174. Ling, P.R., Schwartz, J.H., Jeevanandam, M., Gauldie, J. and Bistran, B.R. Metabolic changes in rats during a continuous infusion of recombinant interleukin-1. *Am. J. Physiol.* 270:E305-E312, 1996.
175. Xing, Z., Tremblay, G.M., Sime, P.J. and Gauldie, J. Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-E1 and myofibroblast accumulation. *Am. J. Pathol.* 150:59-66, 1997.
176. Xing, Z., Ohkawara, Y., Jordana, M., Graham, F.L. and Gauldie, J. Adenoviral vector-mediated interleukin-10 expression *in vivo*: intramuscular gene transfer inhibits cytokine responses in endotoxemia. *Gene Ther.* 4:140-149, 1997.
177. Tremblay, G.M., Nonaka, M., Sarnstrand, B., Dolovich, J., Gauldie, J. and Jordana, M. Myofibroblasts in nasal polyposis: regulation by topical steroids. *Can. Respir. J.* 4:205-210, 1997.
178. Foley, R., Ellis, R., Walker, I., Wan, Y., Carter, R., Boyle, M., Braciak, T., Addison, C., Graham, F. and Gauldie, J. Intramarrow cytokine gene transfer by adenoviral vectors in dogs. *Hum. Gene Ther.* 8:545-553, 1997.
179. Sallenave, J.M., Si-Tahar, M., Cox, G., Chignard, M. and Gauldie, J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. *J. Leukoc. Biol.* 61:695-702, 1997.
180. Thibault, V., Richards, C.D., Botelho, F. and Gauldie, J. Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation. *FEBS Lett.* 408:182-186, 1997.
181. Wan, Y., Bramson, J., Carter, R., Graham, F. and Gauldie, J. Dendritic cells transduced with an adenovirus vector encoding a model tumor-associated antigen for tumor vaccination. *Hum. Gene Ther.* 8:1355-1363, 1997.
182. Sime, P.J., Xing, Z., Graham, F.L., Csaky, K.G. and Gauldie, J. Adenovector-mediated gene transfer of active TGF-E1 induces prolonged severe fibrosis in rat lung. *J. Clin. Invest.* 100:768-776, 1997.

183. Thibault, V., Terlain, B., Graham, F.L. and Gauldie, J. Construction and characterization of a replication-deficient adenovirus expressing rat-soluble interleukin-6 receptor. *Mol. Med.* 3:519-529, 1997.
184. Vadas, P., Grouix, B., Stefanski, E., Wloch, M., Pruzanski, W., Schroeder, J. and Gauldie, J. Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells. *Clin. Exp. Immunol.* 108:175-180, 1997.
185. Sallenave, J.M., Tremblay, G.M., Gauldie, J. and Richards, C.D. Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha<sub>1</sub>-proteinase inhibitor in A549 human alveolar epithelial cells. *J. Interferon Cytokine Res.* 17:337-346, 1997.
186. Stewart, A.K., Lassam, N.J., Graham, F.L., Gauldie, J., Addison, C.L., Bailey, D.J., Dessureault, S., Dube, I.D., Gallenger, S., Krajden, M., Rotstein, L.E., Quirt, I.C., and Moen, R. Clinical Protocol. A Phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. *Hum. Gene Ther.* 8:1403-1414, 1997.
187. Sakic, B., Szechtman, H., Braciak, T., Richards, C., Gauldie, J. and Denburg, J.A. Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. *Brain Res. Bull.* 44:155-165, 1997.
188. Lukacs, N.W., Addison, C.L., Gauldie, J., Graham, F., Simpson, K., Strieter, R.M., Warmington, K., Chensue, S.W. and Kunkel, S.L. Transgene-induced production of IL-4 alters the development and collagen expression of T helper cell 1-type pulmonary granulomas. *J. Immunol.* 158:4478-4484, 1997.
189. Sime, P.J., Xing, Z., Foley, R., Graham, F.L. and Gauldie, J. Transient gene transfer and expression in the lung. *Chest* 111:89S-94S, 1997.
190. Putzer, B.M., Hitt, M., Muller, W.J., Emtage, P., Gauldie, J. and Graham, F.L. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. *Proc. Natl. Acad. Sci. USA* 94:10889-10894, 1997.
191. Bramson, J.L., Hitt, M., Gauldie, J. and Graham, F.L. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. *Gene Therapy* 4:1069-1076, 1997.
192. Xing, Z., Gauldie, J., Tremblay, G.M., Hewlett, B.R. and Addison, C. Intradermal transgenic expression of granulocyte-macrophage colony-stimulating factor induces neutrophilia, epidermal hyperplasia, Langerhans' cell/macrophage accumulation, and dermal fibrosis. *Lab. Invest.* 77:615-622, 1997.

193. Marr, R.A., Addison, C.L., Snider, D., Muller, W.J., Gauldie, J. and Graham, F.L. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF $\Delta$ . *Gene Ther.* 4:1181-1188, 1997.
194. Zisman, D.A., Kunkel, S.L., Strieter, R.M., Gauldie, J., Tsai, W.C., Bramson, J., Wilkowski, J.M., Bucknell, K.A. and Standiford T.J. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine *Escherichia coli* peritoneal sepsis. *Shock* 8:349-356, 1997.
195. Hogaboam, C.M., Vallance, B.A., Kumar, A., Addison, C.L., Graham, F.L., Gauldie, J. and Collins, S.M. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. *J. Clin. Invest.* 100:2766-2776, 1997.
196. Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F. and Achong, M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. *J. Clin. Invest.* 101:311-320, 1998.
197. Emtage, P.C.R., Wan, Y., Bramson, J.L., Graham, F.L. and Gauldie, J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. *J. Immunol.* 160:2531-2538, 1998.
198. Marr, R., Hitt, M., Muller, W.J., Gauldie, J. and Graham, F.L. Tumour therapy in mice using adenovirus vectors expressing human TNF-alpha. *Intl. J. Oncol.* 12:509-515, 1998.
199. Stewart, A.K., Schimmer, A.D., Bailey, D.J., Dube, I.D., Cappe, D., Moen, R.C., Gauldie, J. and Graham, F.L. *In vivo* adenoviral mediated gene transfer of interleukin 2 in cutaneous plasmacytoma. *Blood* 91:1095-1097, 1998.
200. Parks, E., Strieter, R.M., Lukacs, N.W., Gauldie, J., Hitt, M., Graham, F.L. and Kunkel, S.L. Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. *J. Immunol.* 160:4615-4619, 1998.
201. Zhao, J., Sime, P.J., Bringas, P., Gauldie, J. and Warburton, D. Epithelium-specific adenoviral transfer of a dominant-negative mutant TGF-E type II receptor stimulates embryonic lung branching morphogenesis in culture and potentiates EGF and PDGF-AA. *Mech. Dev.* 72:89-100, 1998.
202. Boehler, A., Chamberlain, D., Xing, Z., Slutsky, A.S., Jordana, M., Gauldie, J., Liu, M. and Keshavjee, S. Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans. *Hum. Gene Ther.* 9:541-551, 1998.
203. Wei, M.X., Li, F., Ono, Y., Gauldie, J. and Chiocca, E.A. Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. *J. Neurovirol.* 4:237-241, 1998.

204. Sime, P.J., Marr, R.A., Gauldie, D., Xing, Z., Hewlett, B.R., Graham, F.L. and Gauldie, J. Transfer of TNF $\alpha$  to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of TGF-E1 and myofibroblasts. *Am. J. Pathol.* 153:825-832, 1998.
205. Foley, R., Walker, I., Greene, K., Wan, Y., Couban, S., Messner, H. and Gauldie, J. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. *Bone Marrow Transplant.* 21:769-773, 1998.
206. Tremblay, G.M., Chakir, J., Boulet, L.P., Jordana, M., Richards, C.D. and Gauldie, J. Bronchial myofibroblasts and tissue remodelling in asthma. *Can. Respir. J.* 5:59-61, 1998.
207. Sallenave, J.M., Xing, Z., Simpson, A.J., Graham, F.L. and Gauldie, J. Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. *Gene Ther.* 5:352-360, 1998.
208. Lei, X.F., Ohkawara, Y., Stampfli, M.R., Gauldie, J., Croitoru, K., Jordana, M. and Xing, Z. Compartmentalized transgene expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in mouse lung enhances allergic airways inflammation. *Clin. Exp. Immunol.* 113:157-165, 1998.
209. Emtage, P.C.R., Wan, Y., Muller, W., Graham, F.L. and Gauldie, J. Enhanced Interleukin-2 gene transfer immunotherapy of breast cancer by co-expression of B7-1 and B7-2. *J. Interferon Cytokine Res.* 18:927-937, 1998.
210. Wang, J., Palmer, K., Lotvall, J., Milan, S., Lei, X.F., Matthaei, K.I., Gauldie, J., Inman, M.D., Jordana, M. and Xing, Z. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. *J. Clin. Invest.* 102:1132-1141, 1998.
211. Lee, W.C., Zhong, C., Qian, S., Wan, Y., Gauldie, J., Mi, Z., Robbins, P.D., Thomson, A.W. and Lu, L. Phenotype, function, and *in vivo* migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGFE. *Transplantation* 66:1810-1817, 1998.
212. Addison, C.L., Bramson, J.L., Hitt, M.M., Muller, W.J., Gauldie, J. and Graham, F.L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. *Gene Ther.* 5:1400-1409, 1998.
213. Gabaglia, C.R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E.E., Graham, F.L., Gauldie, J. and Braciak, T.A. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against *Leishmania major* infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice. *J. Immunol.* 162:753-760, 1999.
214. Van Assche, G., Barbara, G., Deng, Y., Lovato, P., Gauldie, J. and Collins, S.M. Neurotransmitters modulate cytokine-stimulated interleukin 6 secretion in rat intestinal smooth muscle cells. *Gastroenterology* 111:346-353, 1999.

215. Wan, Y., Emtage, P., Foley, R., Carter, R. and Gauldie, J. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. *Int. J. Oncol.* 14:771-776, 1999.
216. Emtage, P.C.R., Wan, Y., Hitt, M., Graham, F.L., Muller, W.J., Zlotnik, A. and Gauldie, J. Adenoviral vectors expressing lymphotactin and interleukin-2 or lymphotactin and interleukin-12 synergize to facilitate tumor regression in murine breast cancer models. *Hum. Gene Ther.* 10:697-709, 1999.
217. Cox, G., Whitehead, L., Dolovich, M., Jordana, M., Gauldie, J. and Newhouse, M.T. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. *Chest* 115:1271-1277, 1999.
218. Sallenave, J.-M., Donnelly, S.C., Grant, I.S., Robertson, C., Gauldie, J. and Haslett, C. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. *Eur. Respir. J.* 13:1029-1036, 1999.
219. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J. and Graham, F.L. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase I clinical trial. *Gene Ther.* 6:350-363, 1999.
220. Lee, W.C., Wan, Y., Li, W. Fu, F., Sime, P.J., Gauldie, J., Thomson, A.W., Fung, J.J., Lu, L. and Qian, S. Enhancement of dendritic cell tolerogenicity by genetic modification using adenoviral vectors encoding cDNA for TGFE1. *Transplant. Proc.* 31:1195, 1999.
221. Wan, Y., Emtage, P. Zhu, Q., Foley, R., Pilon, A., Roberts, B. and Gauldie, J. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. *Cell. Immunol.* 198:131-138, 1999.
222. Xing, Z., Braciak, T., Chong, D., Feng, X., Schroeder, J.A. and Gauldie, J. Adenoviral-mediated gene transfer of interleukin-6 in rat lung enhances antiviral immunoglobulin A and G responses in distinct tissue compartments. *Biochem. Biophys. Res. Commun.* 258:332-335, 1999.
223. Zhao, J., Sime, P.J., Bringas, P., Gauldie, J. and Warburton, D. Adenovirus-mediated decorin gene transfer prevents TGF-E-induced inhibition of lung morphogenesis. *Am. J. Physiol.* 277:L412-422, 1999.
224. Murphy, P.G., Ramer MS, Borthwick L, Gauldie, J. and Richardson, P.M. and Bisby, M.A. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. *Eur. J. Neurosci.* 11:2243-2253, 1999.

225. Marr, R.A., Hitt, M., Gauldie, J., Muller, W.J. and Graham F.L. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor  $\Delta$  expressed from an adenovirus vector induces an antitumor response with reduced toxicity. *Cancer Gene Ther.* 6:465-474, 1999.
226. Hogaboam, C.M., Simpson, K.J., Chensue, S.W., Steinhauser, M.L., Lukacs, N.W., Gauldie, J., Strieter, R.M. and Kunkel, S.M. Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury. *Gene Ther.* 6:573-584, 1999.
227. Palmer, K., Emtage, P.C.R., Strieter, R.M. and Gauldie, J. Transient gene transfer of non-ELR chemokines to rodent lung induces mononuclear cell accumulation and activation. *J. Interferon Cytokine Res.* 19:1381-1390, 1999.
228. Kerr, C., Langdon, C., Graham, F., Gauldie, J., Hara, T. and Richards, C.D. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression *in vivo* in mice. *J. Interferon Cytokine Res.* 19:1195-1205, 1999.
229. Zhao, J., Sime, P.J., Bringas, P., Tefft, J.D., Buckley, S., Bu, D., Gauldie, J. and Warburton, D. Spatial-specific TGF-E1 adenoviral expression determines morphogenetic phenotypes in embryonic mouse lung. *Eur. J. Cell Biol.* 78:715-725, 1999.
230. Wang, S., Baum, B.J., Yamano, S., Mankani, M.H., Sun, D., Jonsson, M., Davis, C., Graham, F.L., Gauldie, J. and Atkinson, J.C. Adenoviral-mediated gene transfer to mouse salivary glands. *J. Dent. Res.* 79:701-708, 2000.
231. Wang, J., Snider, D.P., Hewlett, B.R., Lukacs, N.W., Gauldie, J., Liang, H. and Xing, Z. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. *Blood* 95:2337-2345, 2000.
232. Barbara, G., Xing, Z., Hogaboam, C.M., Gauldie, J. and Collins, S.M. Interleukin 10 gene transfer prevents experimental colitis in rats. *Gut* 46:344-349, 2000.
233. Hitt, M.M. and Gauldie, J. Gene vectors for cytokine expression *in vivo*. *Curr. Pharm. Des.* 6:613-632, 2000.
234. Cameron, M.J., Arreaza, G.A., Waldhauser, L., Gauldie, J. and Delovitch, T.L. Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer. *Gene Ther* 7:1840-1846, 2000.
235. Wan, Y., Bramson, J., Pilon, A., Zhu, Q. and Gauldie, J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. *Cancer Res.* 60:3247-3253, 2000.
236. Murphy, P.G., Borthwick, L.A., Altares, M., Gauldie, J., Kaplan, D. and Richardson, P.M. Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. *Eur. J. Neurosci.* 12:1891-1899, 2000.



237. Gorczynski, R.M., Bramson, J., Catral, M., Huang, X., Lei, J., Xiaorong, L., Min, W.P., Wan, Y. and Gauldie, J. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFE and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. *Clin. Immunol.* 95:182-189, 2000.
238. Braciak, T.A., Gallichan, W.S., Graham, F.L., Richards, C.D., Ramsay, A.J., Rosenthal, K.L. and Gauldie, J. Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung. *Immunology* 101:388-396, 2000.
239. Motyka, B., Korbitt, G., Pinkoski, M.J., Heibein, J.A., Caputo, A., Hobman, M., Barry M., Shostak, I., Sawchuk, T., Holmes, C.F., Gauldie, J. and Bleackley, R.C. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. *Cell* 103:491-500, 2000.
240. Lee, W., Qiani, S., Wan, Y., Li, W., Xing, Z., Gauldie, J., Fung, J.J., Thomson, A.W. and Lu, L. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. *Immunology* 101:233-241, 2000.
241. Hamelmann, E., Takeda, K., Haczku A., Cieslewicz, G., Shultz, L., Hamid, Q., Xing, Z., Gauldie, J. and Gelfand, E.W. Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice. *Am. J. Respir. Cell Mol. Biol.* 23:327-334, 2000.
242. Palmer, K., Hitt, M.M., Emtage, P.C., Gyorffy, S. and Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. *Gene Ther.* 8:282-290, 2001.
243. Kolb, M., Margetts, P.J., Galt, T., Sime, P.J., Xing, Z., Schmidt, M. and Gauldie, J. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. *Am. J. Respir. Crit Care Med.* 163:770-777, 2001.
244. Sakic, B., Gauldie, J., Denburg, J.A. and Szechtman, H. Behavioral effects of infection with IL-6 adenovector. *Brain Behav. Imm.* 15:25-42, 2001.
245. Trudel, S., Li, Z., Dodgson, C., Nanji, S., Wan, Y., Voralia, M., Hitt, M., Gauldie, J., Graham, F.L. and Stewart, A.K. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma – a phase I study. *Leukemia* 15:846-854, 2001.
246. Kolb, M., Margetts, P.J., Sime, P.J. and Gauldie, J. Proteoglycans decorin and biglycan differentially modulate TGFE-mediated fibrotic responses in the lung. *Am. J. Physiol: Lung Cell. Mol. Physiol.* 280:L1327-L1334, 2001.

247. Gyorffy, S., Palmer, K., Podor, T.J., Hitt, M. and Gauldie, J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: A role for combined anti-angiogenesis and immunotherapy. *J. Immunol.* 166:6212-6217, 2001.
248. Kolb, M., Inman, M., Margetts, P.J., Galt, T. and Gauldie, J. Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. *Am. J. Respir. Crit. Care Med.* 164:866-872, 2001.
249. Chen, Y., Emtage, P., Zhu, Q., Foley, R., Muller, W., Hitt, M., Gauldie, J. and Wan, Y. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. *Gene Ther.* 8:316-323, 2001.
250. Gorczynski, R., Bramson, J., Cattral, M., Huang, X., Lei, J., Min, W., Wan, Y. and Gauldie, J. Dendritic cells expressing TGFE/IL-10, and CHO cells with OX-2, increase graft survival. *Transplant. Proc.* 33:1565-1566, 2001.
251. Kolb, M., Margetts, P.J., Anthony, D.C., Pitossi, F. and Gauldie, J. Transient expression of IL-1E induces acute lung injury and chronic repair leading to pulmonary fibrosis. *J. Clin. Invest.* 107:1529-1536, 2001.
252. Margetts, P.J., Kolb, M., Galt, T., Hoff, C.M., Shockley, T.R. and Gauldie, J. Gene transfer of transforming growth factor- $\beta$ 1 to the rat peritoneum: Effects on membrane function. *J. Am. Soc. Nephrol.* 12:2029-2039, 2001.
253. Gyorffy, S., Palmer, K. and Gauldie, J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. *Am. J. Pathol.* 159:1137-1147, 2001.
254. Khan, W.I., Blennerhassett, P.A., Deng, Y., Gauldie, J., Vallance, B.A. and Collins, S.M. IL-12 gene transfer alters gut physiology and host immunity in nematode-infected mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 281:G102-G110, 2001.
255. Margetts, P.J., Gyorffy, S., Kolb, M., Yu, L., Hoff, C.M., Holmes, C.J. and Gauldie, J. Anti-angiogenic and anti-fibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. *J. Am. Soc. Nephrol.* 13:721-728, 2002.
256. Emtage, P.C.R., Xing, Z., Wan, Y., Zlotnik, A., Graham, F.L. and Gauldie, J. Adenoviral mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4<sup>+</sup>, CD8<sup>+</sup> and NK cells. *J. Interferon Cytokine Res.* 22:573-582, 2002.
257. Gauldie, J., Kolb, M. and Sime, P.J. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? *Respir. Res.* 3:1-3, 2002.

258. Palmer, K., Sharan, N., Emtage, P., Gauldie, J. Muller, W.J. and Wan, Y. Intra-tumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth. *Gene Ther.* 9:898-905, 2002.
259. Gauldie, J. Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 165:1205-1208, 2002.
260. Kolb, M., Bonniaud, P., Galt, T., Sime, P.J., Kelly, M.M., Margetts, P.J. and Gauldie, J. Differences in the fibrogenic response after transfer of active TGFE1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. *Am. J. Respir. Cell Mol. Med.* 27:141-150, 2002.
261. Margetts, P.J., Kolb, M., Yu, L., Hoff, C.M., Holmes, C.J., Anthony, D.C. and Gauldie, J. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. *Am. J. Pathol.* 160: 2285-2294, 2002.
262. Howe, K.L., Gauldie, J. and McKay, D.M. Temporally separate TGFE effects on epithelial ion transport and barrier: reduced Cl-secretion blocked by a p38 MAP kinase inhibitor. *Am. J. Physiol. Cell Physiol.* (in press), 2002.
263. Reed, C.C., Gauldie, J. and Iozzo, R.V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. *Oncogene* 21:3688-3695, 2002.
264. Leigh, R., Ellis, R., Wattie, J., Southam, D.S., de Hoogh, M., Gauldie, J., O'Byrne, P.M. and Inman, M.D. Dysfunction and remodeling of the mouse airway persist after resolution of acute allergen-induced airway inflammation. *Am. J. Respir. Cell Mol. Biol.* 27:526-535, 2002.
265. Dabrosin, C., Gyorffy, S., Margetts, P., Ross, C. and Gauldie, J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. *Am. J. Pathol.* 161:909-918, 2002.
266. Sibson, N.R., Blamire, A.M., Perry, V.H., Gauldie, J., Styles, P. and Anthony, D.C. TNF- $\Delta$  reduces cerebral blood volume and disrupts tissue homeostasis via an endothelin- and TNFR2-dependent pathway. *Brain* 125:2446-2459, 2002.



Books and Non-Refereed Journals

1. Gauldie, J., Tang, H.K. and Sherington, E. Nephelometric inhibition immunoassay of plasma digoxin. In Advances in Automated Analysis (Mediad, Inc., Tarrytown, N.Y.) pp. 278-282, 1977.
2. Walker, W.H.C. and Gauldie, J. Automated determination of immunoglobulins. In Automated Immunoanalysis, Part 1 (ed. R.F. Ritchie). Marcel Dekker Inc., Chapter 8, pp. 203-226, 1978.
3. Gauldie, J. and Bienenstock, J. Automated nephelometric analysis of haptens. In Automated Immunoanalysis, Part 1 (ed. R.F. Ritchie). Marcel Dekker, Inc., Chapter 15, pp. 321-333, 1978.
4. Chui, D.H.K., Brotherton, T.W. and Gauldie, J. Hemoglobin ontogeny in fetal mice. Adult hemoglobin in yolk sac derived erythrocytes. In Cellular and Molecular Regulation of Hemoglobin Switching (eds. G. Stamatoyannopoulos and A.W. Nienhuis). Grune & Stratton, pp. 213-225, 1979.
5. Befus, A.D., Pearce, F.L., Gauldie, J., Horsewood, P., Goodacre, R.L., Cole, F., Heatley, R.V. and Bienenstock, J. Isolation and characteristics of mast cells from the lamina propria of the small bowel. In The Mast Cell: its role in health and disease. (eds. J. Pepys and A.M. Edwards). Pitman Medical Publishing Co. Ltd., Kent, England, pp. 702-709, 1979.
6. Gauldie, J. Principles and clinical applications of nephelometry. In Nonisotopic Alternatives to Radioimmunoassay. Principles and Applications. (eds. L.A. Kaplan and A.J. Pesce). Marcel Dekker, Inc., Chapter 16, pp. 285-308, 1981.
7. Stein, E.A., McNerney, C. and Gauldie, J. Measurement of plasma lipoproteins by automated immunoprecipitation and nephelometry. In Nonisotopic Alternatives to Radioimmunoassay. Principles and Applications. (eds. L.A. Kaplan and A.J. Pesce). Marcel Dekker, Inc., Chapter 17, pp. 309-324, 1981.
8. Clark, D.A., Gauldie, J., Sweeney, G.D. and Safe, S. Suppression of immune defenses by halogenated aromatic hydrocarbons. In Second Annual Ontario Ministry of Environment Technology Transfer Conference, 1982.
9. Gauldie, J. The clinical laboratory and diagnosis of immunologic disorders. Medicine North America -Clin. Allergy Immunol. 4:320-324, 1983.
10. Frings, C.S. and Gauldie, J. Spectral techniques. In Clinical Chemistry (eds. L.A. Kaplan and A.J. Pesce). C.V. Mosby Company, Chapter 3, pp. 51-73, 1984 and pp.49-72, 1989.
11. Hurtubise, P.E., Bassion, S., Gauldie, J. and Horsewood, P. Immunochemical techniques. In Clinical Chemistry (eds. L.A. Kaplan and A.J. Pesce). C.V. Mosby Company, Chapter 10, pp. 179-210, 1984 and pp. 165-190, 1989.

12. Befus, A.D., Egwang, T.G. and Gauldie, J. Inflammatory and immune responses to parasites. In Immunology of the Lung and Upper Respiratory Tract (ed. J. Bienenstock). McGraw-Hill Book Company, N.Y., Chapter 12, pp. 264-281, 1984.
13. Gauldie, J., Sauder, D.N., McAdam, K.P.W.J. and Dinarello, C.A. Purified human monocyte IL-1 stimulates hepatocyte secretion of multiple acute phase proteins *in vitro*. In The Physiologic, Metabolic, and Immunological Actions of Interleukin-1 (eds. M.J. Kluger, J.J. Oppenheim and M.C. Powanda). Alan R. Liss Inc., N.Y. pp. 221-229, 1985.
14. Clark, D.A., Sweeney, G.D. and Gauldie, J. Quantitative assessment of immunotoxicity of haloaromatic hydrocarbons: key role of the thymus gland in susceptibility to dioxin and implications for definition of "no effect" exposure levels. In Sixth Annual Ontario Ministry of Environment Technology Transfer Conference, 1985.
15. Bienenstock, J., Scicchitano, R. and Gauldie, J. Cellular communication in respiratory immunity. In Pulmonary Diseases and Disorders, 2nd ed., Volume 1 (ed. A.P. Fishman). McGraw-Hill, N.Y., Chapter 38, pp. 579-588, 1988.
16. Gauldie, J., Richards, C., Harnish, D. and Baumann, H. Interferon  $\beta 2$  is identical to monocytic HSF and regulates the full acute phase protein response in liver cells. In Monokines and Other Non-Lymphocytic Cytokines, Progress in Leukocyte Biology, Vol. 8 (eds. M.C. Powanda, J.J. Oppenheim, M.J. Kluger and C.A. Dinarello). Alan R. Liss, Inc., New York, pp. 15-20, 1988.
17. Whicher, J.T., Gauldie, J., Baumann, H. and Westacott, C. Acute phase proteins. In Interleukin-1, Inflammation and Disease, Research Monographs in Cell and Tissue Physiology, Volume 16. (eds. R. Bomford and B. Henderson) Elsevier, Amsterdam, pp.191-216, 1989.
18. Gauldie, J. Interleukin-1 in the acute phase response. In Acute Phase Proteins in the Acute Phase Response. The Argentueil Symposia Series. (ed. M.B. Pepys) Springer-Verlag, London, Chapter 1, pp.1-20, 1989.
19. Gauldie, J. Interleukin 6 in the inflammatory response. In Therapeutic Approaches to Inflammatory Diseases (eds. A.J. Lewis, N.S. Doherty and N.R. Ackerman) Elsevier Science Publ. Co. Inc., NY, pp. 38-46, 1989.
20. Denburg, J.A., Jordana, M., Vancheri, C., Gauldie, J., Harnish, D., Ohtoshi, T., Tsuda, T., Gibson, P., Ruhno, J., Bienenstock, J., Hargreave, F.E. and Dolovich, J. Locally derived hemopoietic cytokines for human basophils, mast cells and eosinophils in respiratory disease. In Mast Cell and Basophil Differentiation and Function in Health and Disease (eds. S.J. Galli and K.F. Austen), Raven Press, Ltd., NY, pp. 59-69, 1989.
21. Fey, G.H. and Gauldie, J. The acute phase response of the liver in inflammation. Prog. Liver Dis. 9:89-116, 1990.

22. Dolovich, J., Ohtoshi, T., Jordana, M., Gauldie, J. and Denburg, J. Nasal polyps: local inductive microenvironment in the pathogenesis of the inflammation. *In* Rhinitis and Asthma: Similarities and Differences (eds. N. Mygind, U. Pipkorn and R. Dahl), Munksgaard, Copenhagen, pp.233-241, 1990.
23. Bienenstock, J., Blennerhassett, M.G., Croitoru, K., Ernst, P.B., Gauldie, J., Jordana, M., Marshall, J.S., Perdue, M.H., Stanisiz, A.M. and Stead, R.H. Nerves, neuropeptides and the regulation of the mucosal immune response. *In* Molecular Aspects of Immune Response and Infectious Diseases, (eds. H. Kiyono, E. Jirillo and C. DeSimone), Raven Press, Ltd., NY, pp. 55-66, 1990.
24. Gauldie, J. Acute and chronic inflammation. *In* Effects of Immune Cells and Inflammation on Smooth Muscle and Enteric Nerves. (eds. W.J. Snape, Jr. and S. Collins), CRC Press Inc., Boca Raton, Florida, Chapter 1, pp. 1-9, 1991.
25. Gauldie, J. and Baumann, H. Cytokines and acute phase protein expression. *In* Cytokines and Inflammation. (ed. E.S. Kimball) CRC Press, Inc., Boca Raton, Florida, Chapter 10, pp. 275-305, 1991.
26. Gauldie, J. Acute phase response. *In* Encyclopedia of Human Biology, Vol. 1, (ed. R. Dulbecco), Academic Press, San Diego, pp. 25-35, 1991.
27. Jordana, M., Cox, G., Ohtoshi, T., Xing, Z., Dolovich, J., Denburg, J. and Gauldie, J. The 'TDR' concept in chronic airways inflammation: Tissue Driven Response. *In* Clinical Impact of the Monitoring of Allergic Inflammation (eds. P. Matsson, S. Ahlstedt, P. Venge and J. Thorell) Academic Press, London, pp. 33-46, 1991.
28. Richards, C., Gauldie, J. and Baumann, H. Cytokine control of acute phase protein expression. *In* Cytokines and Inflammation (eds. J. Bienvenu and D. Fradelizi), John Libbey Eurotext, Paris, pp. 29-50, 1991.
29. Dolovich, J., Denburg, J.A., Gauldie, J., Ohtoshi, T., O'Byrne, P., Hargreave, F.E., Cox, G. and Jordana, M. The late asthmatic response (LAR) and the tissue driven response (TDR). *Advances in Asthmology 1990, Japan*, (eds. S. Kobayashi and J.A. Bellanti), Elsevier Science Publishers, pp. 247-252, 1991.
30. Jordana, M. and Gauldie, J. The biology of fibrosis of the lung. *In* Pulmonary Fibrosis. (spanish) (eds. A. Xaubet and M. Jordana), DOYMA, Barcelona, pp. 5-22, 1991.
31. Cox, G. and Gauldie, J. Structure and function of Interleukin-6. *In* Cytokines in Health and Disease. (eds. S.L. Kunkel and D.G. Remick), Marcel Dekker, Inc., NY, pp. 97-120, 1992.
32. Jordana, M., Kirpalani, H. and Gauldie, J. Heterogeneity of human lung fibroblast proliferation in relation to disease expression. *In* Pulmonary Fibroblast Heterogeneity (ed. R.P. Phipps), CRC Press, Boca Raton, FL, pp. 229-249, 1992.



PCL XL error

Subsystem: KERNEL

Error: IllegalTag

Operator: 0x18

Position: 8358



Abstracts

1. Hiebert, M.B., Gauldie, J. and Hillcoat, B.L. Multiple forms of dihydrofolate reductase from cultured mammalian cells. *Proc. Can. Fed. Biol. Soc.* 14, 1971.
2. Gauldie, J., Bienenstock, J. Perey, D.Y.E. and Underdown, B.J. A new chicken immunoglobulin: gamma A. *Proc. Can. Fed. Biol. Soc.* 15:166, 1972.
3. Mant, M.J., Doery, J.C.G. and Gauldie, J. Unusual platelet changes occurring in ethylene diamine tetraacetic acid (EDTA). *Clin. Res.* 20:934, 1972.
4. Mant, M.J., Hirsh, J., Gauldie, J., Bienenstock, J. and Pineo, G.F. Late onset of bleeding in patients with laboratory features of von Willebrand's disease. *Annual Scientific Meeting Can. Soc. Haematol.*, Edmonton, Alberta, 1973.
5. Gauldie, J., Perey, D.Y.E. and Bienenstock, J. Chicken IgA: Further definition. *Fed. Proc.* 32:968, 1973.
6. Gauldie, J., Bienenstock, J. and Perey, D.Y.E. Immunoglobulin synthesis in the fowl. *Proc. Can. Fed. Biol. Soc.* 16, 1973.
7. Hargreave, F.E., Dolovich, J., Chalmers, R., Shier, K.J., Gauldie, J. and Bienenstock, J. Relationship between late cutaneous allergic responses and IgE-dependent reactions. *Can. Thoracic Soc. Annual Mtg.*, 1973.
8. Dolovich, J., Hargreave, F.E., Chalmers, R., Shier, K.J., Gauldie, J. and Bienenstock, J. Relationship between late cutaneous allergic responses and IgE-dependent reactions. *Am. Acad. Allergy in J. Allergy Clin. Immunol.* 51:123, 1973.
9. Gauldie, J., Bhandari, S.C. and Singal, D.P. Non-involvement of carbohydrates in the HL-A antigenic site. *Fed. Proc.* 33:719, 1974.
10. Moore, S., Friedman, R.J., Singal, D.P., Gauldie, J. and Blajchman, M. Inhibition of injury induced thromboatherosclerotic lesions by antiplatelet serum in rabbits. *International Society on Thrombosis and Haemostasis*, Paris, 1975.
11. Gauldie, J., Sherington, E. and Sircar, P.K. Automated nephelometric inhibition immunoassay of digoxin and morphine. *Fed. Proc.* 34:104, 1975.
12. Friedman, R.J., Stemmerman, M.B., Spaet, T.H., Moore, S. and Gauldie, J. The effect of thrombocytopenia on arteriosclerotic plaque formation. *Fed. Proc.* 35:207, 1976.
13. Gauldie, J., Tang, H.K. and Sherington, E. Nephelometric inhibition of plasma digoxin. *In Proceedings of the 7th Technicon International Congress*, New York, pp 278, 1976.
14. Moore, S., Belbeck, L.W. and Gauldie, J. Thrombocytopenia induced by busulphan and antiplatelet serum inhibits aortic lesions caused by injury. *American Heart Assoc.*, Miami, 1977.



15. Stein, E.A., Gauldie, J., Glueck, L.J. and Wesselman, A. High density lipoprotein and very low density lipoprotein quantitation by immunoprecipitation and nephelometry. Presented at the Xth International Congress of Clinical Chemists, Mexico City, 1978.
16. Gauldie, J. and Collins, S.M. Differences in specificity of antibodies to DNA in Systemic Lupus Erythematosus detected by crithidia immunofluorescence and Farr radioassay. Presented at 4th European Immunology Meeting, Budapest, 1978.
17. Gauldie, J. and Horsewood, P. Nephelometric activity as an assessment of antisera suitable for immunofluorescence. Presented at VIth International Conference on Immunofluorescence and Related Staining Techniques, Vienna, 1978.
18. Gauldie, J. and Lamontagne, L.R. Antibody induced alpha-1-antitrypsin deficiency in the mouse. Fed. Proc. 37:1195, 1978.
19. Lamontagne, L.R. and Gauldie, J. Ontogeny of mouse serum protease inhibitors: alpha-1-antitrypsin and antithrombin III. Proc. C.F.B.S. 21:129, 1978.
20. Horsewood, P., Befus, A.D., Cazenave, J.-P., Denburg, J.A. and Gauldie, J. Anti-inflammatory polypeptide of bee venom with mast-cell and platelet degranulating activity. Proc. C.F.B.S. 21:127, 1978.
21. Brotherton, T.W., Gauldie, J. and Chui, D.H.K. Immunocytochemical identification of adult and embryonic hemoglobins in yolk sac derived erythrocytes during normal mouse fetal development. Presented at American Federation of Clinical Research Meeting, San Francisco, 1978.
22. Track, N.S., Watters, L.M. and Gauldie, J. Motilin and human pancreatic polypeptide (HPP) plasma concentrations in 196 fasting subjects. Presented at 2nd International Symposium on Gastrointestinal Hormones, 1978.
23. McCulloch, P.B., Dent, P.B., Poon, M.A., Gauldie, J. and Walker, W.H.C. Tumor marker studies in breast carcinoma. Presented at Royal College of Physicians and Surgeons (Canada) and Affiliated Societies Meeting, Montreal, 1979.
24. Befus, A.D., Pearce, F.L., Gauldie, J., Horsewood, P., Goodacre, R.L., Cole, F., Heatley, R.V. and Bienenstock, J. Isolation and characteristics of mast cells from the small bowel lamina propria. Presented at International Symposium "The Mast Cell", Davos, Switzerland, 1979.
25. Denburg, J.A., Gauldie, J. and Bienenstock, J. Basophil stimulating factor from guinea pig splenic T-lymphocytes. Clin. Res. 27:470a, 1979.
26. Lamontagne, L.R., Horsewood, P. and Gauldie, J. Immunohistochemical localization of  $\Delta$ -1 antitrypsin in normal mouse liver-altered distribution caused by acute inflammation. Proc. C.F.B.S. 22:205, 1979.

27. Heatley, R.V., Thomas, P., Prokipchuk, E.J., Gauldie, J. and Bienenstock, J. Pulmonary disorders in patients with inflammatory bowel diseases. Submitted to Gastroenterology, 1979.
28. Denburg, J.A., Gauldie, J. and Bienenstock, J. Basophilopoietin from guinea pig splenic T-lymphocytes. Blood 54:151a, 1979.
29. Denburg, J.A., Gauldie, J., Horsewood, P., Blajchman, J., Beattie, H., Evans, G., Thomson, G., Gill, G. and Bienenstock, J. Allergy to tobacco glycoprotein in human peripheral vascular disease. Presented at Royal College of Physicians & Surgeons, 1980.
30. Gauldie, J., Lamontagne, L.R. and Horsewood, P. Altered distribution of alpha-1-antitrypsin containing cells in mouse liver and pancreas during acute inflammatory response. Fed. Proc. 39:2006, 1980.
31. Gauldie, J., Lamontagne, L.R. and Horsewood, P. The induction of alpha-1-antitrypsin containing cells in mouse liver and pancreas during inflammatory responses. Presented at 4th International Congress of Immunology, Paris, 1980.
32. Lamontagne, L.R. and Gauldie, J. Molecular polymorphism of alpha-1-antitrypsin in rodents. Proc. C.F.B.S. 23:303, 1980.
33. Clark, D.A., Gauldie, J., Sweeney, G.D. and Szewczuk, M.R. Selective inhibition of murine T cell function by TCDD. Proc. C.F.B.S. 23:295, 1980.
34. Kelton, J.G., Denomme, G. and Gauldie, J. The majority of platelet associated IgG (PAIgG) is in the interior of platelets and not measurable using standard assays. Transfusion 20:625A, 1980.
35. Kelton, J.G., Brain, M.C., Neame, P.B., Hirsh, J. and Gauldie, J. Plasmapheresis is effective in thrombotic thrombocytopenia purpura (TTP) by altering the binding characteristics of immune complexes. Circulation 62 (Supp.III):105, 1980.
36. Clark, D.A., Gauldie, J., Sweeney, G.D. and Szewczuk, M.R. Selective suppression of cytotoxic T cell (CTL) generation by halogenated aromatic hydrocarbons. Fed. Proc. 40:4918, 1981.
37. Gauldie, J., Lamontagne, L.R. and Befus, A.D. The acute phase response in the early stage of parasite infection. Fed. Proc. 40:4776, 1981 and Symposium on Inflammation Markers, Lyon, France, 1981.
38. Lamontagne, L.R., Gauldie, J., Horsewood, P. and Jenkins, E. Synthesis and tissue localization of mouse alpha-1-antitrypsin. Proc. C.F.B.S. 24:699, 1981.
39. Williams, D. and Gauldie, J. Rat x mouse hybridoma secreting antibody to mouse alpha-1-antitrypsin. Proc. C.F.B.S. 24:726, 1981.
40. Lamontagne, L.R., Gauldie, J. and Jenkins, E. Synthesis of alpha-1-antiprotease inhibitor by normal and activated murine alveolar macrophages. Fed. Proc. 41:2442, 1982.

41. Horsewood, P. and Gauldie, J. Monoclonal antibodies to human ferritin with direct precipitating activity. *Fed. Proc.* 41:1924, 1982.
42. Chung, S.W., Wong, S.C., Gauldie, J., Clarke, B.J. and Chui, D.H.K. Anti-Hb portland antibodies: a sensitive probe for human embryonic hemoglobin. Presented at Am. Fed. Clin. Res., 1982.
43. Kelton, J.G., Keystone, J., Neame, P.B., Moore, J., Gauldie, J. and Jensen, J.B. The mechanism of malaria-induced thrombocytopenia. *Clin. Res.* 30:318A, 1982.
44. Kelton, J.G., McBride, J., Wilson, W. and Gauldie, J. The pretreatment identification of those patients with idiopathic thrombocytopenic purpura who respond to plasmapheresis. *Clin. Res.* 30:318A, 1982.
45. Gauldie, J., Lamontagne, L.R., Befus, A.D., McAdam, K.P.W.J., Baltz, M. and Pepys, M. The acute phase response in parasite infection. *Molec. Biochem. Parasitol. Suppl.* 365, 1982.
46. Egwang, T.G., Gauldie, J. and Befus, A.D. Altered helminthotoxic activity of rat alveolar macrophages during *Nippostrongylus brasiliensis* infection. *Molec. Biochem. Parasitol. Suppl.* 5, 1982.
47. Chung, S.W., Walker, W.H.C., Wong, S.C., Gauldie, J., Clarke, B.J. and Chui, D.H.K. Monospecific anti-hemoglobin portland antibodies. Presented at American Society of Hematology, 1982.
48. Gauldie, J., Lamontagne, L.R., Stadnyk, A.W. and Jenkins, L. Alveolar macrophage releases IL1 after activation *in vivo* by infection. *Fed. Proc.* 42:4293, 1983.
49. Richards, C.D. and Gauldie, J. Immunoglobulin and complement receptors on normal and activated alveolar macrophage. *Fed. Proc.* 42:3881, 1983.
50. Egwang, T.G., Gauldie, J. and Befus, A.D. Alterations in numbers and helminthotoxicity of rat bronchoalveolar leukocytes during *Nippostrongylus brasiliensis* infection. *Fed. Proc.* 42:5596, 1983.
51. Stadnyk, A.W., Befus, A.D., Gauldie, J. and McElroy, P.J. Characterization of *Nippostrongylus brasiliensis* infection in mice. *Proc. C.F.B.S.* 26:PO-140, 1983.
52. Richards, C.D. and Gauldie, J. Fc receptors on mouse mast cells and alveolar macrophages. *Proc. C.F.B.S.* 26:PO-334, 1983.
53. Gauldie, J. Hybridoma: The use of monoclonal antibodies in biotechnology. *Proc. C.F.B.S.* 26:S-58, 1983.
54. Hammerberg, O., Davidson, S. and Gauldie, J. The value of serial C-reactive protein (CRP) levels in early discontinuation of antimicrobics in neonates. Presented at Royal College of Physicians and Surgeons Meeting, 1983.

55. Hammerberg, O., Davidson, S. and Gauldie, J. Serial C-reactive protein levels for early discontinuation of antimicrobics in neonates. Presented at Canadian Infectious Diseases Meeting, 1983.
56. Jordana, M., Gauldie, J., Newhouse, M.T. and Bienenstock, J. Alveolar macrophage derived products affect proliferation of human adult lung fibroblast cell lines *in vitro*. ARRD 129:A15, 1984.
57. Gauldie, J., Koj, A., Sauder, D.N., Sweeney, G.D. and Regoeczi, E. Human monocyte-derived and epidermal cell-derived cytokines stimulate cultured rat hepatocytes to increased synthesis of acute-phase proteins. Fed. Proc. 43:2978, 1984.
58. Lamontagne, L.R., Richards, C.D., Gauldie, J. and Piessens, W.F. The expression of IgA Fc receptors on murine eosinophils. Fed. Proc. 43:1466, 1984.
59. Clark, D.A., Gauldie, J. and Sweeney, G.D. Immunoregulation by dioxin and related haloaromatic hydrocarbons. J. Leuk. Biol. 36:392, 1984.
60. Gauldie, J., Jordana, M., Richards, C.D. and Stadnyk, A.W. Alveolar macrophage factors modulate the *in vitro* response of lymphocytes, fibroblasts and hepatocytes. J. Leuk. Biol. 36:411, 1984.
61. Kelton, J.G., Singer, J., Gauldie, J., Horsewood, P., Denburg, J.A., Rodger, C. and Dent, P. Serum IgG is the major *in vivo* determinant of clearance of IgG-sensitized erythrocytes. Clin. Res. 32:350A, 1984.
62. Dolovich, M., Jordana, M., Goto, T., Chambers, C., Gauldie, J. and Newhouse, M.T. Lung epithelial permeability changes in rats after exposure to bleomycin. ARRD 131:A312, 1985.
63. Jordana, M., Gauldie, J., Newhouse, M.T. and Bienenstock, J. Proliferative response of normal and fibrotic human lung fibroblast to peripheral blood monocyte cytokines. ARRD 131:A33, 1985.
64. Stadnyk, A.W. and Gauldie, J. The acute phase response associated with GI inflammation due to enteric parasites. Fed. Proc. 44:7582, 1985.
65. Richards, C.D., Gauldie, J. and Horsewood, P. Purification of hepatocyte stimulating factor from rat alveolar macrophages. Fed. Proc. 44:4541, 1985.
66. Stadnyk, A.W., Gauldie, J. and Schroeder, J.A. The acute inflammatory response due to enteric parasites. Proc. C.F.B.S. 28:PO-75, 1985.
67. Richards, C.D., Gauldie, J., Horsewood, P. and Schroeder, J.A. Purification of hepatocyte stimulating factor (HSF) from alveolar macrophages (AMO). Proc. C.F.B.S. 28:PO-140, 1985.
68. Gauldie, J., Sauder, D.N., McAdam, K.P.W.J. and Dinarello, C.A. Purified human monocyte IL-1 stimulates hepatocyte secretion of multiple acute phase proteins *in vitro*. Presented at Symposium - The Physiologic, Metabolic and Immunologic Actions of Interleukin-1, 1985.

69. Kelly, M., Swanston, W., Gauldie, J., Dent, P.B., Liao, S.-K. and Denburg, J.A. Neuronal antibodies (NA) in neuropsychiatric systemic lupus erythematosus (NP-SLE) probably access the central nervous system through a damaged blood-brain barrier. Presented at the American Rheumatism Association Meeting, 1985.
70. Gauldie, J., Jordana, M., Befus, A.D., Newhouse, M.T. and Bienenstock, J. Human lung fibroblasts express an H<sub>2</sub> histamine receptor which can modulate *in vitro* proliferation. ARRD 133:A35, 1986.
71. Jordana, M., Schulman, J., Newhouse, M.T. and Gauldie, J. Characteristics of human adult lung fibroblast strains and clonally-derived lines from normal and fibrotic tissue. ARRD 133:A36, 1986.
72. Irving, L.B., Jordana, M., O'Brodovich, H. and Gauldie, J. Alveolar macrophage activation in bronchopulmonary dysplasia. ARRD 133:A207, 1986.
73. Jordana, M., Richards, C.D., Irving, L.B. and Gauldie, J. Unstimulated release of IL-1 by alveolar macrophages after intratracheal bleomycin in rats. Presented at 6th International-Congress of Immunology, 1986.
74. Irving, L.B., Jordana, M., Dolovich, M., Gauldie, J. and Newhouse, M.T. Inflammatory lung changes following *Nippostrongylus brasiliensis* infection. Presented at Sixth International Congress of Immunology, 1986.
75. Richards, C.D. and Gauldie, J. Purification and molecular biology of hepatocyte stimulating factor (HSF) derived from human peripheral blood monocytes (PBM). Presented at Sixth International Congress of Immunology, 1986.
76. Koj, A., Zero, D., Rokita, H., Cieszka, K. and Gauldie, J. Specific features of the acute phase response of cultured Morris hepatoma cells. Presented at Sixth International Congress of Immunology, 1986.
77. Gauldie, J., Baumann, H., Saklatvala, J. and Van Damme, J. Comparison of hepatocyte stimulation of acute phase proteins by purified monocyte derived Interleukin-1 and hepatocyte stimulating factor. Presented at Sixth International Congress of Immunology, 1986.
78. Stadnyk, A.W., Schroeder, J.A., Baumann, H. and Gauldie, J. Models of inflammation and the acute phase response in host defense. Presented at Sixth International Congress of Immunology, 1986.
79. Stadnyk, A.W., Baumann, H. and Gauldie, J. The acute phase response in host defense in enteric nematodes. Presented at Sixth International Congress of Parasitology, 1986.
80. Jordana, M., Dolovich, M., Irving, L.B., Chambers, C., Gauldie, J. and Newhouse, M. Lung epithelial permeability (LEP) changes after a second intratracheal (IT) instillation of bleomycin (B). Sarcoidosis 3:186, 1986.
81. Gauldie, J., Richards, C., Jordana, M. and Baumann, H. Macrophage derived IL-1 and hepatocyte stimulating factor (HSF) are distinct entities that induce acute phase protein synthesis. Presented at RES Meeting, Denver, 1986.

82. Irving, L.B., Gauldie, J. and Newhouse, M.T. Interstitial lung disease, hepato-splenomegaly and clubbing. Presented at American College of Chest Physicians Meeting, 1986.
83. Gauldie, J., Jordana, M., McSharry, C., Irving, L., Schulman, J., Harnish, D., Wilsher, M. and Turner-Warwick, M. Characteristics of lung fibroblast lines established from familial cryptogenic fibrosing alveolitis tissue. ARRD 135:A306, 1987.
84. McSharry, C., Jordana, M., Harnish, D., Kelly, J., Newhouse, I. and Gauldie, J. Procollagen gene expression by primary fibroblast lines derived from control and fibrotic lung tissue in humans. ARRD 135: A306, 1987.
85. Jordana, M., Schulman, J. and Gauldie, J. Phenotypic alterations of human adult lung fibroblast lines and clonally-derived fibroblasts chronically exposed *in vitro* to inflammatory mediators. ARRD 135:A66, 1987.
86. Irving, L.B., Jordana, M., McSharry, C., Gauldie, J. and Harnish, D. Differences in *in vitro* behaviour between neonatal and adult human primary and cloned lung fibroblast lines. ARRD 135:A66, 1987.
87. Richards, C., Gauldie, J., Baumann, H., Onorato, L. and Jahreis, G. Separate PBM monocyte cytokines regulate synthesis of distinct sets of acute phase proteins. Presented at CSI Spring Meeting, Banff, 1987.
88. Gauldie, J., Baumann, H. and Richards, C. Human hepatocyte stimulating factor (HSF) and recombinant Interleukin-1 (IL-1) and tumor necrosis factor (TNF) stimulate distinct sets of acute phase reactant proteins (APR) *in vitro*. Presented at Cold Spring Harbor Symposium, 1987.
89. Gauldie, J., Koj, A., Kurdowska, A. and Dayer, J.M. Modulation of the acute phase response of rat hepatocytes by human recombinant IL-1 and TNF. Presented at Cold Spring Harbor Symposium, 1987.
90. Gauldie, J., Richards, C., Harnish, D. and Baumann, H. Interferon  $\beta_2$  is identical to HSF and regulates the full acute phase protein response in liver cells. Presented at International Workshop on Monokines and other Non-Lymphocytic Cytokines, South Carolina, 1987.
91. Koj, A., Magielska-Zero, D., Bereta, J., Dayer, J.M. and Gauldie, J. Comparison of interleukin 1 and tumor necrosis factor as inducers of the acute phase response of cultured hepatocytes and hepatoma cells. Immunobiology 175:65, 1987.
92. Vancheri, C., Jordana, M., Stanis, A., Bienenstock, J. and Gauldie, J. Interactions between normal human adult lung fibroblasts and human peripheral eosinophils *in vitro*. ARRD 137:49, 1988.
93. Irving, L., Jordana, M. and Gauldie, J. Modulation of PGE2 release and procollagen mRNA expression in human lung fibroblasts by peripheral blood monocyte supernatants. ARRD 137:431, 1988.

94. Jordana, M., Schulman, J., Irving, L.B. and Gauldie, J. Spontaneous *in vitro* release of growth factors by human lung fibroblasts. ARRD 137:49, 1988.
95. Gauldie, J., Jordana, M., Richards, C., McSharry, C., Irving, L.B. and Harnish, D. The release of interferon  $\beta$ 2/BSF2/IL-6 by the human lung fibroblast mediates the acute phase response during lung inflammation. ARRD 137:48, 1988.
96. Cox, G., Irving, L.B., Jordana, M., Gauldie, J., Dolovich, M. and Newhouse, M.T. Mast cell involvement in the enhanced inflammatory changes following a second dose of intratracheal bleomycin in the rat. ARRD 137:44, 1988.
97. Gauldie, J., Richards, C., Harnish, D. and Baumann, H. Hepatocyte stimulating factor (HSF) is identical to interferon  $\beta$ 2/IL-6 and regulates the full acute phase protein response of the liver in inflammation. Presented at Canadian Society for Immunology Spring Meeting, 1988.
98. Cox, G., Irving, L.B., Jordana, M., Gauldie, J., Dolovich, M. and Newhouse, M. Potential role of mast cell products in lung permeability changes after a second dose of bleomycin in the rat. Presented at 7th European Congress on Diseases of the Chest, 1988.
99. Jordana, M., Dolovich, J., Denburg, J., Vancheri, C., Ohtoshi, T., Harnish, D., Rhuno, J. and Gauldie, J. Hemopoietic function of the microenvironment in chronic airway inflammation. Presented at 4th International Symposium "Intrinsic Asthma", Davos, Switzerland, 1988.
100. Low, R.B., Mitchell, J.J., Woodcock-Mitchell, J., Leslie, K., Absher, P.M., Jordana, M., Schulman, J. and Gauldie, J. Alpha-smooth muscle actin containing cells of the pulmonary parenchyma. Presented at Lyon, France, 1988.
101. Gauldie, J., Richards, C. and Baumann, H. IFN $\beta$ 2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. Presented at NYAS Conference on Regulation of the Acute Phase and Immune Responses: A New Cytokine, 1988.
102. Richards, C.D. and Gauldie, J. Cytokines involved in the acute phase response of liver. Br. J. Rheumatol. 27:63, 1988.
103. Hayes, M.A., Wollenberg, G., Semple, E., Farber, E. and Gauldie, J. Effects of dexamethasone on inhibitory effects of transforming growth factors E1 and E2 in normal and neoplastic rat hepatocytes. Proc. Am. Assoc. Cancer Res. 29:228, 1988.
104. Kirpalani, H., Jordana, M., Irving, L., Post, M. and Gauldie, J. Effects of oxygen exposure on human neonatal pulmonary fibroblast (NPF) proliferation. Ped. Res., 1988.
105. Ohtoshi, T., Vancheri, C., Cox, G., Gauldie, J., Dolovich, J., Jordana, M. and Denburg, J. Epithelial cells derived from nasal polyps and inferior turbinate tissues produce neutrophilic and monocytic differentiating activity. J. Allergy Clin. Immunol. 83:A299, 1989.
106. Cox, G., Vancheri, C., Ohtoshi, T., Gauldie, J., Dolovich, J., Jordana, M. and Denburg, J. Fibroblasts derived from human nasal tissues produce neutrophilic and basophilic differentiating factors

including granulocyte macrophage colony stimulating factor (GM-CSF). J. Allergy Clin. Immunol. 83:A300, 1989.

107. Jordana, M., Vancheri, C., Ohtoshi, T., Tsuda, T., Cox, G., Harnish, D., Dolovich, J., Denburg, J. and Gauldie, J. Hemopoietic function of fibroblasts and epithelial cells derived from normal and inflamed upper respiratory airway tissues. Am. Rev. Respir. Dis. 139:A251, 1989.
108. Cox, G., McSharry, C., Dolovich, M., Newhouse, M., Jordana, M. and Gauldie, J. Capsaicin pre-treatment prevents the early development of increased solute clearance following a second dose of bleomycin in the rat. Am. Rev. Respir. Dis. 139:A239, 1989.
109. Bradley, C., Bacchetti, S. and Gauldie, J. Characteristics of human lung fibroblast lines transformed by SV40 in recombinant plasmid. Presented at American Thoracic Society Meeting, 1989.
110. Stadnyk, A.W. and Gauldie, J. Interleukins and hepatocyte-stimulating activities in parasitized rat intestinal cells. Presented at Canadian Society of Immunology Meeting, 1989.
111. Jordana, M., Dolovich, J., Gauldie, J., Ohtoshi, T., Vancheri, C., Tsuda, T. and Denburg, J. Modulation of upper airway inflammation by fibroblast and epithelial cell derived cytokines. Clin. Research 37:A239, 1989.
112. Kirpalani, H., Jordana, M., Buch, S., Gauldie, J. and Post, M. PDGF expression in human neonatal pulmonary fibroblasts following hyperoxia. Presented at The Society for Pediatric Research Meeting, 1989.
113. McCallum, R.E., Hill, M.R. and Gauldie, J. Endotoxin effects on liver metabolism are mediated by IL-6. Presented at ASM Annual Meeting, 1989.
114. McCallum, R.E., Hill, M.R. and Gauldie, J. TNF modulates gene expression of PEPCK and fibrinogen through IL-6. Presented at Second International Conference on Tumor Necrosis Factor and Related Cytokines, 1989.
115. Gauldie, J. and Northemann, W. The expression of IL-6 by normal hepatocytes occurs only *in vitro* and under non-physiologic conditions. Presented at Cold Spring Harbor Laboratory Conference on Regulation of Liver Gene Expression, 1989.
116. Denburg, J.A., Dolovich, J., Gauldie, J., Abrams, J., Ohtoshi, T., Tsuda, T. and Jordana, M. Hemopoietic cytokines derived from respiratory epithelial cells and fibroblasts: role in allergic and non-allergic inflammation. Presented at 7th International Congress of Immunology, 1989 and CSCI/Royal College Meeting, 1989.
117. Gauldie, J., Xaubet, A., Ohtoshi, T., Jordana, M. and Stanisiz, A. Neuropeptide mediated release of IL-6 and other cytokines from human fibroblasts. Presented at 7th International Congress of Immunology, 1989.



118. Denburg, J.A., Dolovich, J., Ohtoshi, T., Tsuda, T., Gauldie, J. and Jordana, M. The microenvironmental differentiation hypothesis of airway inflammation. Presented at International Symposium in Allergy of the Nose, Baltimore, 1989.
119. Bienenstock, J., Stanis, A., Perdue, M., Denburg, J., Pezzati, P., Jordana, M. and Gauldie, J. Role of neuropeptides and nerves in the regulation of mucosal immunity. Presented at International Conference on Molecular Aspects of Immune Response and Infectious Diseases, Rome, Italy, 1989.
120. Driscoll, K., Maurer, J., Crosby, L., Gauldie, J. and Jordana, M. Generation of alveolar macrophage (AM)-derived cytokines in a model of inflammatory lung disease. Presented at Second International Workshop on Cytokines, Hilton Head, SC, 1989.
121. Gauldie, J., Geisterfer, M. and Northemann, W. Two species of IL-6 mRNA with different polyadenylation sites occur in human monocytes. Presented at Second International Workshop on Cytokines, Hilton Head, SC, 1989.
122. Gauldie, J. and Northemann, W. Normal hepatocytes express IL-6 only *in vitro* and under non-physiological conditions. Presented at Second International Workshop on Cytokines, Hilton Head, SC, 1989.
123. Northemann, W., Braciak, T.A., Gauldie, J. and Fey, G.H. Interleukin 6 (IL6) and IL6-like activities produced by rat macrophages and hepatoma cell lines. Presented at Second International Workshop on Cytokines, Hilton Head, SC, 1989.
124. Wollenberg, G.K., LaMarre, J., Gauldie, J. and Hayes, M.A. Effects of dexamethasone and  $\Delta 2$ -macroglobulin on proliferation of normal and neoplastic hepatocytes inhibited by transforming growth factor-Es. Proc. Amer. Assoc. Cancer Res. 30:315, 1989.
125. Cox, G., Vancheri, C., Ohtoshi, T., Gauldie, J., Dolovich, J., Jordana, M. and Denburg, J. Human bronchial epithelial cell derived granulocyte macrophage colony stimulating factor (GM-CSF) prolongs survival of human eosinophils *in vitro*. Presented at American Academy of Allergy and Immunology, 1990.
126. Cox, G., Ohtoshi, T., Gauldie, J., Denburg, J. and Jordana, M. Human bronchial epithelial cells cause differentiation of HL-60 cells and prolong the *in vitro* survival of eosinophils. Presented at 1990 World Conference on Lung Health, 1990.
127. Ohtoshi, T., Kawabori, S., Xaubet, A., Abrams, J.S., Gauldie, J., Dolovich, J., Denburg, J.A. and Jordana, M. Human upper airway fibroblast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) induces basophilic differentiation of human hemopoietic progenitor cells. Presented at 1990 World Conference on Lung Health, 1990.
128. Torry, D., Podor, T., Braciak, T. and Gauldie, J. IL-6 is an exogenous hormone and is delivered systemically to target tissue. Presented at Canadian Society of Immunology Meeting, 1990.

129. Gauldie, J., Geisterfer, M. and Northemann, W. Two species of IL-6 mRNA with different polyadenylation sites occur in human monocytes. Presented at Canadian Society of Immunology Meeting, 1990.
130. Xing, Z., Jordana, M. and Gauldie, J. Extracellular matrix modifies gene expression of inflammatory cytokines in macrophages. Presented at Canadian Society of Immunology Meeting, 1990.
131. Podor, T.J., Hirsh, J., Braciak, T., Torry, D., Zeheb, R., Gelehrter, T. and Gauldie, J. Type 1 plasminogen activator inhibitor (PAI-1) is not a hepatic acute phase reactant. Presented at 10th International Congress on Fibrinolysis, 1990.
132. Gauldie, J. Cytokines in the lung microenvironment. Presented at Joint Meeting SEP-SEPCR, London, U.K., 1990.
133. Gauldie, J., Jordana, M., Cox, G., Denburg, J. and Dolovich, J. Heterogeneous expression of cytokine and cytoskeletal genes in airways fibroblasts. Presented at 6th International Colloquium on Pulmonary Fibrosis, Stowe, Vermont, 1990.
134. Gauldie, J. Cytokines and acute phase protein regulation. Presented at Fifth Symposium on Inflammation Markers, Lyon, France, 1990.
135. Otterness, I.G., Bliven, M.L. and Gauldie, J. Regulation of IL-6 production *in vitro* by tenidap. Presented at Inflammation Research Association Meeting, 1990.
136. Ohtoshi, T., Xing, Z., Gauldie, J., Andersson, B., Vanzieleghe, M., Liehl, E., Ceska, M., Dolovich, J., Jordana, M. and Denburg, J. Human upper airway epithelial cell and fibroblast IL-8 production and its modulation by steroids. *J. Allergy Clin. Immunol.* 87:A174, 1991.
137. Ohno, I., Cox, G., Lea, R., Dolovich, J., Clark, D., Gauldie, J. and Jordana, M. Synthesis and localization of GM-CSF in human airway tissues. *Am. Rev. Respir. Dis.* 143:A201, 1991.
138. Cox, G., Howie, K., Denburg, J., Gauldie, J. and Jordana, M. Human bronchial epithelial cells promote the survival of neutrophils *in vitro*. *Am. Rev. Respir. Dis.* 143:A527, 1991.
139. Xing, Z., Ohtoshi, T., Ralph, P., Jordana, M. and Gauldie, J. Regulation of human peripheral blood monocyte survival by human airway structural cells. *Am. Rev. Respir. Dis.* 143:A527, 1991.
140. Ludwin, D., Sandler, S., Russell, D., Churchill, D. and Gauldie, J. Relationship between cadaver donor IL-6 levels and delayed graft function (DGF) in kidney transplantation. Presented at American Society of Transplant Physicians, Chicago, IL, 1991.
141. Braciak, T.A., Graham, F.L., Richards, C.D. and Gauldie, J. The construction and *in vitro* expression of a recombinant human adenovirus type 5 containing the murine interleukin 6 cDNA. Presented at Canadian Society for Immunology Spring Meeting, 1991.

142. Ohno, I., Lea, R.G., Dolovich, J., Clark, D., Jordana, M. and Gauldie, J. The expression of the TGF-E subtypes in nasal polyposis tissues. Presented at Canadian Society for Immunology Spring Meeting, 1991.
143. Gauldie, J. Regulation of the acute phase response. Presented at the International Conference on Cytokines, Cytokine Receptors, and their Antagonists, Vienna, Austria, 1991.
144. Marshall, J.S., Nielsen, L., Gauldie, J. and Bienenstock, J. LIF production by rat mast cell lines. FASEB J. 5:A1084, 1991.
145. Gauldie, J., Geisterfer, M., Richards, C., Baumann, M., Fey, G. and Gwynne, D. IL-6 and IL-6 receptor expression and modulation during acute inflammation in the rat. Presented at Third International Workshop on Cytokines, Stresa, Italy, 1991.
146. Gauldie, J., Geisterfer, M., Richards, C. and Gwynne, D. IL-6 regulation of the hepatic acute phase response. Presented at International Symposium on IL-6: Physiopathology and Clinical Potentials, Montreux, Switzerland, 1991.
147. Rothwell, N.J., Busbridge, N.J., LeFeuvre, R.A., Hardwick, A.J., Gauldie, J. and Hopkins, S.J. Interleukin-6 as a mediator of fever in the central nervous system. Presented at British Society of Immunology Meeting, Manchester, UK, 1991.
148. Gauldie, J., Driscoll, K. and Jordana, M. Contribution of fibroblasts to the regulation of the inflammatory response. Presented at Society of Toxicology Annual Meeting, Seattle, Washington, 1992.
149. Finotto, S., Ohno, I., Lea, R., Marshall, J., Denburg, J., Dolovich, J., Gauldie, J. and Jordana, M. Tumor necrosis factor $\Delta$  (TNF $\Delta$ ) gene expression by eosinophils in nasal polyp (NP) tissues. Am. Rev. Respir. Dis. 145:A440, 1992.
150. Ohno, I., Finotto, S., Marshall, J., Gauldie, J. and Jordana, M. Cytokine gene expression in airway tissues from patients with chronic airflow limitation (CAL). Am. Rev. Respir. Dis. 145:A440, 1992.
151. Xing, Z., Ohtoshi, T., Jordana, M. and Gauldie, J. Lypopolysaccharides induce GM-CSF, IL-8 and IL-6 gene expression in human nasal fibroblasts but not in lung fibroblasts. Am. Rev. Respir. Dis. 145:A637, 1992.
152. Driscoll, K.E., Maurer, J.K., Hassenbein, D.H., Ohno, I., Gauldie, J. and Jordana, M. Expression of TNF and MIP-2 in rat lung after cadmium chloride induced lung injury. Am. Rev. Respir. Dis. 145:A695, 1992.
153. Woolley, K.L., Jones, N.L., Heigenhauser, G.J. and Gauldie, J. Effect of a short-term, maximal exercise stimulus on serum interleukin-6. Am. Rev. Respir. Dis. 145:A440, 1992.
154. Geisterfer, M., Richards, C., Baumann, M., Fey, G., Gwynne, D. and Gauldie, J. IL-6 and IL-6 receptor (IL-6R) expression and modulation during acute inflammation in the rat. FASEB J. 6:A1896, 1992.

155. Braciak, T.A., Graham, F.L., Richards, C.D. and Gauldie, J. Construction and *in vivo* effects of a recombinant human adenovirus type 5 expressing the murine interleukin 6 cDNA on replication. Presented at Canadian Society for Immunology Meeting, Mont-Rolland, Quebec, 1992 and FASEB J. 6:A1781, 1992.
156. Richards, C.D., Agro, A. and Gauldie, J. Regulation of TIMP expression in synovial fibroblasts by PGE<sub>2</sub> and cytokines. FASEB J. 6:A941, 1992.
157. Khan, I., Blennerhassett, P., Gauldie, J. and Collins, S.M. Cytokine mRNA profile in smooth muscle from the inflamed intestine of the nematode-infected rat. Presented at the American Gastroenterological Association Meeting, San Francisco, CA, 1992.
158. Gauldie, J., Braciak, T., Graham, F., Richards, C. and Geisterfer, M. *In vivo* effects of rodent IL-6 expressed by infection with recombinant human adenovirus type 5 containing cytokine cDNA. Presented at 8th International Congress of Immunology, Budapest, Hungary, 1992.
159. Gauldie, J., Braciak, T., Graham, F., Richards, C. and Geisterfer, M. The use of recombinant human adenovirus (AD5) expressing IL-6 during replication to deliver raised levels of plasma and tissue IL-6 *in vivo*. Presented at Collegium Internationale Allergologicum 19th Symposium, Capri, Italy, 1992.
160. Woolley, K.L., Lands, L.C., Heigenhauser, G.J., Jones, N.L. and Gauldie, J. Effects of high intensity exercise on serum interleukin-6 levels in cystic fibrosis patients and healthy controls. Presented at Sixth Annual North American CF Conference, Washington, D.C., 1992.
161. Gauldie, J., Braciak, T.A., Graham, F.L. and Richards, C.D. *In vivo* effects of a recombinant human adenovirus type 5 expressing rodent interleukin-6 cDNA on replication. Folia Histochemica Cytobiologica 30:A236, 1992.
162. Driscoll, K.E., Maurer, J., Hassenbein, D.H., Ohno, I., Gauldie, J. and Jordana, M. *In situ* characterization TNF expression after acute lung injury. Presented at Society of Toxicology Meeting, New Orleans, LA, 1993.
163. Torry, D.J., Richards, C.D. and Gauldie, J. Anchorage-independent growth of fibroblast colonies from lines established from human idiopathic pulmonary fibrotic tissue. Am. Rev. Respir. Dis. 147:A158, 1993.
164. Sallenave, J.-M., Silva, A., Crossley, J., Jordana, M. and Gauldie, J. The precursor of elafin (pre-elafin): gene structure and regulation. Am. Rev. Respir. Dis. 147:A678, 1993.
165. Xing, Z., Kirpalani, H., Torry, D., Driscoll, K.E., Jordana, M. and Gauldie, J. Detection of tumor necrosis factor  $\Delta$  (TNF $\Delta$ ) and macrophage inflammatory peptide 2 (MIP-2) in the lung of rats exposed to a single intratracheal instillation of lipopolysaccharide (LPS). Am. Rev. Respir. Dis. 147:A730, 1993.

166. Ohno, I., Miura, K., Takanashi, S., Kanai, N., Kirpalani, H., Dolovich, J., Gauldie, J. and Jordana, M. Platelet derived growth factor B (PDGF-B) gene expression by eosinophils in chronically inflamed upper airway tissues. *Am. Rev. Respir. Dis.* 147:A822, 1993.
167. Ohno, I., Driscoll, K.E., Hassenbein, D., Miura, K., Takanashi, S., Gauldie, J. and Jordana, M. Sequential expression of cytokines in lung tissues from rats exposed to cadmium chloride (CdCl<sub>2</sub>). *Am. Rev. Respir. Dis.* 147:A734, 1993.
168. Ohno, I., Kirpalani, H., Miura, K., Takanashi, S., Gauldie, J. and Jordana, M. Cytokine detection in the sputum of smokers with minimal airflow limitation (CAL). *Am. Rev. Respir. Dis.* 147:A865, 1993.
169. Thibault, V., Geisterfer, M. and Gauldie, J. Expression and purification of the full length and soluble (extracellular) forms of rat IL-6 receptor (GP80). Presented at Canadian Society for Immunology Meeting, 1993.
170. Kishter, S., Gauldie, J., Rosenberg, S.A. and Mulé, J. Transfection with a recombinant adenovirus (mIL-6) construct produces high levels of cytokine in both cultured and fresh tumor, but not in tumor infiltrating lymphocytes (TIL). Presented at AACR Meeting, 1993.
171. Kirpalani, H., Xing, Z., Schmidt, B., deSa, D., Gauldie, J. and Jordana, M. Tumor necrosis factor- $\Delta$  (TNF- $\Delta$ ) in a piglet model of barotrauma induced acute lung injury. Presented at American Pediatric Society Meeting, 1993.
172. Woolley, K.L., Lands, L.C., Heigenhauser, G.J., Jones, N.L. and Gauldie, J. Serum interleukin-6 levels in cystic fibrosis patients and healthy controls at rest and after high intensity exercise. *J. Allergy Clin Immunol* 91 (Suppl), 1993.
173. Teoh, K., Bradley, C., Burrows, H. and Gauldie, J. Enhanced inflammatory response following normothermic cardiopulmonary bypass. Presented at The Canadian Transplant Society Meeting, Whistler, BC, 1993.
174. Gauldie, J., Jordana, M., Ohno, I., Cox, G. and Kirpalani, H. Growth- and colony-stimulating factors mediate eosinophil/fibroblasts interactions in chronic airway inflammation. Presented at Cells and Cytokines in Lung Inflammation Meeting and published in *Mediators of Inflammation*, Paris, France, 1993.
175. Ludwin, D., Alexopoulou, I. and Gauldie, J. Expression of interleukin 6 (IL-6) mRNA in ischemically damaged kidneys. Presented at Canadian Transplant Society & Royal College Meeting, 1993.
176. Russell, J.D., Ludwin, D., Carlisle, E.J., Holland, D.C., Gauldie, J. and Lazarovits, A.I. Prevention of OKT3 induced symptoms by blockade of tumour necrosis factor $\Delta$  with pentoxifylline. Presented at American Society of Transplant Physicians Meeting, 1993.

177. Gauldie, J., Xing, Z., Sallenave, J.-M. and Jordana, M. Neutrophil activation and recruitment to the lung. Presented at CCFF Eighth Broken Arrow Conference: Cystic Fibrosis Lung Disease: From Theory to Therapy. Mont Ste-Anne, Quebec, 1993.
178. Gauldie, J. Molecular regulation in acute and chronic lung injury. Presented at 4th Zao Symposium, Yamagata, Japan, 1993.
179. Gauldie, J. Acute phase proteins as markers of inflammation in rheumatic diseases: mechanism of regulation and modulation by tenidap. Presented at Symposium in Gleneagles - Can Rheumatoid Disease be Modified, Gleneagles, Scotland, 1993.
180. Braciak, T.A., Graham, F.L., Schall, T.J., Richards, C.D. and Gauldie, J. Recombinant adenovirus-mRANTES gene transfer into B16 mouse melanoma cells reduces tumorigenicity *in vivo*. FASEB J 8:A201, 1994.
181. Thibault, V. and Gauldie, J. Expression and purification of the soluble form of the interleukin-6 receptor using two different expression systems: E. coli and baculovirus. FASEB J 8:A139, 1994.
182. Tremblay, G.M., Nonaka, M., Sarnstrand, B., Dolovich, J., Gauldie, J. and Jordana, M. Myofibroblast differentiation in nasal polyposis: down-regulation by topical steroids. Am. J. Respir. Crit. Care Med. 149:A632, 1994.
183. Tremblay, G.M., Sallenave, J.-M., Israel-Assayag, E., Dakhama, A., Cormier, Y. and Gauldie, J. Elafin and secretory leukocyte proteinase inhibitor in bronchoalveolar lavage fluid of farmer's lung. Am. J. Respir. Crit. Care Med. 149:A867, 1994.
184. Sallenave, J.-M., Cox, G., Chignard, M. and Gauldie, J. Secretory leukocyte proteinase inhibitor and elafin: production by neutrophils and stimulation by proinflammatory mediators. Am. J. Respir. Crit. Care Med. 149:A869, 1994.
185. Xing, Z., Braciak, T., Vezina, J., Jordana, M. and Gauldie, J. Adenovirus-mediated interleukin-6 gene transfer in rat lung. Am. J. Respir. Crit. Care Med. 149:A32, 1994.
186. Ohno, I., Yamauchi, K., Tamura, G., Tanno, Y., Gauldie, J., Jordana, M. and Shirato, K. Expression of TNF, TGFE1 and PDGF-B by eosinophils in asthmatic bronchial tissues. Am. J. Respir. Crit. Care Med. 149:A957, 1994.
187. Braciak, T.A., Graham, F.L., Richards, C.D. and Gauldie, J. Recombinant human type 5 adenoviruses expressing interleukin 6 upon infection *in vivo* enhance the acute phase response. Presented at Keystone Symposium "The Cellular and Molecular Regulation of the Acute Inflammatory Response", Tamarron, Colorado, 1994.
188. Gauldie, J., Xing, Z., Ohno, I., Driscoll, K. and Jordana, M. Mechanisms of chronic inflammation. Presented at Keystone Symposium "The Cellular and Molecular Regulation of the Acute Inflammatory Response", Colorado. J. Cell. Biochem. 18B:314, 1994.

189. Ludwin, D., Hudoba, P., Alexopoulou, I. and Gauldie, J. The role of interleukin-6 (IL-6) in acute renal injury. Presented at American Society of Transplant Physicians Meeting, Chicago, IL, 1994.
190. Gauldie, J. and Richards, C. Regulation of local and systemic acute phase protein gene expression by cytokines. Presented at British Society of Rheumatology Meeting, Brighton, UK, 1994.
191. Addison, C., Braciak, T., Levy, L., Ralston, R., Muller, W.J., Gauldie, J. and Graham, F.L. Gene therapy of cancer using recombinant adenovirus vectors expressing cytokines. Presented at J.P. Lecocq Conference on Gene Therapy, Strasbourg, France, 1994.
192. Westergren-Thorsson, G., Sarnstrand, B., Jordana, M., Gauldie, J. and Malmstrom, A. Hyaluronan and proteoglycan production is different between different clones of fibroblasts. Presented at 8th Fibrosis Colloquium, Dijon, France, 1994.
193. Gauldie, J., Tremblay, G.M., Sarnstrand, B., Nonaka, M., Dolovich, J. and Jordana, M. Myofibroblast differentiation in chronic airways inflammation. Presented at 8th Fibrosis Colloquium, Dijon, France, 1994.
194. Teoh, K., Bradley, C., Gauldie, J. and Burrows, H. Steroid inhibition of cytokine mediated vasodilation after warm heart surgery. Presented at Canadian Cardiovascular Society Meeting, Edmonton, Alberta, 1994.
195. Teoh, K.H.T., Bradley, C.A., Gauldie, J. and Burrows, H. Steroid inhibition of cytokine mediated vasodilation after warm heart surgery. Presented at American Heart Association Meeting, Dallas, Texas, 1994.
196. Braciak, T.A., Xing, Z., Bacon, K., Graham, F.L., Schall, T.J., Richards, C.D., Croitoru, K. and Gauldie, J. Tissue directed recruitment of mononuclear cells to the lung using a recombinant adenovirus expressing murine RANTES. Cytokine 6:A32, 1994.
197. Xing, Z., Braciak, T., Foley, R., Graham, F.L. and Gauldie, J. Adenovirus-mediated cytokine gene transfer to immune effector cells *in vitro*. Cytokine 6:A205, 1994.
198. Thibault, V. and Gauldie, J. Purification and bioactivity of the soluble form of the interleukin-6 receptor expressed in a baculovirus expression system. Cytokine 6:A102, 1994.
199. Foley, R., Braciak, T., Addison, C., Brazolot-Millan, C., Walker, I., Carter, R., Graham, F. and Gauldie, J. Effective cytokine gene transfer to human bone marrow stromal cells using E1 deleted adenoviral vectors. Cytokine 6:A22, 1994.
200. Addison, C., Braciak, T., Levy, L., Ralston, R., Muller, W.J., Gauldie, J., Graham, F.L. Gene therapy of cancer using recombinant adenovirus vectors expressing cytokines. Presented at European Working Group on Human Gene Transfer and Therapy Meeting, 1994.
201. Foley, R., Braciak, T., Addison, C., Millan, C., Walker, I., Graham, F. and Gauldie, J. Effective cytokine gene transfer in human long-term bone marrow cultured cells using adenoviral vectors. Presented at ASH Annual Meeting, Nashville, 1994.

202. Gauldie, J., Graham, F., Xing, Z., Braciak, T. and Foley, R. Adenovirus vector cytokine gene transfer to lung tissue. *FASEB J.* 9:A858, 1995.
203. Richards, C.D., Xing, Z., Gauldie, J. and Jordana, M. Oncostatin M inhibits neutrophil influx in LPS-induced acute lung inflammation in Sprague-Dawley rats. *FASEB J.* 9:A492, 1995.
204. Xing, Z., Braciak, T., Addison, C., Graham, F.L. and Gauldie, J. Adenovirus-mediated gene transfer to alveolar macrophages. *Am. J. Respir. Crit. Care Med.* 151:A124, 1995.
205. Tremblay, G.M., Chakir, J., Dubé, J., Boulet, J.P., Laviolette, M., Sarnstrand, B., Vincic, L., Jordana, M. and Gauldie, J. Smooth muscle actin expression by myofibroblasts from bronchial tissue of asthmatic subjects. *Am. J. Respir. Crit. Care Med.* 151:A541, 1995.
206. Sallenave, J.-M., Kirpalani, H., Mistry, R., Sabry, M., Cox, G., Wilson, W., Newhouse, M., Tetley, T., Jordana, M. and Gauldie, J. Up-regulation of secretory leukocyte proteinase inhibitor (SLPI) and down-regulation of elafin in pulmonary chronic inflammation. *Am. J. Respir. Crit. Care Med.* 151:A531, 1995.
207. Sallenave, J.-M., Xing, Z., Braciak, T., Graham, F. and Gauldie, J. Construction of recombinant human adenovirus type 5 expressing human elafin and pre-elafin cDNAs. *Am. J. Respir. Crit. Care Med.* 151:A544, 1995.
208. Sime, P.J., Graham, F.L. and Gauldie, J. Construction of a recombinant human adenovirus type 5 vector expressing porcine transforming growth factor E1 cDNA. *Am. J. Respir. Crit. Care Med.* 151:A671, 1995.
209. Sarnstrand, B., Westergren-Thorsson, G., Sime, P.J., Jordana, M., Gauldie, J. and Malmstrom, A. Fibroblast clones differs in proliferation rates and proteoglycan production. *Am. J. Respir. Crit. Care Med.* 151:A560, 1995.
210. Foley, R., Braciak, T., Addison, C., Brazolot-Millan, C., Walker, I., Graham, F., Carter, R. and Gauldie, J. Effective cytokine gene transfer to bone marrow stromal cells using adenoviral vectors. Presented at Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, CO, 1995.
211. Gauldie, J., Graham, F., Xing, Z., Braciak, T. and Foley, R. Adenovirus vector cytokine gene transfer to lung tissue. *J. Cell. Biochem.* 21A:377, 1995.
212. Braciak, T., Addison, C., Graham, F., Muller, W., Richards, C. and Gauldie, J. Intratumor injection of a Rec-Adenovirus expressing murine IL-6 attenuates tumor growth in a transgenic breast carcinoma model. Presented at Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, CO, 1995.
213. Addison, C., Braciak, T., Ralston, R., Muller, W.J., Gauldie, J. and Graham, F.L. Gene therapy of cancer using recombinant adenovirus vectors expressing cytokines. Presented at Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, CO, 1995.



214. Xing, Z., Ohkawara, Y., Jordana, M., Graham, F.L. and Gauldie, J. Adenovirus vector-mediated transient overexpression of GM-CSF induces eosinophilia and monocytosis in the lung. *Cytokine*:7:608(A81), 1995.
215. Ohkawara, Y., Xing, Z., Jordana, M., Graham, F.L. and Gauldie, J. Construction and characterization of a recombinant adenovirus expressing murine interleukin-10. *Cytokine* 7:611(A95), 1995.
216. Thibault, V., Graham, F. and Gauldie, J. Generation of an adenovirus expressing rat soluble interleukin-6 receptor: *in vitro* and *in vivo* roles of SIL-6R. Presented at 3rd International Cytokine Conference, Harrogate, UK, 1995.
217. Addison, C.L., Bramson, J., Braciak, T., Muller, W.J., Ralston, R., Gauldie, J. and Graham, F.L. Regression of established tumors in a murine breast cancer model by adenoviral vectors expressing IL-2 or IL-4. Presented at 4th International Conference on Gene Therapy of Cancer, San Diego, CA, 1995.
218. Bramson, J., Addison, C., Hitt, M., Muller, W.J., Gauldie, J. and Graham, F. Treatment of murine breast cancer using an adenovirus vector expressing interleukin-12. Presented at 4th International Conference on Gene Therapy of Cancer, San Diego, CA, 1995.
219. Foley, S., Carter, R., Wan, Y., Braciak, T., Sime, P., Addison, C. and Gauldie, J. Intra-marrow administration of adenoviral vectors for localized cytokine delivery. Presented at ASH Meeting Seattle, WA, 1995.
220. Sime, P.J., Xing, Z., Graham, F.L. and Gauldie, J. Effects of adenoviral mediated transfer of porcine transforming growth factor beta 1 cDNA to the respiratory tract of rats. Presented at The Great Lakes Lung Conference, Niagara-on-the-Lake, 1995.
221. Ohkawara, Y., Xing, Z., Gauldie, J. and Jordana, M. Adenovirus vector-mediated gene transfer of murine interleukin-10 (mIL-10) inhibits antigen induced airways inflammation in sensitized mice. *Am. J. Respir. Crit. Care Med.* 153:A143, 1996.
222. Stampfli, M.R., Ohkawara, Y., Xing, Z., Lei, X.-F., Gauldie, J. and Jordana, M. Inhibition of sensitization by adenovirus vector-mediated gene transfer of murine interleukin-10 (IL-10) in a murine model of airways inflammation. *Am. J. Respir. Crit. Care Med.* 153:A249, 1996.
223. Xing, Z., Ohkawara, Y., Braciak, T., Tremblay, G.M., Sime, P.J., Jordana, M., Graham, F. and Gauldie, J. Disparate functional consequences of transient overexpression of GM-CSF and IL-5 in the lung. *Am. J. Respir. Crit. Care Med.* 153:A793, 1996.
224. Sime, P.J., Xing, Z., Graham, F.L. and Gauldie, J. Adenoviral mediated transfer of transforming growth factor beta 1 cDNA to the respiratory tracts of rats, alone, and in combination with acute neutrophilic lung inflammation. *Am. J. Respir. Crit. Care Med.* 153:A793, 1996.

225. Sime, P.J., Sarnstrand, B., Graham, F.L., Weindel, K., Fisher, L.W. and Gauldie, J. Recombinant human adenovirus type 5 vectors expressing the core proteins of the proteoglycans decorin and biglycan. *Am. J. Respir. Crit. Care Med.* 153:A112, 1996.
226. Sallenave, J.-M., Xing, Z., Graham, F. and Gauldie, J. Adenovirus (Ad)-mediated expression of pre-elafin (PE) a potent elastase inhibitor, in human and rodent cells. *Am. J. Respir. Crit. Care Med.* 153:A112, 1996.
227. Cox, G., Whitehead, L., Dolovich, M., Jordana, M., Gauldie, J. and Newhouse, M. A randomized controlled trial of inhaled steroid therapy on measures of airway inflammation in adult smokers. *Am. J. Respir. Crit. Care Med.* 153:A126, 1996.
228. Tremblay, G.M., Chakir, J., Boulet, L-P., Gauldie, J. and Richards, C.D. Altered expression of collagenase and TIMP-1 mRNA in asthmatic bronchial fibroblasts. *Am. J. Respir. Crit. Care Med.* 153:A395, 1996.
229. Bramson, J., Hitt, M., Addison, C., Muller, W.J., Gauldie, J. and Graham, F. Immunotherapy of murine breast cancer using an adenovirus vector expressing interleukin-12. Presented at AACR Meeting, 1996.
230. Wan, Y.H., Addison, C., Xing, Z., Bramson, J., Foley, S., Carter, R., Graham, F. and Gauldie, J. Role of bone marrow-derived dendritic cells in tumor vaccination. Presented at Canadian Society for Immunology Spring Meeting, Sainte-Adele, Quebec, 1996.
231. Palmer, K., Braciak, T., Sime, P.J., Graham, F. and Gauldie, J. Adenovirus vector delivery of cytokine anti-sense cDNA inhibits stromal cell production of TGFE and IL-6. Presented at Canadian Society for Immunology Spring Meeting, Sainte-Adele, Quebec, 1996.
232. Waldhauser, L., Guan, J., Dupré, J., Addison, C., Kunkel, S., Chensue, S. and Gauldie, J. Gene therapy directed to selected organs by adenovirus-mediated expression of immunomodulatory cytokines. Presented at Canadian Society for Immunology Spring Meeting, Sainte-Adele, Quebec, 1996.
233. Sime, P.J., Sarnstrand, B., Xing, Z., Graham, F., Fisher, L. and Gauldie, J. Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung. Presented at Aspen Lung Conference, Aspen, 1996.
234. Sallenave, J.-M., Xing, Z., Graham, F. and Gauldie, J. *In vivo* adenovirus (Ad) mediated expression of human pre-elafin (PE), a potent neutrophil elastase inhibitor. Presented at Aspen Lung Conference, Aspen, 1996.
235. Gauldie, J., Sime, P.J., Xing, Z. and Graham, F.L. Adenovirus vector mediated transfer of activated (mutant) transforming growth factor beta 1 cDNA to the respiratory tracts of rats causes fibrosis. Presented at 9th International Colloquium on Pulmonary Fibrosis, Oaxaca City, Mexico, November, 1996.

236. Thibault, V., Botelho, F., Richards, C.D. and Gauldie, J. Antibodies directed against the rat soluble interleukin-6 receptor behave as agonist or antagonist depending on the cell type. Presented at First Joint Meeting - International Cytokine Society and International Society for Interferon and Cytokine Research, Geneva, Switzerland, October, 1996.
237. Gauldie, J., Sime, P.J., Xing, Z. and Graham, F.L. Adenovirus vector mediated transfer of activated (mutant) transforming growth factor beta 1 cDNA to the respiratory tracts of rats causes fibrosis. Presented at First Joint Meeting - International Cytokine Society and International Society for Interferon and Cytokine Research, Geneva, Switzerland, October, 1996.
238. Gauldie, J., Bramson, J., Hitt, M., Addison, C., Muller, W.J. and Graham, F. Immunotherapy of murine breast cancer using an adenovirus vector expressing interleukin-12. Presented at First Joint Meeting - International Cytokine Society and International Society for Interferon and Cytokine Research, Geneva, Switzerland, October, 1996.
239. Van Assche, G., Deng, Y., Gauldie, J. and Collins, S.M. A novel component of the neuro-immune axis in the gut: neural modulation of cytokine production by intestinal smooth muscle. Presented at American Gastroenterological Association and American Association for the Study of Liver Diseases, 1996.
240. Hogaboam, C.M., Addison, C.L., Gauldie, J. and Collins, S.M. Interleukin-4 gene transfer to the intestine causes inflammation and muscle dysfunction in the mouse. Presented at American Gastroenterological Association and American Association for the Study of Liver Diseases, 1996.
241. Wan, Y., Bramson, J., Carter, R., Graham, F. and Gauldie, J. Dendritic cells transfected with adenovirus vectors encoding a model tumor-associated antigen for tumor immunotherapy. Presented at Cold Spring Harbor Laboratory Meeting, 1996.
242. Bramson, J., Hitt, M., Gauldie, J. and Graham, F. Pre-existing immunity to adenovirus reduces virus dissemination but does not prevent tumor regression following intratumoral administration of a vector expressing IL-12. Presented at Cold Spring Harbor Laboratory Meeting, 1996.
243. Sime, P.J., Xing, Z., Graham, F.L. and Gauldie, J. Overexpression of activated [mutant] transforming growth factor-E1 in rat lung induces extensive fibrosis. Presented at The Third Great Lakes Lung Conference, Niagara-on-the-Lake, Ontario, 1996.
244. Foley, R., Walker, I., Greene, K., Couban, S., Messner, H. and Gauldie, J. Monitoring Interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation: a marker of acute graft-versus-host disease. Presented at 5th International Meeting of the Canadian Bone Marrow Transplantation Group, Calgary, 1996.
245. Tremblay, G.M., Sallenave, J.-M., Chakir, J., Laviolette, M., Boulet, L.-P. and Gauldie, J. Pre- and post-allergen challenge bronchoalveolar lavage (BAL) serine protease inhibitor levels in asthma. *Am. J. Respir. Crit. Care Med.* 155:A655, 1997.

246. Sallenave, J.-M., Donnelly, S.C., Gauldie, J. and Haslett, C. Secretory leukocyte proteinase inhibitor (SLPI), alpha-1 proteinase inhibitor (alpha-1Pi) and elafin levels are augmented in the adult respiratory distress syndrome (ARDS). *Am. J. Respir. Crit. Care Med.* 155:A651, 1997.
247. Lei, X.-F., Ohkawara, Y., Stampfli, M.R., Gauldie, J., Jordana, M. and Xing, Z. Compartmentalized GM-CSF transgene expression and its effect on antigen-induced airways eosinophilic inflammation. *Am. J. Respir. Crit. Care Med.* 155:A205, 1997.
248. Sime, P.J., Xing, Z., Graham, F.L. and Gauldie, J. Adenovirus-mediated transient overexpression of active TGF-E1 in rat lung induces prolonged and aggressive interstitial and pleural fibrosis with induction of myofibroblasts. *Am. J. Respir. Crit. Care Med.* 155:A447, 1997.
249. Redington, A.E., Sime, P.J., Telemaque, S., Yanagisawa, M. and Gauldie, J. Adenovirus-mediated expression of endothelin-1 by pulmonary epithelial cells and fibroblasts. *Am. J. Respir. Crit. Care Med.* 155:A357, 1997.
250. Xing, Z., Achong, M., Lei, X.-F., Cox, G., Jordana, M. and Gauldie, J. Enhanced pulmonary inflammatory responses to local endotoxin challenge in interleukin-6 deficient mice. *Am. J. Respir. Crit. Care Med.* 155:A500, 1997.
251. Richards, C.D., Langdon, C., Tremblay, G.M., Sallenave, J.-M. and Gauldie, J. Oncostatin M regulation of alpha-1-proteinase inhibitor expression in lung fibroblasts. *Am. J. Respir. Crit. Care Med.* 155:A749, 1997.
252. Xing, Z., Tremblay, G.M., Graham, F.L. and Gauldie, J. Intradermal GM-CSF gene transfer in rat induces skin pathologies similar to chronic atopic dermatitis. *J. Allergy Clin. Immunol.* 99:A1078, 1997.
253. Driscoll, K., Hassenbein, D., Howard, B., Carter, J., Gauldie, J., Janssen, Y. and Mossman, B. Cytokines, oxidative stress and inflammation. Presented at 6<sup>th</sup> International Inhalation Symposium, Hannover, Germany, 1997.
254. Emtage, P.C.R., Wan, Y., Bramson, J.L., Graham, F.L. and Gauldie, J. A double recombinant adenovirus expressing mB7-1 and hIL-2 induces complete tumor regression in a murine breast adenocarcinoma model. Presented at Canadian Society for Immunology Spring Meeting, Lake Louise, 1997.
255. Lukacs, N.W., Addison, C., Gauldie, J., Simpson, K., Strieter, R.M. Chensue, S.W. and Kunkel, S.L. Transgene-induced production of IL-4 alters the development and collagen expression of Th1 type pulmonary granulomas. *FASEB J* 11:A229, 1997.
256. Eddy, A., Sime, P. and Gauldie, J. Renal effects of intramuscular TGF-E1 adenovirus gene therapy in tolerant rats. Presented at American Society of Nephrology Meeting, November, 1997.
257. Carter, B., Addison, C., Graham, F.L. and Gauldie, J. Interleukin-4 expression in an adenoviral vector induced murine breast cancer regression - a histologic study. Presented at Royal College Meeting, 1997.

258. Gauldie, J., Bramson, J.L., Wan, Y., Addison, C., Emtage, P.C.R. and Graham, F.L. Adenoviral vector mediated cytokine gene therapy of cancer. Presented at CFBS Meeting, Quebec City, 1997.
259. Boehler, A., Chamberlain, D., Xing, Z., Liu, M., Slutsky, A.S., Gauldie, J., Jordana, M., Keshavjee, S. Adenoviral-mediated IL-10 gene transfer attenuates post-transplant fibrous airway obliteration in an animal model for bronchiolitis obliterans. *Eur. Respir. J.* 10:20S, 1997.
260. Lau, K., Kruth, S., Ellis, R., Walker, I., Gauldie, J. and Foley, R. Intramarrow administration of an adenoviral vector expressing canine GM-CSF to alleviate neutropenia in dogs treated with chemotherapy. Presented at ASH Annual Meeting, San Diego, CA, 1997.
261. Lam, W., Walker, I., Gauldie, J. and Foley, R. Adenoviral-based gene transfer of two forms of stem cell factor to human bone marrow stromal cells. Presented at ASH Annual Meeting, San Diego, CA, 1997.
262. Wan, Y., Ross, C., Walker, I., Gauldie, J. and Foley, R. Isolation and characterization of cultured human dendritic cells: a potential target for adenoviral-based gene transfer of tumour peptides. Presented at ASH Annual Meeting, San Diego, CA, 1997.
263. Sallenave, J.M., Xing, Z., Graham, F. and Gauldie, J. *In vivo* adenovirus-mediated expression of human pre-elafin, a potent neutrophil elastase inhibitor. *Chest* 111:128S-129S, 1997.
264. Sime, P.J., Sarnstrand, B., Xing, Z., Graham, F.L., Fisher, L. and Gauldie, J. Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung. *Chest* 111:137S, 1997.
265. Gauldie, J., Sime, P.J., Marr, R., Tremblay, G. and Xing, Z. TGFE gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Presented at Diexiemes Entretiens du Centre Jacques Cartier, Lyon, France, December, 1997.
266. Sime, P.J., Gauldie, D., Xing, Z., Marr, R., Graham, F.L. and Gauldie, J. Expression of TNF- $\Delta$  in rat lung induces neutrophilia, monocytosis, and patchy interstitial fibrosis. *Am. J. Respir. Crit. Care Med.* 157:A356, 1998.
267. Sime, P.J., Sussman, K.A., Stampfli, M.R., Lei, X.-F., Mastruzzo, C., Cox, G.P., Gauldie, J. and Jordana, M. Gene transfer of TGF-E1 to the airways accelerates resolution of antigen-induced airways inflammation in a murine model of experimental asthma. *Am. J. Respir. Crit. Care Med.* 157:A263, 1998.
268. Waldhauser, L.K., Lukacs, N.W., Lei, X.-F., Jordana, M., Gauldie, J. and Xing, Z. Adenovirus-mediated gene transfer of interleukin-4 in mouse lung induces marked airways eosinophilia. *Am. J. Respir. Crit. Care Med.* 157:A477, 1998.
269. Wakeham, J., Wang, J., Gauldie, J., Magram, J., Croitoru, K., Harkness, R., Dunn, P., Zganiacz, A. and Xing, Z. Lack of types 1 and 2 cytokines, and tissue immune-inflammatory

- responses during pulmonary mycobacterial infection in interleukin-12 deficient mice. *Am. J. Respir. Crit. Care Med.* 157:A216, 1998.
270. Sarnstrand, B., Sime, P.J., Gauldie, J., Malmstrom, A. and Westergren-Thorsson, G. Infection with recombinant human adenovirus constructs expressing the cDNA biglycan results in increased synthesis of connective tissue components *in vitro* and *in vivo*. *Am. J. Respir. Crit. Care Med.* 157:A245, 1998.
271. Zhao, J., Sime, P.J., Bringas, P., Tefft, J.D., Gauldie, J. and Warburton, D. Spatial-specific TGF-E1 regulation and activation by adenovirus-mediated gene transfer during embryonic mouse lung branching morphogenesis. *Am. J. Respir. Crit. Care Med.* 157:A432, 1998.
272. Lasky, J.A., Ortiz, L.A., Sime, P., Tonthat, B., Liu, J.-Y., Lungarella, G., Grotendorst, G., Gauldie, J., Brody, A.R. and Friedman, M. *In vitro* and *in vivo* support of a role for connective tissue growth factor (CTGF) in lung fibrogenesis. *Am. J. Respir. Crit. Care Med.* 157:A247, 1998.
273. Sime, P.J., Xing, Z., Varia, M.H., Brenner, D.A., Graham, F.L. and Gauldie, J. Adenovector-mediated overexpression of active TGF-E1 induces tissue specific pathologic outcomes. Presented at Keystone Symposia – Wound Repair, January, 1998.
274. Emtage, P.C.R., Wan, Y., Bramson, J.L., Graham, F.L. and Gauldie, J. A double recombinant adenovirus expressing B7-1 and IL-2 induces regression and protection from metastases in murine breast cancer. Presented at Keystone Symposia – Molecular and Cellular Biology of Gene Therapy, January, 1998.
275. Wan, Y., Emtage, P., Roberts, B., Carter, R. and Gauldie, J. Enhancement of immune response to melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. *Proc. Amer. Assoc. Cancer Res.* 39:571, 1998.
276. Emtage, P.C.R., Wan, Y., Hitt, M., Graham, F., Muller, W., Zlotnik, A. and Gauldie J. Adenoviral vectors expressing lymphotactin and IL-2 or lymphotactin and IL-12 synergise to facilitate tumor regression in murine breast cancer models. *Proc. Amer. Assoc. Cancer Res.* 39: 1998.
277. Wan, Y., Emtage, P., Carter, R. and Gauldie, J. Adenovirally transduced dendritic cells overcome immunologic barriers to adenovirus-based cancer vaccines. Presented at Keystone Symposia – Cellular and Molecular Biology of Dendritic Cells, March, 1998.
278. Palmer, K., Emtage, P., Strieter, R. and Gauldie, J. Adenovirus gene transfer of human interferon inducible protein 10 in rodent lung. Presented at Canadian Society for Immunology Meeting, March, 1998.
279. Emtage, P.C.R., Wan, Y., Hitt, M., Graham, F., Muller, W., Zlotnik, A. and Gauldie, J. Adenoviral vectors expressing lymphotactin and IL-2 or lymphotactin and IL-12 synergise to facilitate tumor regression in murine breast cancer models. Presented at the Canadian Society for Immunology Meeting, March, 1998.

280. Emtage, P.C.R., Xing, Z., Wan, Y., Zlotnik, A., Graham, F.L. and Gauldie, J. Gene transfer of lymphotactin to the lungs of mice and rats results in the infiltration and accumulation of CD4<sup>+</sup>, CD8<sup>+</sup> and NK cells. Presented at the Canadian Society for Immunology Meeting, March, 1998.
281. Gauldie, J., Sime, P.J., Marr, R., Tremblay, G. and Xing, Z. TGFE gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Presented at 10<sup>th</sup> International Colloquium on Lung Fibrosis, Siena, Italy, October, 1998.
282. Sime, P.J., Hewlett, B., Marshall, J.S., Xing, Z., Graham, F.L. and Gauldie, J. Mast cell accumulation in a TGF-E1-induced model of pulmonary fibrosis. Presented at 10<sup>th</sup> International Colloquium on Lung Fibrosis, Siena, Italy, October, 1998.
283. Gauldie, J., Sime, P.J., Marr, R., Tremblay, G. and Xing, Z. Myofibroblast as a marker of fibrogenesis and tissue remodelling is induced by TGFE *in vivo*. Presented at International Symposium on "Airway inflammation and bronchial asthma: molecular and cellular pathways", Taormina, Italy, June, 1998.
284. Gabaglia, C.R., Pedersen, B., Burdin, N., Hitt, M., Sercarz, E.E., Graham, F.L., Gauldie, J. and Braciak, T.A. Adenoviruses expressing cytokines can alter T cell differentiation and affect recovery against murine cutaneous leishmaniasis. FASEB J. 12:A572, 1998.
285. Wan, Y., Emtage, P., Zhu, Q., Panju, M. and Gauldie, J. Adenovirus-transduced dendritic cells prime both CD8 class I and CD4 class II-restricted CTL via CD4-dependent mechanism. Presented at 5<sup>th</sup> International Symposium on Dendritic Cells in Fundamental and Clinical Immunology, Pittsburgh, September, 1998.
286. Vallance, B.A., Radojevic, N., Barbara, G., Galeazzi, F., Graham, F.L., Gauldie, J. and Collins, S.M. The facilitative role of epithelial barrier disruption in successful gene transfer to the colon. Gastroenterology 114:G4517, 1998.
287. Kouroukis, C., Soamboonsrup, P., Schroeder, J., Sime, P., Gauldie, J. and Foley, R. Loss of CD3<sup>+</sup>/CD38<sup>+</sup>-cells during *ex vivo* expansion of purified CD34<sup>+</sup> stem cells using adenoviral-based gene transfer of stem cell factor to bone marrow stromal cells. ASH, Miami, FL, 1998.
288. Boehler, A., Chamberlain, D., Bai, X.H., Xing, Z., Liu, M., Jordana, M., Gauldie, J., Slutsky, A.S. and Keshavjee, S. IL-10 gene transfer downregulates allograft tracheal transplant induced IL-2 gene expression. Am. J. Respir. Crit. Care Med. 159:A402, 1999.
289. Zhao, J., Sime, P.J., Gauldie, J. and Warburton, D. Adenovirus-mediated decorin gene transfer prevents TGF-E-induced inhibition of embryonic lung branching morphogenesis. Am. J. Respir. Crit. Care Med. 159:A402, 1999.
290. Sime, P.J., Hewlett, B.R., Marshall, J.S., Xing, Z., Graham, F.L. and Gauldie, J. Mast cell hyperplasia and heterogeneity in a TGF-E1-induced model of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 159:A402, 1999.

291. Zhao, J., Sime, P.J., Bringas, P., Lee, M., Gauldie, J. and Warburton, D. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. *FASEB J.* 13:A354, 1999.
292. Galt, T., Sime, P.J. and Gauldie, J. Immune response is not involved in fibrogenesis induced by TGF-E1 gene transfer with adenovirus vectors. Presented at the Canadian Society for Immunology Meeting, Lake Louise, 1999.
293. Palmer, K., Hitt, M., Gyorffy, S. and Gauldie, J. Intra-tumor administration of adenovirus vectors expressing interferon inducible protein-10 and interleukin-12. Presented at the Canadian Society for Immunology Meeting, Lake Louise, 1999.
294. Gyorffy, S., Hitt, M., Palmer, K. and Gauldie, J. Treatment of a murine breast cancer model with Ad-5 adenovirus expressing angiostatin and interleukin-12. A role for combination anti-angiogenesis and immunotherapy therapy. Presented at the Canadian Society for Immunology Meeting, Lake Louise, 1999.
295. Wan, Y., Chen, Y., Emtage, P., Hitt, M., Zhu, Q., Foley, R., Muller, W. and Gauldie, J. Induction of HER-2/NEU specific antitumor immunity with adenovirus-transduced dendritic cells. Presented at the 4<sup>th</sup> World Congress on Advances in Oncology and 2<sup>nd</sup> International Symposium on Molecular Medicine. Athens, Greece, October, 1999.
296. Singh, R.R., Chin, J.N., Bui, T.V., Saxena, V., Graham, F., Gauldie, J. and Braciak, T.A. Recombinant adenovirus-mediated cytokine gene transfer in murine lupus: *In vivo* cytokine regulation of autoantibody production. Presented at Arthritis Research Conference, August, 1999.
297. Singh, R.R., Chin, J.N., Graham, F.L., Gauldie, J. and Braciak, T.A. A single administration of the IL-4 or IL-12 gene along with self-peptides have long-lasting but opposite effects on autoantibody production in lupus mice. Presented at the American College of Rheumatology Meeting, 1999.
298. Gauldie, J. Regulation of inflammation by cytokine gene transfer. *Mediators of Inflammation* 8:S74, 1999.
299. Margetts, P.J., Galt, T.M., Kolb, M. and Gauldie, J. The effect of transient overexpression of transforming growth factor E on the peritoneal membrane. Presented at the Second Combined International Peritoneal Adhesion and Repair and Mesothelioma Meeting, 1999.
300. Gauldie, J. and Richards, C. Cytokine gene transfer to the liver and regulation of the acute phase response. Presented at the Falk Symposium No 113: Cytokines and Cell Homeostasis in the Gastrointestinal Tract, Regensburg, Germany, September, 1999.
301. Gauldie, J., Sime, P.J., Marr, R. and Xing, Z. Cytokine gene transfer in models of pulmonary inflammation. *Resp. Med.* 93:A.7, 1999.
302. Braciak, T.A., Ward, E.S., Pedersen, B., Chin, J., Hsiao, C., Graham, F.L., Gauldie, J., Sercarz, E.E. and Kumar, V. A single administration of a recombinant adenovirus expressing the



<sup>v</sup>E8.2 TCR protects mice against experimental autoimmune encephalomyelitis. Presented at Keystone Conference "Tolerance and Autoimmunity", 1999.

303. Särnstrand, B., Westergren-Thorsson, G., Sime, P.J., Jordana, M., Gauldie, J. and Malmström, A. Lung fibroblast clones from normal and fibrotic subjects differ in hyaluronan and decorin production and rate of proliferation. *Am. J. Respir. Crit. Care Med.* 161:A479, 2000.
304. Kolb, M., Galt, T., Margetts, P., Sime, P. and Gauldie, J. Administration of AdDecorin reduces experimental lung fibrosis. *Am. J. Respir. Crit. Care Med.* 161:A751, 2000.
305. Kolb, M., Inman, M. and Gauldie, J. Budesonide improves transgene expression in a model of repeated delivery of Adenovectors. *Am. J. Respir. Crit. Care Med.* 161:A285, 2000.
306. Margetts, P.J., Galt, T., Kolb, M., Hoff, C.M., Shockley, T.R. and Gauldie, J. Solute transport after overexpression of TGFE1 in the rat peritoneum using adenovirus mediated gene transfer. Presented at Canadian Society of Nephrology Meeting, 2000.
307. Palmer, K., Hitt, M., Emtage, P., Gyorffy, S. and Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. *Proc. AACR* 41:A82, 2000.
308. Wan, Y., Bramson, J., Pilon, A., Zhu, Q. and Gauldie, J. Genetically modified dendritic cells prime auto-reactive T cells through a pathway independent of CD40L and IL-12: Implications for cancer vaccines. Presented at 6<sup>th</sup> International Symposium on Dendritic Cells, Australia, May, 2000.
309. Foley, R., Tozer, R., Wan, Y., McCulloch, P., Dent, P. and Gauldie, J. A Phase I/II study investigating the role of autologous CD34+ derived dendritic cells transduced with an adenovirus expressing human gp100 in patients with metastatic melanoma. Presented at 6<sup>th</sup> International Symposium on Dendritic Cells, Australia, May, 2000.
310. Gauldie, J., Galt, T. and Warburton, D. Transfer of TGFE gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia (BPD). *Am. J. Respir. Crit. Care Med.* 163:A492, 2001.
311. Gauldie, J., Galt, T., Anzano, M.A., Deng, C. and Roberts, A.B. SMAD3 KO mouse is resistant to gene-based TGFE1 induced fibrosis: lack of activation of CTGF. *Am. J. Respir. Crit. Care Med.* 163:A759, 2001.
312. Kolb, M., Sime, P.J., Galt, T., Margetts, P.J. and Gauldie, J. Differences in TGFE mediated fibrogenesis in various mouse strains. *Am. J. Respir. Crit. Care Med.* 163:A946, 2001.
313. Kolb, M., Margetts, P.J., Galt, T. and Gauldie, J. Overexpression of Interleukin-1E results in lung fibrosis through induction of TGFE. *Am. J. Respir. Crit. Care Med.* 163:A423, 2001.
314. Kolb, M., Inman, M., Wattie, J. and Gauldie, J. Chronic airway challenge results in pulmonary hypertension in mice. *Am. J. Respir. Crit. Care Med.* 163:A404, 2001.

315. Wiley, R.E., Emtage, P., Gajewska, B.U., Stämpfli, M.R., Gauldie, J., White, J. and Jordana, M. Expression of the chemokine MIP-3 $\Delta$  in the airways of mice enriches antigen-presenting cell populations and permits non-allergic sensitization to aerosolized ovalbumin. *Am. J. Respir. Crit. Care Med.* 163:A593, 2001.
316. Dabrosin, C., Gyorffy, S. and Gauldie, J. Therapeutic effect of angiostatin gene transfer in a murine endometriosis model. Presented at Keystone Symposia, Keystone, Colorado, April 2001.
317. Margetts, P.J., Gyorffy, S., Kolb, M., Hoff, C.M. and Gauldie, J. Anti-angiogenic and anti-fibrotic adenovirus mediated gene therapy in a rodent chronic inflammatory model of peritoneal dialysis. Presented at ASN Meeting, San Francisco, October, 2001.
318. Margetts, P.J., Kolb, M., Hoff, C.M. and Gauldie, J. The role of angiopoietins in resolution of neoangiogenesis resulting from adenoviral mediated gene transfer of TGFE1 or VEGF to the rat peritoneum. Presented at ASN Meeting, San Francisco, October, 2001.
319. Margetts, P.J., Kolb, M., Hoff, C.M. and Gauldie, J. Different fibrogenic and angiogenic responses to transient overexpression of TNF $\Delta$  or IL-1E by adenoviral mediated gene transfer to the rat peritoneum. Presented at ASN Meeting, San Francisco, October, 2001.
320. Gyorffy, S., Woods, J.P., Foley, R., Kruth, S., Liaw, P.C.Y. and Gauldie, J. Bone marrow derived dendritic cell vaccination of spontaneous canine melanoma using human GP100 antigen. Clinical and immunological findings. Presented at 43<sup>rd</sup> ASH Annual Meeting, December, 2001.
321. Palmer, K., Sharan, N., Emtage, P., Gauldie, J., Muller, W.J. and Wan, Y. Intra-tumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth. Presented at AACR Meeting, San Francisco, April, 2002.
322. Patton, L., Wan, Y., Long, J., Bramson, J. and Gauldie, J. Evaluation of a dendritic cell-based vaccine expressing multiple melanoma differentiation antigens. Presented at AACR Meeting, San Francisco, April, 2002.
323. Kolb, M., Bonniaud, P., Kelly, M., Margetts, P., Galt, T., Groffen, J. and Gauldie, J. TGFE3 induces a marked fibroproliferative but not progressive fibrotic response in the lung. Presented at ATS Meeting, May, 2002.
324. Jeganathan, P., Gauldie, J. and Fox-Robichaud, A.E. Hepatic leukocyte-endothelial cell interactions in a model of chronic IL-1 expression. *FASEB J* 16:A123, 2002.
325. Braciak, T.A., Gauldie, J., Graham, F.L., Sercarz, E.E. and Kumar, V. Vbeta 8.2 TCR-centered regulation of experimental autoimmune encephalomyelitis is disrupted by co-administration with adenovirus vectors expressing either interleukin-4 or 10. *FASEB J* 16:A1058, 2002.

326. Margetts, P.J., Galt, T., Yu, L., Hoff, C.M., Holmes, C.J. and Gauldie, J. Adenovirus mediated gene transfer of transforming growth factor E3 to the rat peritoneum leads to transient ultrafiltration dysfunction. Presented at ASH Meeting, September, 2002.
327. Kelly, M., Leigh, R., Gauldie, J., Ellis, R., Wattie, J., Smith, M.J., O'Byrne, P. and Inman, M. Airway remodeling in a murine model of asthma: the role of smooth muscle cells in the increased extracellular matrix. Presented at the 12<sup>th</sup> International Colloquium on Lung Fibrosis, Glion, Switzerland, October, 2002.
328. Bonniaud, P., Margetts, P., Kolb, M., Sime, P. and Gauldie, J. Connective tissue growth factor overexpression induces a transient fibrotic response in the lung. Presented at the 12<sup>th</sup> International Colloquium on Lung Fibrosis, Glion, Switzerland, October, 2002.
329. Kolb, M., Bonniaud, P. and Gauldie, J. Differences in the fibrogenic response after transfer of active TGFE1 gene to lungs of a "fibrosis-prone" and a "resistant" mouse strain. Presented at the 12<sup>th</sup> International Colloquium on Lung Fibrosis, Glion, Switzerland, October, 2002.
330. Rodriguez-Lecompte, J.C., Gyorffy, S., Majumdar, A., Gauldie, J. and Wan, Y. Dendritic cells transduced with adenovirus expressing human tert or gp100 tumor-associated antigens as cancer vaccines. Presented at VCS Meeting, New York, 2002.
331. Kolb, M., Bonniaud, Kelly, M., Margetts, P., Galt, T., Groffen, J. and Gauldie, J. TGFE3 induces a marked fibroproliferative but not pregressive fibrotic response in the lung. *Am. J. Respir. Crit. Care Med.* 165:A170, 2002.
332. Margetts, P.J., Gyorffy, S., Kolb, M., Hoff, C.M. and Gauldie, J. Anti-angiogenic and anti-fibrotic adenovirus mediated gene therapy in a rodent chronic inflammatory model of peritoneal dialysis. Presented at ASN Meeting, 2002.
333. Margetts, P.J., Galt, T., Yu, L., Hoff, C.M., Holmes, C.J., Groffen, J. and Gauldie, J. Adenovirus mediated gene transfer of transforming growth factor E3 to the rat peritoneum leads to transient ultrafiltration dysfunction. To be presented at ASN Meeting, 2003.
334. Bonniaud, P., Kolb, M., Galt, T., Roberts, A.B., Margetts, P.J. and Gauldie, J. Smad 3 KO mice are resistant to TGF-E1 mediated fibrogenesis and do not induce a pro-fibrotic microenvironment. To be presented at ATS Meeting, 2003.
335. Bonniaud, P., Margetts, P.J., Kolb, M., Kapoun, A.M., Protter, A.A. and Gauldie, J. TGF-E1 receptor I inhibitor, SD-208, dramatically inhibits lung fibrosis induced by TGF-E1 overexpression in rat lungs. To be presented at ATS Meeting, 2003.

Exhibit B: Adenoviral-based gene delivery in the  
lower GI tract induces antigen-specific immune  
responses and protection from Tumour challenge





## **Adenoviral-based gene delivery in the lower GI tract induces antigen-specific immune responses and protection from Tumour challenge**

### **Background:**

The entry of pathogenic organisms most often occurs at the mucosal surfaces. To prevent infectious diseases, such as sexually transmitted disease, in the genital-urinary (GU) and the lower gastrointestinal (GI) tracts, induction of protective immunity at these mucosal sites against microbial access is critical. Induction of systemic immune responses against further invasion of pathogens into the body through the mucosa is also important. In addition, induction of a potent Cytotoxic T Lymphocyte response (CTL) is important both for control of viral infections and for tumour surveillance and protection.

### **Aim:**

To investigate potential of local gene expression within the rectal tissue, using adenoviral vectors (AdV), to promote local mucosal and systemic antigen-specific cell and humoral immune responses. To document the efficacy of the rectal route for generation of protective immunity at both the local tissue site and for systemic immunity.

### **Methods:**

1. AdV encoding the LacZ reporter gene (AdLacZ) or an immunogenic antigen, such as chicken ovalbumin (AdOVA  $5 \times 10^9$  pfu), was administered intrarectally (iR) through the anus of mice. Mice were first subjected to a 50% Ethanol wash (enema) for one hour. AdV was then delivered into the lumen of the colo-rectum.
2. 14 days post iR immunization with AdOVA, a homologous tumor cell line (EL4) expressing OVA antigen (E.G7-OVA) was injected intra-mucosally in the rectal tissue (local challenge) or subcutaneously (systemic challenge) into mice and tumor formation and growth was followed

over a period of time at regular intervals as well as survival on the mouse. When tumor volumes reached more than 1000 mm<sup>3</sup>, mice were euthanized.

3. Colo-rectal tissues and local draining lymph nodes (iliac node) as well as non-draining nodes (cecal node) were examined for gene expression and local responses to the OVA gene. 14 days after AdOVA administration, spleen cells were also collected for measurement of cytokine production and determination of antigen-specific CTL activities using specific OVA peptide (SIINFEKL) pulsed target cells (EL4 based). Mice deficient in CD8 T cells (CD8 KO) were used to investigate the role of CD8 T cells in the CTL response and protection from tumour challenge.

### **Results:**

1. Staining for  $\beta$ -galactosidase showed that the expression of the transferred gene was widespread across the crypts and villi of the colo-rectal epithelial layer from one to three days post iR administration (Fig 1, 4, 5). The transgene expression was dose dependent (Fig 6).

2. 14 days after AdOVA iR immunization, mice were protected from tumor challenge with OVA-antigen expressing tumour cells (EG7-OVA) either delivered to a systemic site, subcutaneously (Fig 2, 9, 10), or to a local site, intra-mucosally (Fig 11). The protection from tumour challenge after iR immunization was shown to be CD8 dependent through the use of CD8 KO mice where the protection was abolished (Fig 12). Protection was not seen when OVA protein alone was delivered to the rectal tissue (Fi 12).

3. OVA-specific systemic (spleen) and local (Draining lymph nodes) CTL responses were detected 14 days after AdOVA iR immunization (from 20% to 60% in separate experiments vs. ~1% in the control) (Fig 3, 7, 8).

4. The production of INF- $\gamma$ , but not IL-4, was dramatically increased in the culture of spleen cells re-stimulated with OVA protein (1076.7 pg/ml vs. 42.8 pg/ml).

**Conclusions:**

1. Transgenes can be effectively delivered by AdV in the lower GI tract and expressed widespread across the crypts and villi of the colo-rectal mucosal surfaces.
2. Adenovirus-based mucosal intra-rectal (iR) gene delivery induces both strong systemic and local mucosal immune responses, which are antigen specific. This method offers direct advantages as a vaccination route to induce local immune responses within the colo-rectal tissue and within the common mucosal tissue in general. This route of immunization also offers induction of protective CTL activity and long-lasting immune protection from tumour challenge.



Fig 1. LacZ expression visilized in the colo-rectum one day after AdLacZ iR delivery.




Fig 2. Tumor protection and tumor growth after E.G7-OVA challenge in iR AdOVA-immunized mice.







Fig 3. Spleen CTL response against EL-4 pulsed with OVA peptide SIINFEKL. The results represent the CTL response from 2 independent experiments.



# Visualization of gene expression in the colon

Day 2 after AdLacZ  $5 \times 10^9$  pfu IR Fig 4




# Visualization of gene expression in the colon

Fig 5

Day 2 after AdLacZ  $5 \times 10^9$  pfu IR



AdLacZ staining



Anti-LacZ Ab

Gene expression is found across the villi and crypts of the epithelium and “maybe the LP” of the colon, implying efficiency of gene delivery by Adv at high doses.




# Visualization of gene expression in the colon

--- Dose dependent study ----

Fig 6

Day 3 after AdLacZ IR




$5 \times 10^8$  pfu       $1 \times 10^9$  pfu       $2 \times 10^9$  pfu

Adv IR-administrated gene can be delivered onto the epithelial cells and be expressed.



# Induction of cellular immune responses by AdOVA IR

--- Systemic (spleen)---



Systemic CTL responses induced by AdOVA IR were antigen-specific.


Fig 7



# Induction of cellular immune responses after AdOVA IR

--- Local (DLNs)---

Day 5



Local DLN primary CTL responses induced by AdOVA IR were also antigen-specific.


Fig 8



# Induction of protective immunity by AdOVA IR

--- Systemic immunity against tumor challenge ---

Short term



Systemic immune responses induced by AdOVA were protective



Fig 9



# Induction of protective immunity by AdOVA IR

## --- Systemic immunity against tumor challenge ---

Long term




Systemic immune responses induced by AdOVA were protective

Fig 10



# Induction of protective immunity by AdOVA IR

## Local Immunity against tumor challenge in the rectal mucosa




Mucosal immune responses induced by AdOVA were protective

Fig 11

# Induction of protective immunity by AdOVA IR

--- CD8 dependent ---



The CTL responses are CD8 dependent (CD8 KO not protected). Also, OVA protein alone was not able to induce protective immune responses

Fig 12



Exhibit C: Induction of protective distal mucosal  
immunity against HSV-2 infection





## Summary: Induction of protective distal mucosal immunity against HSV-2 infection

### Abbreviations:

Adv	Adenoviral vector
IR	Intrarectal
IVAG	Intravaginal
gB	Glycoprotein B
pfu	Plaques forming unit
HSV-2	Herpes simplex virus type 2
tw	Tissue weight
LD <sub>50</sub>	50% lethal dose
vw	Vaginal wash

## Materials and Methods

### *Animals, cell cultures and viruses*

Female C57BL/6 mice were 6-8 weeks of age during immunization with Adv. Vero cells were grown in complete  $\alpha$ -MEM media. Recombinant AdgB is an Adenovirus vector that encodes gB8, the surface protein gene from HSV. HSV-2 strain 333 was propagated and titered on Vero cells.

### *IR immunization and virus challenge*

Mice were anesthetized with isoflurane and instilled with 50% ethanol into the colo-rectum, and kept under anesthesia for 30 min. One hour later, AdgB was IR delivered by insertion of a pipet tip into the rectum, followed by one-hour incubation period. 21 days after AdgB IR immunization, mice were IR (rectal challenge) or IVAG (vaginal challenge) challenged with HSV-2 strain 333. For IR challenge, the procedure was as the same as that for IR immunization. For IVAG challenge, mice were injected SC with 2.5 mg of progesterone (Depo-Provera) 5 days prior to administration of HSV-2. 20  $\mu$ l of HSV-2 was given IVAG, followed by one-hour incubation.

### *Viral replication and pathology in the anal and genital tract*

After IVAG inoculation of HSV-2, vaginal washes were obtained daily by pipetting twice 30  $\mu$ l of PBS into and out of vaginal tract, and stored at -70°C before use. Virus shedding was determined by plaque assay on Vero cell monolayers and expressed by virus retrieved from per vaginal wash (vw) in 60  $\mu$ l.

Anal or genital pathology was monitored and scored daily after HSV-2 challenge. Genital pathology was scored by a 6-point scale from 0 to 5 (adapted from Overall et al, 1975; Gallichan et al, 1998, 2001; Kuklin et al, 1998): 0, no change; 1, redness of external vagina; 2, swelling of external vagina, severe redness; 3, perineal hair loss or genital ulceration, severe swelling; 4, perineal ulceration; and 5, hind limb paralysis or death. Anal pathology was also scored on a 6-point scale based on the descriptions by Phillips et al (1998, 2000): 0, no change; 1, redness of anus; 2, swelling of anus, severe redness; 3, perineal hair loss or anal ulceration, severe



swelling of anus and perineum; 4, perineal lesion; and 5, hind limb paralysis, anal restrictions or death.

## Results

### *Dose dependent study of IR challenge of HSV-2*

To determine the LD<sub>50</sub>, naive mice were IR inoculated with HSV-2 strain 333, and monitored for anal pathology (daily for the first 2 weeks). As shown in Table 1, 50% of mice died from HSV-2 IR inoculation at a dose of  $2 \times 10^4$  pfu. Anal pathology developed rapidly and no mice survived when the doses were increased to  $2 \times 10^5$  pfu and  $2 \times 10^6$  pfu. When mice received the latter dose, which is 100-fold higher than LD<sub>50</sub>, they were all paralyzed by the first week. Because this dose was highly lethal, leading to early onset of anal pathology and rapid death, it was used to challenge AdgB IR-immunized mice.

Table 1. Survival rate (%) of naive mice IR inoculated with HSV-2 (8 mice/group).


Dose (pfu)\week	1	2	3	4
$2 \times 10^3$	100	75	75	75
$2 \times 10^4$	87.5	50	50	50
$2 \times 10^5$	87.5	0	0	0
$2 \times 10^6$	0	0	0	0

### *Pathology and survival from IntraRectal HSV-2 challenge in AdgB IR-immunized mice*

21 days after a single IR immunization with AdgB, mice were monitored for pathology and survival following a lethal IR challenge of  $2 \times 10^6$  pfu of HSV-2. All unimmunized mice (n=8) rapidly developed pathology, and were unable to survive the challenge by day 7. In AdgB IR-immunized mice (n=12), 41% of mice had overt pathology and 92% survived the HSV challenge. For those mice that developed pathology, the severity of infection was less than non-immunized mice (maximum score points:  $3.6 \pm 0.9$  vs.  $5 \pm 0.0$ ), and external indications of infection were no longer visible by week 2, indicating the ability of immunized mice to withstand the infection at high lethal doses.

The development of genital pathology after challenge of  $2 \times 10^5$  pfu of HSV-2, which is 10-fold higher than conventional dose ( $2 \times 10^4$  pfu), was also assessed. All unimmunized mice died within the first week of challenge, whereas 100% of immunized mice survived. Although 60% of immunized mice demonstrated overt genital pathology ( $3.7 \pm 0.6$  vs.  $5 \pm 0.0$ ), they were also able to control the infection, characterized by regression of some mild perineal lesions.

*Virus titers in vaginal washes of IntraVaginal HSV-2 challenge in AgB IR immunized mice*



Previous studies have shown that virus shedding peaks at day 3 post infection. Virus shedding was compared on monolayer Vero cells by measuring plaques formed by virus obtained from vaginal washes. Three days after HSV challenge at a dose of  $2 \times 10^5$  pfu, virus was detected in the samples of all unimmunized mice ( $8.0 \times 10^3 \pm 3.7 \times 10^3$  pfu/vw,  $n=5$ ). Although 80% of immunized mice ( $n=5$ ) were detected positive for virus shedding, compared to those from unimmunized mice, the virus titers from these immunized mice were at least one log lower ( $8.7 \times 10^2 \pm 7.0 \times 10^2$  pfu/vw). While all unimmunized mice retained similar levels of virus shedding until death, 40% of immunized mice were no longer positive for virus by day 5, and all were virus free by day 10.

7200 Lake Ellenor Dr.  
Suite 252  
Orlando, Florida 32809  
USA



# Van Dyke & Associates, PA

INTELLECTUAL PROPERTY LAW

Phone: (407) 228-0328  
Fax: (407) 228-0329  
info@patentinternational.com  
www.patentinternational.com

## FACSIMILE COVER SHEET

*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

TO	:	Examiner Schnizer
COMPANY	:	USPTO
FAX No.	:	703-872-9306
No of PAGES	:	<u>18</u> (including cover sheet)
FROM	:	Van Dyke & Associates, P.A.
DATE	:	November 25, 2002
RE	:	Attorney Docket No. GDI-1 Application No.: 09/360,199 Supplementary Response

---

**VIA FACSIMILE WITH MAIL CONFIRMATION TO FOLLOW**

*If you do not receive all pages or if any portion of this transmission is not legible, call the sender at (407) 228-0328.*

HP Fax Series 900  
Plain Paper Fax/Copier



Fax History Report for  
Rita Wheatley  
(317)326-2299  
Nov 25 2002 3:17pm

---

Last Fax

<u>Date</u>	<u>Time</u>	<u>Type</u>	<u>Identification</u>	<u>Duration</u>	<u>Pages</u>	<u>Result</u>
Nov 25	2:59pm	Sent	17038729306	6:08	18	OK

---

Result:

OK - black and white fax



**Adenoviral-based gene delivery in the lower GI tract induces antigen-specific immune responses and protection from Tumour challenge**

**Background:**

The entry of pathogenic organisms most often occurs at the mucosal surfaces. To prevent infectious diseases, such as sexually transmitted disease, in the genital-urinary (GU) and the lower gastrointestinal (GI) tracts, induction of protective immunity at these mucosal sites against microbial access is critical. Induction of systemic immune responses against further invasion of pathogens into the body through the mucosa is also important. In addition, induction of a potent Cytotoxic T Lymphocyte response (CTL) is important both for control of viral infections and for tumour surveillance and protection.

**Aim:**

To investigate potential of local gene expression within the rectal tissue, using adenoviral vectors (AdV), to promote local mucosal and systemic antigen-specific cell and humoral immune responses. To document the efficacy of the rectal route for generation of protective immunity at both the local tissue site and for systemic immunity.

**Methods:**

1. AdV encoding the LacZ reporter gene (AdLacZ) or an immunogenic antigen, such as chicken ovalbumin (AdOVA  $5 \times 10^9$  pfu), was administered intrarectally (iR) through the anus of mice. Mice were first subjected to a 50% Ethanol wash (enema) for one hour. AdV was then delivered into the lumen of the colo-rectum.
2. 14 days post iR immunization with AdOVA, a homologous tumor cell line (EL4) expressing OVA antigen (E.G7-OVA) was injected intra-mucosally in the rectal tissue (local challenge) or subcutaneously (systemic challenge) into mice and tumor formation and growth was followed

over a period of time at regular intervals as well as survival on the mouse. When tumor volumes reached more than 1000 mm<sup>3</sup>, mice were euthanized.

3. Colo-rectal tissues and local draining lymph nodes (iliac node) as well as non-draining nodes (cecal node) were examined for gene expression and local responses to the OVA gene. 14 days after AdOVA administration, spleen cells were also collected for measurement of cytokine production and determination of antigen-specific CTL activities using specific OVA peptide (SIINFEKL) pulsed target cells (EL4 based). Mice deficient in CD8 T cells (CD8 KO) were used to investigate the role of CD8 T cells in the CTL response and protection from tumour challenge.

### Results:

1. Staining for  $\beta$ -galactosidase showed that the expression of the transferred gene was widespread across the crypts and villi of the colo-rectal epithelial layer from one to three days post iR administration (Fig 1, 4, 5). The transgene expression was dose dependent (Fig 6).

2. 14 days after AdOVA iR immunization, mice were protected from tumor challenge with OVA-antigen expressing tumour cells (EG7-OVA) either delivered to a systemic site, subcutaneously (Fig 2, 9, 10), or to a local site, intra-mucosally (Fig 11). The protection from tumour challenge after iR immunization was shown to be CD8 dependent through the use of CD8 KO mice where the protection was abolished (Fig 12). Protection was not seen when OVA protein alone was delivered to the rectal tissue (Fi 12).

3. OVA-specific systemic (spleen) and local (Draining lymph nodes) CTL responses were detected 14 days after AdOVA iR immunization (from 20% to 60% in separate experiments vs. ~1% in the control) (Fig 3, 7, 8).

4. The production of INF- $\gamma$ , but not IL-4, was dramatically increased in the culture of spleen cells re-stimulated with OVA protein (1076.7 pg/ml vs. 42.8 pg/ml).

**Conclusions:**

1. Transgenes can be effectively delivered by AdV in the lower GI tract and expressed widespread across the crypts and villi of the colo-rectal mucosal surfaces.
2. Adenovirus-based mucosal intra-rectal (iR) gene delivery induces both strong systemic and local mucosal immune responses, which are antigen specific. This method offers direct advantages as a vaccination route to induce local immune responses within the colo-rectal tissue and within the common mucosal tissue in general. This route of immunization also offers induction of protective CTL activity and long-lasting immune protection from tumour challenge.




Fig 1. LacZ expression visualized in the colo-rectum one day after AdLacZ iR delivery.




Fig 2. Tumor protection and tumor growth after E.G7-OVA challenge in iR AdOVA-immunized mice.





Fig 3. Spleen CTL response against EL-4 pulsed with OVA peptide SIINFEKL. The results represent the CTL response from 2 independent experiments.

# Visualization of gene expression in the colon

Day 2 after AdLacZ  $5 \times 10^9$  pfu IR

Fig 4




# Visualization of gene expression in the colon

Fig 5

Day 2 after AdLacZ  $5 \times 10^9$  pfu IR



AdLacZ staining



Anti-LacZ Ab

Gene expression is found across the villi and crypts of the epithelium and "maybe the LP" of the colon, implying efficiency of gene delivery by Adv at high doses.



# Visualization of gene expression in the colon

--- Dose dependent study ---

Fig 6

Day 3 after AdLacZ IR



5x10<sup>8</sup> pfu      1x10<sup>9</sup> pfu      2x10<sup>9</sup> pfu


Adv IR-administrated gene can be delivered onto the epithelial cells and be expressed.





# Induction of cellular immune responses by AdOVA IR

--- Systemic (spleen)---



Systemic CTL responses induced by AdOVA IR were antigen-specific.

Fig 7

# Induction of cellular immune responses after AdOVA IR

--- Local (DLNs)---

Day 5




Local DLN primary CTL responses induced by AdOVA IR were also antigen-specific.

Fig 8

# Induction of protective immunity by AdOVA IR

--- Systemic immunity against tumor challenge ---

Short term




Systemic immune responses induced by AdOVA were protective

Fig 9

# Induction of protective immunity by AdOVA IR

## --- Systemic immunity against tumor challenge ---

### Long term




Systemic immune responses induced by AdOVA were protective

Fig 10

# Induction of protective immunity by AdOVA IR

## Local Immunity against tumor challenge in the rectal mucosa



Mucosal immune responses induced by AdOVA were protective

Fig 11

# Induction of protective immunity by AdOVA IR

--- CD8 dependent ---

AdOVA SC (WT)

AdOVA IR (WT)

AdOVA SC (CD8 KO)


AdOVA IR (CD8 KO)

OVA protein IR

Days post SC challenge

No Immunization (CD8 KO)<sup>5</sup>

No treatment (WT)



The CTL responses are CD8 dependent (CD8 KO not protected).  
Also, OVA protein alone was not able to induce protective immune responses

Fig 12